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 Abstract 
 
Clinical outcomes for patients with end-stage kidney disease on haemodialysis 
remain poor and have similar mortality risk to some cancers. A significant proportion 
of haemodialysis patients have chronic unexplained inflammation – the 
pathophysiology of this syndrome is unclear but is associated with poor quality of life 
and survival. A large number of studies have proposed that circulating endotoxin, 
fragments of gram negative bacterial cell wall, plays a key role in driving chronic 
inflammation in dialysis patients in the absence of clinical infection. However, 
interpretation of published literature is difficult for several reasons. Firstly, reports 
have mainly been cross-sectional in nature. Secondly, various different types of 
endotoxin detection assays have been used and reported blood endotoxin levels in 
clinically stable non-infected patients were exceedingly high which is incompatible 
with the clinical state. Additionally, nearly all studies used endotoxin detection 
assays that could be also be activated by (1-3)-β-D glucan, a cell wall constituent of 
cereals, yeast and fungi. This is a particularly important given that materials used to 
construct some dialyser membranes are known to leach (1-3)-β-D glucan. 
The doctoral research project had two central hypotheses requiring investigation. 
Firstly, that endotoxin and other exogenous molecules in the gut including (1-3)-β-D 
glucan are contributors to unexplained inflammation in patients with chronic kidney 
disease.  Second, that their presence in blood is a result of translocation from the gut 
due to increased gastrointestinal permeability in the uraemic state. 
The clinical importance of these hypotheses is that if the relationship between 
presence of endotoxin and (1-3)-β-D glucan in blood of patients with chronic kidney 
disease and inflammation were clarified, and a positive association was confirmed, 
this would justify embarking on endotoxin or (1-3)-β-D glucan lowering interventional 
studies such as extracorporeal endotoxin adsorption therapy or exploring therapies 
to modify gut flora. 
In order to address these hypotheses systematically, the studies were designed with 
the following specific aims: 
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1. To determine the prevalence of chronic unexplained inflammation in 
patients receiving haemodialysis to determine the scope and extent of 
the clinical problem. 
2. To determine the optimum endotoxin assay, in terms of accuracy and 
precision, for measurement of endotoxin in uraemic human blood and 
to limit interference of other factors in the assay such as presence of 
(1-3)-β-D glucan. 
3. To determine the relationship of blood levels of endotoxin measured 
with an optimised assay and (1-3)-β-D glucan in patients with chronic 
kidney disease with patient symptoms and inflammation both cross-
sectionally and longitudinally. 
4. To determine factors influencing the presence of endotoxin and (1-3)-β-
D glucan in the blood of patients requiring haemodialysis to determine 
whether increased gut permeability, potentially induced by 
intravascular volume depletion during dialysis, is a potential contributor.  
To determine the extent of unexplained inflammation, a retrospective study was 
performed of 444 prevalent haemodialysis patients at the East and North Herts NHS 
Trusts in which medical records and serial CRP measurements over 3 months were 
reviewed. Specific potential causes of inflammation were sought for each patient. 
64.8% of patients had evidence of elevated CRP >5mg/L on at least two occasions 
one month apart and 23.4% of the study population had chronic unexplained 
inflammation. 
To determine the optimum blood endotoxin detection assay, a literature review was 
conducted to identify candidate assays for testing. All published endotoxin studies in 
dialysis patients used variations of assays based on the Limulus Amoebocyte Lysate 
(LAL) assay. The kinetic turbidimetric, kinetic chromogenic LAL and Endotoxin 
Scattering Photometry assay were compared in a direct head-to-head study in terms 
of accuracy and precision. The kinetic turbidimetric LAL assay was found to have the 
best performance and used for blood endotoxin detection in clinical studies.  
In a study of 40 haemodialysis patients, blood samples were measured 
simultaneously for endotoxin and (1-3)-β-D glucan. Endotoxin signals correlated 
significantly with (1-3)-β-D glucan. However, on modifying the kinetic turbidimetric 
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LAL assay with a blocker which prevents assay activation by (1-3)-β-D glucan, all 
previously detected signals were extinguished and true endotoxemia in 
haemodialysis patients in this study was low, contrary to findings from previous 
studies. ‘Endotoxin’ signals detected using LAL assays suffer from significant false 
positive interference from elevated (1-3)-β-D glucan in haemodialysis patients.  
Given the low prevalence of endotoxemia detected, haemodialysis patients were 
further studied during clinical states that were hypothesised to increase endotoxin 
influx including during exercise and after haemodialysis. Blood samples were 
collected from 10 haemodialysis patients before and after haemodialysis and intra-
dialytic exercise. Similarly, after modifying the LAL assay with a blocker to prevent 
false activation from (1-3)-β-D glucan, only one sample tested positive for endotoxin 
whereas 43% of samples had elevated (1-3)-β-D glucan. 
The relationship between (1-3)-β-D glucan with kidney function, inflammation and 
endotoxin levels were further studied in a study of 60 haemodialysis patients (30 with 
high-risk features including chronic unexplained inflammation, hypotension during 
haemodialysis or high ultrafiltration requirements and 30 low-risk patient [no 
inflammation, hypotension and low ultrafiltration requirement], 15 peritoneal dialysis 
patients, 20 patients with CKD 4-5, 20 patients with CKD 1-3 and 20 healthy 
controls. Similarly, while endotoxin signals were highest in haemodialysis patients, 
most signals disappeared after modifying the LAL assay with a (1-3)-β-D glucan 
blocking buffer. Low level endotoxemia was found in only 3 haemodialysis patients. 
BG levels increased with worsening CKD stage and were highest in haemodialysis 
patients, 22% having significantly elevated levels. (1-3)-β-D glucan correlated 
strongly with endotoxin signals (r=0.545, p<0.001) suggesting that previous reports 
of elevated endotoxin may be artefactual due to raised blood (1-3)-β-D glucan in 
renal impairment. (1-3)-β-D glucan correlated strongly with markers of inflammation 
and were associated with higher depression and kidney disease related symptoms 
scores.  
Intestinal barrier dysfunction and increased intestinal permeability has been 
proposed as a source of inflammation in haemodialysis patients and the 
haemodialysis procedure has been suggested to exacerbate intestinal permeability 
due to the large blood volume changes that occur during treatment. Intestinal 
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permeability has not been studied directly in haemodialysis patients since 
conventional assays rely on measurement of probes in urine but this method cannot 
be applied to anuric dialysis patients. Using a novel intestinal permeability assay 
which measures probes in plasma instead, intestinal permeability was measured in 
10 haemodialysis patients before and after haemodialysis treatment and compared 
with 5 healthy controls. Direct comparison of intestinal permeability between 
haemodialysis patients and healthy controls was difficult since concentration of 
probes in plasma was influenced by level of kidney function, although there was a 
suggestion that small intestinal permeability was increased in haemodialysis 
patients. However, intestinal permeability was not significantly affected by the 
haemodialysis procedure. 
The main finding of this work is that endotoxemia is relatively uncommon in dialysis 
patients and hence unlikely to be the sole cause of unexplained chronic inflammation 
in these patients. Previous reports of apparent high levels of blood endotoxin in 
dialysis patients were due, in part at least, to false positive interference of LAL 
assays by elevated (1-3)-β-D glucan present in the blood of patients with kidney 
disease. The work presented in this thesis supports this. Furthermore, the clinical 
studies carried out did not demonstrate a convincing association between endotoxin 
and inflammation. In contrast, this work has demonstrated a progressive increase in 
levels of (1-3)-β-D glucan with worsening degree of kidney disease and an 
association of these levels with inflammation, higher depression and kidney-disease 
related symptom scores. The cause of elevated (1-3)-β-D glucan in dialysis patients 
is unclear and warrants further study, though an intestinal source is a possibility. The 
direct intestinal permeability studies carried out in dialysis patients suggest impaired 
intestinal barrier function, although until an accurate method of assessing intestinal 
permeability in vivo in uraemic patients is available, this hypothesis remains to be 
proven. 
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 Thesis Structure and Prelude 
 
This work is organised into four main sections to defend the thesis offered. 
The first section provides an overview of kidney failure and a review of the literature 
of endotoxemia in patients with kidney disease and methods of endotoxin detection 
in blood. 
The second section describes general methodology relevant to all studies presented 
in this work.  
The third section describes the laboratory and clinical studies used in defence of the 
hypothesis. This section consists of an initial chapter documenting laboratory 
experiments conducted to determine the optimum endotoxin detection assay. 
Subsequent clinical studies using this assay follows which examines endotoxin and 
(1-3)-β-D glucan levels in haemodialysis and CKD patients. 
The fourth section summarises the conclusions derived from the studies described in 
this thesis and suggests recommendations for future work. 
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Chapter 1 
1. Inflammation in end-stage kidney disease 
 
1.1 The kidneys – anatomy, structure and function 
The human body usually contains two kidneys which are bean-shaped organs 
located in the rear of the abdominal cavity in the retroperitoneal space. They are 
situated on either side of the spine below the diaphragm. Due to the close proximity 
of the right kidney to the liver, the right kidney is slightly lower and smaller than the 
left kidney. The size of the kidneys is dependent on body size and each weighs 
approximately 150g. The upper parts of both kidneys are protected by the 11th and 
12th ribs. The kidneys are surrounded by tough fibrous tissue, the renal capsule 
which itself is surrounded by perinephric fat, renal fascia and paranephric fat. The 
kidney parenchmya consists of the outer cortex and the inner medulla. These 
structures form approximately eight to eighteen cone-shaped renal lobules, each 
lobule containing renal cortex surrounding a portion of medulla called a renal 
pyramid. Between each pyramid are projections of cortex called the columns of 
Bertin. The functional unit of the kidney is the nephron which spans cortex and 
medulla. There are approximately 1 million nephrons in each kidney. Each nephron 
is a comprised of a renal corpuscle located in the outer cortex. This drains into the 
renal tubules consisting of the primary convoluted tubule, loop of Henle, distal 
convoluted tubule and collecting ducts. The renal corpuscle is the initial blood-
filtering component of the kidney and contains the glomerulus and Bowman’s 
capsule. The glomerulus is a tuft of capillaries which have large fenestrae to allow 
the passage of filtrate. The Bowman’s capsule consists of an outer parietal layer of 
simple squamous epithelium and an inner visceral layer of modified squamous 
epithelial cells called podocytes. These podocytes have long foot processes that 
wrap around the glomerular capillaries leaving slits in between them. The fenestrated 
glomerular capillaries, filtration slits formed by the podocytes, together with the fused 
basal laminar of the glomerular endothelial cells and podocytes form a filtration 
barrier permitting the passage of water, ions and smaller molecules including low 
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molecular weight proteins but preventing the passage of red blood cells, leucocytes, 
platelets and larger molecules . Large volumes of blood are filtered in the kidneys 
under hydrostatic pressure and approximately 150L of ultrafiltrate are produced daily 
and enter Bowman’s space. A large proportion of the ultrafiltrate is selectively 
reabsorbed along the renal tubules to generate approximately 2L of urine per day 
containing waste products of metabolism which are excreted.  
The principal function of the kidneys is to remove the end-products of metabolism 
such as urea, but they also regulate the volume of fluid in the body together with its 
osmolarity, acidity, electrolyte content and concentration. The kidneys also have 
important endocrine functions and are responsible for the production and secretion 
of a number of important enzymes and hormones including renin, erythropoietin and 
1,25-Di-hydroxyvitamin D3. Renin is an enzyme, produced by the granular cells of 
the juxtaglomerular apparatus, which catalyses the formation of angiotensin from 
angiotensinogen. Angiotensin is a potent vasoconstrictor peptide and helps to 
regular salt balance and blood pressure. Erythopoietin is a glycosylated protein 
produced by the renal cortical interstitial cells and stimulates the maturation of 
erythrocytes in the bone marrow. 1,25-Di-hydroxyvitamin D3 is the active form of 
vitamin D3 and is produced by the proximal tubules cells. This steroid hormone 
promotes intestinal absorption of calcium, increases reabsorption of calcium in the 
renal tubules, and suppresses the production of parathyroid hormone. 1,25-
dihydroxy vitamin D also increases release of calcium from bones via the stimulation 
of osteoblasts which in turn activate osteoclasts (Briggs et al. 2009). Impairment of 
kidney function leads to a number of clinically significant problems and the type and 
severity of problems encountered depends on the severity of impairment. 
1.2 Measurement of kidney function  
Kidney function is quantified according to the glomerular filtration rate (GFR). GFR is 
defined as the volume of fluid filtered through the glomerular capillaries into 
Bowman’s capsule per unit time. The level of GFR reported in healthy individual 
ranges from 100-130 mL/min/1.73m2 in adult men and women (Delanaye et al. 
2012). GFR can be measured directly by determining the clearance of an ideal 
exogenous filtration marker. Inulin, a fructose polymer made from the Jerusalem 
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artichoke, is considered the gold-standard filtration marker since it is freely filtered 
through the glomerulus, not secreted, reabsorbed, or metabolized by the kidneys. It 
is nontoxic, physiologically inert in humans and is exclusively eliminated by 
glomerular filtration with no apparent extra-renal clearance, making it ideal for 
measuring GFR. The inulin clearance method first described by Homer Smith and 
James Shannon (Shannon & Smith 1935) requires the continuous intravenous 
infusion of inulin and bladder catheterization together with multiple urine and blood 
collections to measure its renal (urinary) clearance. This method is invasive and 
impractical and therefore cannot be used routinely in clinical practice. Therefore, 
GFR is usually estimated using endogenous blood based markers. Creatinine is the 
most commonly used endogenous marker of renal function. Creatinine is a product 
of metabolism of creatinine and phosphocreatine in skeletal muscle and levels 
remain fairly constant throughout the day with a variability of about 8%. Creatinine is 
freely filtered at the glomerulus and is not reabsorbed but approximately 15% is 
actively secreted by the tubules (Traynor et al. 2006).  However, serum creatinine 
cannot itself be used to estimate GFR since it can be affected by a number of factors 
including age, diet, gender, ethnicity and muscle mass (Stevens et al. 2006). 
However GFR can be estimated by creatinine clearance which also incorporates 
involves estimation the volume of, and creatinine concentration in 24 hour urine 
collection. This has been largely superseded in clinical practice by use of estimated 
GFR (eGFR). A number of equations based on serum creatinine have been derived 
which are able to estimate creatinine clearance or GFR with reasonable accuracy, 
albeit with some limitations. The three most commonly used equations are the 
Cockroft-Gault equation, the abbreviated MDRD (Modification of Diet in Renal 
Disease) formula and the most recent CKD-Epidemiology Collaboration (CKD-EPI) 
formula (Florkowski & Chew-Harris 2011). The Cockroft-Gault equation was 
originally introduced in 1976 and predicts creatinine clearance based on age, weight, 
and height and serum creatinine. However, the equation was derived mainly from 
hospitalised men and the necessity to obtain height and weight for calculation limited 
its widespread use on a population-wide basis. Subsequently, the MDRD equation 
was derived from a study cohort of 1628 patients with CKD in 1999. This utilises only 
four variables (age, gender, ethnicity and serum creatinine) and generates an 
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estimated GFR corrected for body surface area. The lack of requirement of weight 
and height made the MDRD equation the preferred formula in clinical practice. 
However, the MDRD equation tends to underestimate renal function in those with 
eGFR>90mL/min/1.73m2. The CKD-EPI was developed in 2009 from 8254 data 
points from six studies and four clinical populations and was designed to match the 
accuracy of MDRD equation at eGFR<60mL/min/1.73m2 but to increase the 
accuracy at higher GFR to avoid inappropriately over diagnosing CKD in the general 
population. The CKD-EPI equation actually consists of eight different equations, four 
equations for whites (male, female, above and below specific cut-offs of creatinine) 
and four equations for blacks with different coefficients. Both US and UK NICE 
clinical practice guidelines currently recommend the use of CKD-EPI equations for 
estimating GFR (NICE Clinical Guidelines 2014; KDIGO Workgroup 2013). The 
CKD-EPI equations are shown below:-  
𝐹𝑒𝑚𝑎𝑙𝑒 𝑤𝑖𝑡ℎ 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 ≤ 62; 𝑢𝑠𝑒 𝑒𝐺𝐹𝑅 = 144 × (
𝐶𝑟
61.9
)
−0.329
 ×  0.993𝐴𝑔𝑒 × 1.159 [𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
𝐹𝑒𝑚𝑎𝑙𝑒 𝑤𝑖𝑡ℎ 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 > 62; 𝑢𝑠𝑒 𝑒𝐺𝐹𝑅 = 144 × (
𝐶𝑟
61.9
)−1.209  ×  0.993𝐴𝑔𝑒 × 1.159 [𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
𝑀𝑎𝑙𝑒 𝑤𝑖𝑡ℎ 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 ≤ 80; 𝑢𝑠𝑒 𝑒𝐺𝐹𝑅 = 141 × (
𝐶𝑟
79.6
)−0.411  ×  0.993𝐴𝑔𝑒 × 1.159 [𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
𝑀𝑎𝑙𝑒 𝑤𝑖𝑡ℎ 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 > 80; 𝑢𝑠𝑒 𝑒𝐺𝐹𝑅 = 141 × (
𝐶𝑟
79.6
)−1.209  ×  0.993𝐴𝑔𝑒 × 1.159 [𝑖𝑓 𝑏𝑙𝑎𝑐𝑘] 
where serum creatinine is measured in μmol/L. 
1.3 Classification of chronic kidney disease 
Chronic kidney disease (CKD) is defined as an abnormality in either kidney structure 
or function persisting for three or more months. The United States National Kidney 
Foundation have classified CKD into different stages or grades according to level of 
GFR and the amount of proteinuria present (KDIGO Workgroup 2013):- 
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Table 1-1: US KDIGO stages of chronic kidney disease 
 
Indicators of kidney damage can be detected by histology, imaging, blood tests 
(elevated urea and creatinine) or abnormalities in urine dipstick such as the 
presence of blood and protein. Proteinuria is defined as the presence of significant of 
protein in the urine and is an accurate prognostic indicator of CKD progression and 
cardiovascular mortality (Jafar et al. 2001; Keane & Eknoyan 1999). Proteinuria is 
caused by glomerular injury and consist mainly albumin although other proteins such 
as Tamm-Horsfall protein (uromodulin) are present. Proteinuria was traditionally 
detected using 24 hour urine collections but due to the inconvenience and 
unreliability of timed urine collection, these have been largely replaced with the 
random ‘spot’ urine collections to measure the ratio of urine protein or albumin 
concentration to urine creatinine concentration (urine PCR or ACR). Thus, although 
those with stage 1 CKD may have ‘normal’ GFR, these individuals will have other 
indicators of kidney disease such as proteinuria or structural abnormalities of the 
kidney. The most severe stage of kidney disease occurs when GFR falls below 
15mL/min/1.73m2 and uraemic signs and/or symptoms appear. Uraemic signs and 
symptoms may include volume overload, reduced appetite, confusion, severe 
hypertension, nausea and vomiting. Once kidney failure or end-stage kidney disease 
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is established, either transplantation or dialysis treatment is required to reduce the 
risk of morbidity and mortality. 
1.4 Effect of chronic kidney disease on the body 
CKD is a complex and prevalent disease with a high economic cost to health 
systems. Estimated global prevalence of CKD by stages are stage 1: 3.5%; stage 2: 
3.9%; stage 3: 7.6%; stage 4: 0.4%; and stage 5: 0.1% (Hill et al. 2016). Progression 
of CKD itself is associated with a number of serious complications including 
increased incidence of cardiovascular disease, hyperlipidemia, anaemia, metabolic 
bone disease  and inflammation (Thomas et al. 2008).  
1.4.1 CKD-associated anaemia  
CKD or renal anaemia is a very common complication and usually occurs in stage 4 
and 5 CKD. Whilst CKD-associated anaemia may be due to multiple mechanisms 
such as iron deficiency, gastrointestinal bleeding, reduced red cell survival and 
inflammation, the principal cause of CKD-associated anaemia is reduced 
erythropoietin (EPO) synthesis. EPO is a glycoprotein hormone secreted by kidney 
interstitial fibroblasts and is essential for the growth and differentiation of red blood 
cells from the bone marrow. EPO synthesis is impaired with progressive CKD due to 
tubular atrophy and tubulointerstitial fibrosis. Apart from the symptomatic effect of 
anaemia such as fatigue, renal anaemia increases morbidity and mortality from 
cardiovascular complications such as left ventricular hypertrophy and worsening 
heart failure. Treatment of CKD-associated anaemia is with recombinant human 
EPO injections. EPO treatment has largely replaced the need for repeated blood 
transfusions to treat renal anaemia as was practiced historically. 
1.4.2  Bone and mineral disorders 
CKD leads to defective bone and mineral metabolism and renal osteodystrophy. 
Renal osteodystrophy encompasses a broad spectrum of histological changes seen 
in the bony architecture of CKD patients. The kidneys are responsible for phosphate 
excretion and 1-α hydroxylation of vitamin D, with progressive CKD both of these 
processes are impaired leading to phosphate retention and hypocalcaemia. As a 
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consequence, a number of different bone abnormalities may develop including high-
and low bone turnover states. A high bone turnover state is due to a compensatory 
increase in parathyroid hormone that occurs due to hyperphosphatemia, 
hypocalcemia and low levels of 1,25-dihydroxyvitamin D leading to secondary 
hyperparathyroidism. Elevated parathyroid levels stimulate osteoclastic activity in the 
bone leading to weakening and loss of bone mass (osteitis fibrosa cystica). Low 
bone turnover states such as osteomalacia occur due to inadequate bone 
mineralisation from insufficient vitamin D synthesis. Another form of low bone 
turnover disease called adynamic bone disease can also develop predominantly in 
patients established on dialysis treatment and results from over suppression of 
parathyroidism and high calcium dialysate concentrations (Epstein et al. 1995). A 
combination of both high and low bone turnover disease may also co-exist (mixed 
osteodystrophy). The mainstay of treatment of renal osteodystrophy is reduction of 
serum phosphate with dietary phosphate restriction and oral phosphate binders. 
Supplementation with vitamin D and its related compounds is also used to raise 
serum calcium concentration and to suppress parathyroid hormone secretion. In a 
proportion of patients with severe hyperparathyroidism, surgical parathyroidectomy 
may be required. Use of calcimimetics – agents which increase the calcium 
sensitivity of parathyroid gland, thus down-regulating parathyroid hormone secretion 
and reducing hyperplasia of the parathyroid gland - may also be useful in those with 
established hyperparathyroidism. 
1.4.3 Cardiovascular disease 
CKD is associated with a significant increase in mortality compared to the normal 
population. There is an increased incidence of cardiovascular disease, myocardial 
infarction, heart failure, stroke and sudden death (Di Angelantonio et al. 2010). Many 
traditional Framingham risk factors such as hypertension are more prevalent in CKD 
patients compared to the general population. Hyperphosphatemia, raised calcium-
phosphate ion product and hyperparathyroidism are also independent cardiovascular 
risk factors, possibly due to its promotion of vascular calcification, atherosclerosis 
and increased vascular wall stiffness (Thomas et al. 2008). Other non-traditional risk 
factors such as inflammation are also believed to play a role in increasing 
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cardiovascular risk in patients with CKD. Inflammation in kidney disease is discussed 
further in chapter 1.7. 
1.5  Options for renal replacement therapy in kidney failure 
Once kidney function is unable to meet the metabolic demands of daily life, kidney 
failure is established and renal replacement therapy (either dialysis or 
transplantation) is required to prevent death and maintain quality of life. Not all 
patients may wish to embark on renal replacement therapy and very frail patients 
may not be suitable for transplantation or benefit from dialysis. This subset of 
patients may choose a palliative approach to treatment. For those who are able to 
undergo renal replacement therapy, the aim is to replace the excretory function of 
the kidney by providing sufficient removal of metabolic waste products, control of 
fluid and electrolyte balance to maintain health and quality of life.  
1.5.1  Kidney transplantation 
Patients who receive a kidney transplant benefit from improved clinical outcomes 
and quality of life compared to well-matched counterparts who remain on dialysis 
(Wolfe et al. 1999; Rabbat et al. 2000). Kidney transplantation is the preferred option 
for Renal Replacement Therapy (RRT) due to the superior outcomes. However 
many patients with kidney failure are elderly and frail and not medically fit enough to 
receive a kidney transplant. Kidneys are donated from a deceased or living donor 
and in the past transplantation were only carried out between HLA and ABO 
compatible individuals although with development of more effective 
immunosuppressive techniques, HLA- and ABO incompatible transplants are 
increasing being performed (Barry et al. 2005). Following transplantation, lifelong 
immunosuppressive medication is necessary to prevent allograft rejection.  
1.5.2  Dialysis  
For dialysis therapy, two options are available – peritoneal dialysis and 
haemodialysis. In peritoneal dialysis, the peritoneal membrane in the abdomen is 
used for the removal of fluid and uraemic solutes. Fresh dialysis fluid containing 
electrolytes such as sodium, chloride, lactate or bicarbonate and, crucially, a high 
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concentration of glucose to ensure hypersomolarity, is introduced into the abdominal 
cavity via a peritoneal dialysis tube or catheter (Figure 1-1). The high concentration 
of glucose in the dialysate drives the filtration of fluid by osmosis from the peritoneal 
capillaries into the peritoneal cavity. During this process, the peritoneum acts a semi-
permeable membrane and solutes including urea and creatinine are also removed 
simultaneously. Glucose from the dialysate diffuses rapidly into the blood and after 
several hours the glucose osmotic gradient is dissipated and the ‘used’ dialysate is 
drained out and a fresh bag of dialysis fluid is re-instilled. Peritoneal dialysis therapy 
is a continuous daily treatment and peritoneal dialysate exchanges should be carried 
out several times each day, either manually in continuous ambulatory peritoneal 
dialysis (CAPD), or overnight using a mechanical cycler in automated peritoneal 
dialysis (APD). 
 
Figure 1-1: Schematic diagram to illustrate peritoneal dialysis (reproduced with permission 
from Blausen Gallery 2014: Medical Gallery of Blausen Medical 2014. Wiki Journal of Medicine) 
 
In haemodialysis, blood from the patient is passed through a synthetic dialyser which 
removes uraemic waste products before being returned to the patient. The dialyser is 
a semi-permeable membrane with two separate compartments for blood and dialysis 
fluid to flow in counter-current directions and uraemic solutes are removed by a 
combination of diffusion and convection. Systemic anticoagulation with heparin is 
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necessary during dialysis to prevent blood clotting within the extracorporeal circuit. A 
schematic representation of haemodialysis is shown in Figure 1-2. 
 
Figure 1-2: Schematic representation of haemodialysis circuit (reproduced with permission 
from Blausen Gallery 2014: Medical Gallery of Blausen Medical 2014. Wiki Journal of Medicine) 
 
Haemodialysis is the most common form of dialysis used and is usually performed in 
hospital or a haemodialysis centre three times a week with each treatment session 
typically lasting 3-4 hours. However, haemodialysis can also be carried out at home 
by some patients, allowing flexibility, in terms of the timing, duration and frequency of 
dialysis sessions, which is difficult to offer within the constraints of standard thrice-
weekly in-centre haemodialysis. The prospective randomised Frequent 
Haemodialysis Network trials have found favourable outcomes in terms of mortality, 
left ventricular mass and physical health scores for patients who dialyse more 
frequently than patients treated with standard thrice-weekly haemodialysis (Chertow 
et al. 2010; Hall et al. 2012).  
A permanent form of vascular access is required for haemodialysis which enables 
high blood flow to be delivered to the dialyser to achieve efficient removal of uraemic 
solutes from the patient. The preferred vascular access is an arterio-venous fistula 
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(AVF) which is created by surgically joining an artery to a vein, usually between the 
brachial or radial artery and the cephalic vein. Following the creation of the fistula, 
the blood flow through the fistula increases to approximately 700-1000mL/min after 1 
month. The artery and vein dilates and stretches in response to the high flow and 
shear stress, eventually the vein is large enough to be cannulated by two large bore 
needles to allow the efficient delivery and return of blood to the dialyser (Figure 1-3). 
Occasionally, arterio-venous fistula formation may not be possible and a synthetic 
graft, usually made of PTFE is used to connect the artery to the vein. 
 
Figure 1-3: A radio-cephalic fistula (reproduced with permission from Blausen Gallery 2014: 
Medical Gallery of Blausen Medical 2014. Wiki Journal of Medicine) 
 
In some patients, formation of AVF or graft may not be technically possible or the 
AVF may not have matured rapidly enough for use and in these circumstances a 
dialysis catheter is inserted into a large vein, usually the internal jugular vein, for 
haemodialysis (Figure 1-4). Dialysis catheters consist of two lumens – one lumen 
acts as an arterial limb and diverts blood to the dialyser and the second lumen acts 
as a venous limb for blood to be returned to the patient. The catheter is tunnelled 
under the skin and a cuff surrounding the catheter triggers a fibrotic reaction in the 
surrounding tissue which helps to hold the catheter in position and reduce the risk of 
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infection. Dialysis catheters are much less preferable than AVFs due to the high risk 
of infection, malfunction from thrombus formation or kinking. Delivered blood flow 
rates are usually less than those which can be achieved with AVF leading to reduced 
dialysis efficiency. 
 
Figure 1-4: Diagram of a tunnelled dialysis catheter (reproduced with permission from Blausen 
Gallery 2014: Medical Gallery of Blausen Medical 2014. Wiki Journal of Medicine) 
 
Blood is diverted into a dialyser which is usually made from synthetic polymers such 
as polyamide or polysulfone and is more biocompatible than older dialysers which 
used to be made of cellulose and caused activation of complement as blood passed 
through the membrane. Dialyser membranes contain small pores which allow solutes 
and fluid to be exchanged between the blood and dialyser compartment. Solutes 
such as urea, creatinine and phosphate diffuse from the patient’s blood into the 
dialyser, whereas solutes such as bicarbonate and/or calcium move from the dialysis 
fluid into the blood stream (Figure 1-5). 
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Figure 1-5: Solute and fluid movement within the dialyser 
Modern dialysers have been developed which contain larger pores (high-flux 
dialysers) which allow larger uraemic solutes such as β2-microglobulin to be 
removed. β2-microglobulin is a product of normal cell turnover and accumulates in 
renal failure. It is not removed efficiently by low-flux dialysers and cellulose dialysis 
membranes. Dialysis-related amyloid – a disabling condition, is caused by the 
accumulation and polymerisation of β2-microglobulin within tendons, synovium, 
osteoarticular sites and in other organs. The routine use of high-flux dialysers have 
been recommended since the publication of two landmark clinical trials (HEMO and 
MPO study) (Cheung et al. 2003; Locatelli et al. 2009) showed that treatment with 
high-flux dialyser membranes improved survival in patients with hypoalbuminemia or 
had been on dialysis for longer than 3.7 years. Removal of larger uraemic solutes (or 
middle molecules) can be enhanced by the addition of a prescribed convective 
component to standard high-flux haemodialysis, also known as haemodiafiltration 
(HDF). In this procedure, between 12-25L of fluid is removed from the patient using a 
haemodiafiltration pump and replaced with substitution fluid. The development of 
purification techniques to produce cheap ultrapure dialysis fluid on-line, has allowed 
HDF to become a viable routine therapy for kidney failure (Canaud & Lertdumrongluk 
2012). 
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1.6 Outcomes for dialysis patients 
Despite significant advances in many aspects of dialysis therapy, patient outcomes 
and survival remain poor. Studies of large US registry data sets show that following 
dialysis initiation, expected remaining lifespan is approximately 8 years for patients 
aged 40-44, for those initiating between aged 60-64 years expected remaining life 
span is 4.5 years (Collins et al. 2010), comparable to cancer patients with 
metastases. Risk factors for poor survival can be separated into dialysis and non-
dialysis related (Table 1-2).  
Non-dialysis related Dialysis related 
Increased co-morbidity  Inadequate delivered dialysis dose 
Hypertension Excess ultrafiltration rates 
(>10mL/kg/hour) 
Diabetes mellitus Inadequate ultrafiltration and volume 
overload 
Elevated calcium-phosphate product Use of bio-incompatible haemodialysis 
membranes 
Underlying renal disease  
(reduced survival with diabetic 
nephropathy) 
Use of tunnelled dialysis catheters  
Elderly  
Caucasian ethnicity  
(lower mortality rates observed in 
Asian/Blacks compared to Caucasian 
 
Poor nutrition  
Lack of residual renal function  
Presence of inflammation  
Poor compliance with dialysis  
 
Table 1-2 – Dialysis and non-dialysis related risk factors associated with reduced survival in 
dialysis patients 
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The most common cause of death in the dialysis population is cardiovascular 
disease (Kalantar-Zadeh et al. 2006) despite adjustments for age, gender, race and 
diabetes suggesting that dialysis patients are more susceptible to accelerated 
atherosclerosis (Lindner et al. 1974). Traditional Framingham cardiovascular risk 
factors are more common in patients with end-stage kidney disease (ESKD), 
however they do not completely account for the high cardiovascular morbidity 
(Cheung et al. 2000). Furthermore, there is an inverse relationship between some 
conventional cardiovascular risk factors such as cholesterol and obesity with 
mortality (Liu et al. 2004; Kalantar-Zadeh et al. 2005). Non-traditional factors such as 
inflammation are increasingly recognised to be additional important factors. The 
prevalence of elevated inflammatory biomarkers and the realisation of their close 
association with poor outcomes in 1990s established inflammation as a non-
traditional risk factor for patients with ESKD (Carrero & Stenvinkel 2010). 
   
1.7 Inflammation in end-stage kidney disease 
Chronic inflammation is a highly prevalent condition in patients treated with 
haemodialysis and peritoneal dialysis. Between 30-50% of dialysis patients have 
evidence of elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) 
and C-reactive protein (CRP) which are not related to systemic infection (Yeun et al. 
2000; Zimmermann et al. 1999; Herbelin et al. 1991; Stenvinkel & Alvestrand 2002). 
Inflammation in ESKD has been linked with a number of problems including 
increased cardiovascular mortality and protein energy wasting. The term 
Malnutrition-Inflammation Complex Syndrome (MICS) has been used to describe 
patients who exhibit this complicated syndrome and exhibit poor prognostic 
outcomes (Kalantar-Zadeh et al. 2003). Pro-inflammatory cytokines may directly 
cause anorexia via its influence on the brain leading to reduced oral intake and 
malnutrition. Inflammation can also lead to increased resting energy expenditure via 
the suppression of anabolic hormones including insulin growth factor-1 and 
testosterone (Akchurin & Kaskel 2015). 
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Other adverse consequences of inflammation includes anaemia and resistance to 
erythropoietin treatment via multiple mechanisms including suppression of 
production and stimulatory activity by erythropoietin and disruption of iron 
metabolism by increasing production of hepcidin. TNF-α is a potent inducer of NF-kB 
ligand (RANKL), which triggers osteoclast activation and bone resorption and is 
associated with incident fractures in dialysis patients. IL-6 and IL-1 may also 
suppress PTH production and it has been suggested in some patients, low PTH may 
reflect MICS rather than low bone turnover  disease (Akchurin & Kaskel 2015). 
 
Figure 1-6: Causes and consequences of inflammation in kidney disease (adapted from 
Akchurin et al, 2015) 
 
Despite the prevalence of inflammation in patients with kidney disease and the large 
body of evidence which describes this phenomenon, chronic inflammation remains a 
poorly understood syndrome. This issue is further complicated due to the lack of 
consensus on how to define inflammation. CRP is the most commonly reported 
inflammatory biomarker in studies due to its widespread availability and is produced 
by hepatocytes in response to elevated IL-6 levels in the setting of acute 
inflammation.  It is considered a prominent marker of cardiovascular mortality in the 
general population and in CKD patients. However the optimal CRP ‘cut-off’ point to 
diagnose inflammation remains unclear (KDOQI Workgroup 2005).  
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1.7.1 Other biomarkers of inflammation in kidney disease 
IL-6 is a pro-inflammatory cytokine secreted by numerous cell types during an acute 
inflammatory response. It stimulates the production of CRP from hepatocytes and 
other acute-phase reactants.  Studies in haemodialysis patients show that IL-6 is the 
most accurate prognostic marker compared to CRP, tumour necrosis factor alpha 
(TNF-α) and vascular cell adhesion molecules (VCAM-1) and intracellular adhesion 
molecule-1 (ICAM-1) (Tripepi et al. 2005; Pachaly et al. 2008). 
TNF-α is traditional pro-inflammatory cytokine originally associated with killing of 
tumour cells. Together with IL-6 it is elevated in most, if not all inflammatory states 
and has been recognised as a target of therapeutic intervention (Scheller et al. 
2011). TNF-α regulates both pro- and anti-inflammatory cytokine and provides rapid 
host defence against infection but can be fatal in excess (Panichi et al. 2012). TNF-α  
levels are linked with increased risk of coronary artery disease (Mendall et al. 1997) 
and are well reported to be consistently up-regulated in ESKD patients (Panichi et al. 
2012). 
Recently discovered biomarkers such as pentraxin 3 (PTX-3) and soluble tumor 
necrosis factor-like weak inducer of apoptosis (TWEAK) have attracted interest in 
uraemic inflammation (Alles et al. 1994). PTX-3 is an acute phase protein produced 
in the vasculature by numerous cell types including macrophages, fibroblasts, 
endothelial cells, neutrophils and dendritic cells and is considered to be a promising 
inflammatory biomarker. It is released rapidly from neutrophil granules in response to 
microbial challenge or an inflammatory stimulus making it a more sensitive marker of 
early inflammation than CRP. PTX-3 levels increased significantly post 
haemodialysis compared to CRP and IL-6 suggesting that the haemodialysis 
procedure itself may play a significant role in inducing a chronic inflammatory state 
(Sjöberg et al. 2012).  PTX levels are increased in CKD and haemodialysis patients 
and strongly predict cardiovascular and all-cause mortality independent of CRP 
levels (Tong et al. 2007).  
TWEAK is a member of the TNF superfamily which mediates its effect via the Fn14 
receptor (fibroblast growth factor inducible-14) by inducing an inflammatory and 
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muscle wasting response (Rietschel et al. 1994).  TWEAK participates in 
inflammatory reactions with other cytokines in the renal tubules. IL-6 and TWEAK 
levels are associated with increased risk of mortality and muscle wasting in HD 
patients (Carrero et al. 2009).   
 
Overall, the definition of chronic inflammation in ESKD patients requires clarification 
although IL-6 and CRP appear to be the most useful biomarkers. It remains unclear 
whether inflammation causes vascular injury or is a consequence of vascular injury 
itself, although there is evidence to suggest that inflammatory biomarkers IL-6 and 
CRP are not simply markers of inflammation but also mediators of atherosclerosis 
(Paffen & deMaat 2006). High-sensitivity CRP in the general population is able to 
accurately predict future cardiovascular risk independent of cholesterol, Framingham 
coronary risk score, blood pressure and in individuals with and without subclinical 
atherosclerosis (Bassuk et al. 2004).  
Chronic inflammation in the ESKD population is a significant clinical problem and 
targeted anti-inflammatory interventions are currently not available, increasing 
knowledge and understanding of the pathophysiology could potentially facilitate 
development of anti-inflammatory strategies to improve quality of life and survival in 
dialysis patients.  
1.7.2 Causes of inflammation in ESKD 
The underlying mechanism of chronic inflammation remains to be elucidated but 
several patient and dialysis-related factors have been proposed. 
1.7.2.1 Reduced kidney function and the uraemic milieu  
Deteriorating kidney function per se may contribute to increased inflammation due to 
reduced clearance of pro-inflammatory cytokines. Although the relationship may be 
bi-directional as inflammation itself may drive loss of GFR (Guessous et al. 2014). 
Renal failure in animal models induced by nephrectomy leads to a rapid rise in TNF-
α due to decreased clearance (Bemelmans et al. 1993). Studies in humans show 
that urinary excretion of soluble IL-6 receptor is reduced in CKD patients compared 
to healthy controls, yet the ability to release soluble IL-6 receptor from monocytes 
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are similar in both CKD patients and controls suggesting that elevated plasma levels 
of soluble IL-6 receptor is due to reduced renal excretion rather than increased 
generation (Memoli et al. 2000). Bolton et al found that in multiple regression 
analysis serum creatinine is the sole determinant of plasma IL-6 level in pre-dialysis 
and dialysis patients (Bolton et al. 2001). In patients with ESKD treated with 
peritoneal dialysis, inflammatory markers such as CRP are closely associated with 
the level of residual renal function (RRF) (Chung et al. 2001). Reduction of kidney 
function also leads to reduced clearance and subsequent retention of advanced 
glycosylation end (AGE) products and pro-oxidants contributing to a pro-
inflammatory milieu. Uraemia itself also leads to increased carbamylation of proteins 
such as LDL and carbamylated proteins have greater capacity to inflict endothelial 
damage and initiate atherosclerotic plaques contributing to the pathogenesis of 
atherosclerosis (Ok et al. 2005). The retention of uraemic solutes in kidney failure 
increases the availability of substrates for oxidative injury. For example, the 
accumulation and increased availability of β2-microglobulin in kidney disease, leads 
to progressive oxidation and glycosylation by AGE products contributing to the 
acidification of β2-microglobulin. Isoforms of β2-microglobulin with a more acidic 
isoelectric point are recognised as a component of amyloid deposits in dialysis 
patients. In addition, AGE-modified β2-microglobulin binds to AGE receptors on 
monocytes triggering their activation, cytokine production and further reactive oxygen 
species formation (Himmelfarb et al. 2002). The pro-oxidative environment in dialysis 
patients is further compounded by the reduced oral intake of some types of 
antioxidants such as vitamin C (Kalantar-Zadeh et al. 2002). 
1.7.2.2 Patient-related factors 
A number of patient-related factors may contribute to the persistent inflamed stated 
in ESKD patients. Certain underlying renal conditions which may have been the 
original cause of kidney disease such as systemic lupus erythematous or amyloid 
disease may act as a persistent driver of inflammation. Development and 
progression of other conditions such as cardiac ischemia, peripheral vascular 
disease and chronic diabetic ulcers may also have a similar impact.  
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Genetic factors are also likely to play a role due to the observation that the mortality 
risk is higher in Caucasian ethnic groups than Asian groups amongst US-based 
dialysis patients (Wong et al. 1999).  Black ethnicity also confers a survival 
advantage in UK dialysis patients despite greater deprivation and co-morbidity 
scores (Cole et al. 2014). Frequency of single nucleotide polymorphisms in the CRP 
gene that are associated with increased plasma level of CRP are two-fold higher in 
Caucasians than Blacks (Szalai et al. 2002). Whereas single nuclear polymorphisms 
in the gene for the anti-inflammatory cytokine IL-10 that are associated with 
decreased production for IL-10 are found in those with increased inflammation and 
cardiovascular morbidity (Girndt et al. 2002). 
Periodontitis has also been proposed as an occult source of inflammation in the 
haemodialysis population (Kadiroglu et al. 2006). Periodontal disease is a spectrum 
of inflammatory disease affecting the tooth-supporting structures.  The disease 
begins with the adherence of a bacterial biofilm on the surfaces of the teeth resulting 
in gingivitis which can be reversible if the biofilm is removed (Schaudinn et al. 2009).  
The disease can progress leading to destructive periodontitis and tooth loss.  
Periodontal disease is more prevalent in CKD population (Dye et al. 2007) and a 
recent review has found an association between periodontitis in haemodialysis 
patients with inflammation and malnutrition (Akar et al. 2011). Moderate to severe 
periodontitis results in systemic inflammation with elevated levels of pro-
inflammatory cytokines and CRP (Loos 2005; Pradeep et al. 2011). Treatment of 
periodontal disease reduces the levels of inflammatory biomarkers in dialysis 
patients (Siribamrungwong & Puangpanngam 2012). However it remains unclear if 
periodontitis causes inflammation or whether chronic inflammation predisposes 
patients to periodontitis (Kadiroglu et al. 2006). The underlying mechanism is unclear 
but maybe mediated via endotoxemia (Geerts et al. 2002) (see). 
1.7.2.3 Dialysis-related factors  
The dialysis procedure itself can contribute to the chronic inflammatory state seen in 
ESKD patients. The use of dialysis catheters in the haemodialysis population is 
associated with an elevated inflammatory response even in the absence of infection 
(Sabry et al. 2014). Clotted arterio-venous grafts and catheters may harbour chronic 
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or subclinical infection due to biofilm formation. Conversion of haemodialysis 
catheters to fistulas lead to significant reduction in CRP level in incident patients 
compared to those who continue to rely on catheters for haemodialysis (Goldstein et 
al. 2009).  
Contaminated dialysis fluid may be a potential source of inflammation. Although 
dialysis membranes are impermeable to bacteria, soluble pyrogenic bacterial 
products such as endotoxins may penetrate the dialysis membrane and enter the 
blood stream activating monocytes and inducing cytokine production. Endotoxins are 
fragments of bacterial cell wall which are thought to be able to cross the dialysis 
membrane via back-filtration (Panichi et al. 1998). This hypothesis is further 
supported by the observation that using ultrapure dialysis fluid significantly reduce 
IL-6 and CRP levels (Schiffl et al. 2001). UK and European guidelines have 
advocated the routine use of ultrapure dialysis fluid which may reduce the 
prevalence and impact of dialysis fluid contamination (European Best Practice 
Guidelines 2002).  Ultrapure dialysis fluid is produced by treating water with reverse 
osmosis and passing the treated water through a series of filters, the ultrapure water 
is then mixed with the desired acid and bicarbonate concentrate to obtain ultrapure 
dialysis fluid that can be safely infused directly into the patient in high volumes. 
Water quality meets strict criteria as set by the European Best Practice Guidelines 
(EBPG) and Association for Advancement of Medical Instrumentation (AAMI) to 
avoid delivering any pyrogenic or inflammatory stimulus to the patient.  Ultrapure 
dialysis fluid must contain <0.1 colony-forming units (CFU)/ml and <0.03 endotoxin 
units (EU)/ml (Canaud & Lertdumrongluk 2012).  
Repeated exposure of blood to artificial membranes, in particular to bio-incompatible 
membranes made by cuprophane, may activate neutrophils and complements and 
maintain a chronic inflammatory state. Some studies suggest use of biocompatible 
membranes help to decrease inflammatory status (Schindler et al. 2000). Similarly 
for peritoneal dialysis patients, the use of bio-incompatible dialysis fluid may also 
contribute to systemic inflammation, in particular use of very high glucose 
concentration dialysis fluid may increase oxidative stress due to the presence of 
glucose degradation products (Yao et al. 2004).  
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For haemodialysis patients, the gastrointestinal tract has been proposed as another 
source of endotoxins or bacterial products that may lead to chronic inflammation. 
Haemodialysis patients are subject to recurrent episodes of volume overload due to 
oral fluid intake and accumulation during the inter-dialytic period, during 
haemodialysis, excessive ultrafiltration may be utilised to remove the accumulated 
fluid. Gut oedema and ischemia induced by this cycle of volume accumulation and 
depletion may lead to bacterial endotoxin and fragment translocation through the gut 
barrier activating signals to release pro-inflammatory cytokines (Hauser et al. 2011). 
Endotoxemia represents an attractive therapeutic target, recently endotoxin 
extracorporeal methods have been developed for use in the intensive care setting to 
treat severe sepsis with some success reported in terms of improved surrogate 
markers such as inotrope use and haemodynamic stability (Klein et al. 2014). It is 
possible that such methods could be applied during haemodialysis to reduce 
endotoxin burden to improve clinical outcomes. However the association between 
endotoxemia and inflammation requires confirmation before embarking on 
interventional trials since there are significant limitations with current blood endotoxin 
detection methods and interpretation of conclusions drawn from endotoxin literature 
in the dialysis population requires caution (see Chapter 2 – Endotoxemia in end-
stage kidney disease).   
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 Chapter 2 
2. Endotoxemia in end-stage kidney disease 
 
Endotoxins are complex lipopolysaccharides that are found in the outer cell wall of all 
gram negative bacteria (Figure 2-1). The terms lipopolysaccharide (LPS) and 
endotoxin are often used interchangeably.  
 
Figure 2-1: Schematic diagram showing endotoxin embedded in the cell wall of gram negative 
bacteria (reproduced with permission – Wong et al 2014, Seminars in Dialysis) 
LPS refers to the purified form used as standards in commercial endotoxin detection 
assays (Williams 2007). Endotoxins are large molecular structures varying from 10 to 
1000 kDa consisting of a lipid A antigen attached to a carbohydrate core and 
polysaccharide O antigen (Figure 2-2).   
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Figure 2-2: Schematic diagram of endotoxin structure (reproduced with permission Wong et al 
2014, Seminars in Dialysis) 
 
Endotoxins are implicated in the pathogenesis of sepsis, especially with gram 
negative infection. They can activate a systemic inflammatory reaction by triggering 
complement, coagulation, fibrinolytic, and kinin pathways to release vasoactive 
peptides and cytokines from monocytes, neutrophils and vascular endothelial cells 
(Ostro 2013; Hurley 1995). Nearly all these effects are mediated through the lipid A 
region. 
2.1 Endotoxin and inflammation 
Endotoxemia was initially proposed as a cause of chronic inflammation in patients 
with congestive heart failure (Anker et al. 1997), as treatment of this condition with 
diuretics resulted in significant reduction in levels of inflammatory mediators and 
blood endotoxin concentration (Niebauer et al. 1999). Proposed molecular 
mechanisms for the endotoxin-activated inflammation include the production of pro-
inflammatory cytokines such as tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1) 
and interleukin (IL-6) following the activation of the CD14/Toll-like receptor 4 (TLR4) 
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complex found on monocytes and macrophages by the lipid A region of endotoxin 
(Heumann & Roger 2002; Genth-Zotz et al. 2002).  
Activated TLR4 complex stimulates the translation and production of cytokines via 
transcriptional nuclear factor k-light chain enhancer of activated B cells (NF-kB) 
(Figure 2-3) (Hauser et al. 2011). The extent of TLR4 activation is dependent on the 
chemical configuration of the lipid A moieties such as the number of secondary acyl 
chains and the number and position of phosphate groups. The chemical 
configuration varies in different species of bacteria, hence the immunogenic potential 
may differ depending on the bacterial origin of the endotoxin (Gnauck et al. 2016).  
 
Figure 2-3: Proposed molecular signalling of endotoxin (reproduced with permission Wong et 
al 2014, Seminars in Dialysis) 
LPS, lipopolysaccharide; LPS/LBP, lipopolysaccharide binding protein complex; TNF, tumour necrosis 
factor; PAF, platelet-activating factor; IL, interleukin; TLR, toll-like receptor; NF-κβ, nuclear factor- κβ 
Experimentally-induced uraemia in the rat model is associated with elevations in 
blood endotoxin concentration and inflammatory cytokines such as TNF-α (Hauser et 
al. 2010). The association of endotoxemia with inflammatory biomarkers has been 
described in both haemodialysis (El-Koraie & Naga 2013; Christopher McIntyre 
2011; Terawaki et al. 2010) and peritoneal dialysis patients (Szeto et al. 2010; Kwan, 
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Chow, Leung, et al. 2013). Other circulating bacterial products such as bacterial 
DNA fragments have also been associated with inflammation (Bossola et al. 2009; 
Kwan, Chow & Leung 2013; Wang, Jiang, et al. 2012).  
 
2.2 Potential sources of endotoxemia 
2.2.1 : Contamination of haemodialysis apparatus and devices 
Patients with chronic kidney disease and especially those on haemodialysis have 
multiple potential sources for endotoxemia.  It is well known that patients who dialyse 
with tunnelled dialysis catheters have higher rates of infection-related morbidity than 
patients with arteriovenous fistulas and grafts, due to the formation of bacterial 
biofilm which are potential sources of persistent bacteraemia and endotoxin 
(Dasgupta 2002).  Biofilm formation may also occur in fluid pathways of dialysis 
machines and sloughing of bacterial biofilm resulting in bacteraemia and 
endotoxemia has been described (Dasgupta 2002). With the advent of high flux 
dialysis, haemodiafiltration and the increasing use of bicarbonate containing 
dialysates which can support rapid bacterial growth (Oliver et al. 1992), there is a 
concern that cytokine-inducing substances, such as endotoxin may transfer across 
the dialysis membrane by convective transfer (back-filtration) or down a 
concentration gradient (back diffusion) (Glorieux et al. 2012). In-vitro and in-vivo 
studies have demonstrated that endotoxin transfer into blood compartments is much 
higher with high-flux than low-flux membranes (Henrie et al. 2008; Vanholder et al. 
1992). Although a significant proportion of endotoxins are adsorbed onto the dialysis 
membrane, there is evidence to suggest that they are still capable of activating 
monocytes and macrophages (Tsuchida et al. 2004). There have been no studies on 
the differential impact of standard haemodialysis versus haemodiafiltration on 
endotoxin influx or clearance. Due to the added convective element of 
haemodiafiltration, endotoxin influx could be increased due to the increased volumes 
of substitution/dialysis fluid infused into patients, conversely haemodiafiltration could 
have a beneficial effect of increasing clearance of endotoxins and other relevant 
molecules such as pro-inflammatory cytokines from the blood circulation. 
27 
 
More rigorous guidelines for dialysate water purity have been implemented over the 
last 2 decades. Ultrapure dialysis fluid must have <0.1 colony forming units per mL 
(CFU/mL) and <0.03 endotoxin units per mL (EU/mL) according to the international 
guidelines (International Organization for Standardization 2014). However, patients 
on haemodiafiltration can receive convective volumes of up to 25L per session. If 
substitution fluid was contaminated with 0.029 EU/ml, this would meet the 
requirement for microbiological purity but patients could theoretically still receive a 
significant dose of endotoxin over 700 EU with each dialysis session or 
approximately 180 EU/hour. It has been established that 5 EU/kg/hour or 350 
EU/hour in a healthy 70kg adult is sufficient to induce pyrogenic symptoms such 
rigors, fever and nausea (Greisman & Hornick 1969). Recent studies have found that 
switching patients to ultrapure dialysate resulted in reduction of plasma endotoxin 
levels (Kwan & Szeto 2013). In a separate study, the proportion of patients with 
significant endotoxemia reduced from 17% to 9% after switching from standard to 
ultrapure dialysate. Efforts to reduce patient exposure to bacterial contamination and 
exogenous endotoxin should be focused on increasing the use of arteriovenous 
fistulas and increasing microbiological quality of dialysis fluid with regular testing, 
disinfection of haemodialysis systems to detach biofilms (Ledebo & Nystrand 1999; 
Man et al. 1998) and installation of ultra-filters in the dialysis circuit (Lonnemann 
2004). Given the increase in use of haemodiafiltration which increases water 
exposure to patients, it may be necessary to consider reducing the threshold 
tolerated endotoxin contamination from <0.03 EU/ml to <0.001 EU/ml as currently 
practiced in Japan (Kawanishi et al. 2009). 
2.2.2 : CKD and the leaky gut 
The gastrointestinal tract has a huge reservoir of bacteria which may be a significant 
source of endotoxemia in patients with CKD.  The gut flora is altered in uraemia with 
evidence of heavy bacterial colonisation of the duodenum and jejunum which are 
normally not colonised (Simenhoff et al. 1978). This is of particular importance given 
that there are numerous animal and in-vitro studies showing increased intestinal 
permeability documented by the penetration of polyethylene glycols of different 
molecular weights across the intestinal wall in uraemic rats. Bacterial translocation 
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from the gut into mesenteric lymph nodes, liver and spleen in experimental uraemia 
has also been shown (Wang, Zhang, et al. 2012). This suggests that translocation of 
bacterial products or endotoxins may occur in uraemia.  Studies from the cardiology 
literature have demonstrated elevated levels of endotoxins and markers of 
inflammation in patients with congestive heart failure (Niebauer et al. 1999) possibly 
due to the effect of increased gut permeability caused by an oedematous bowel wall 
(Sandek & Bauditz 2007). Invasive assessment of patients with acute heart failure 
have documented higher concentrations of active lipopolysaccharide in the hepatic 
vein than the left ventricle, suggesting intestinal origin of endotoxemia (Peschel et al. 
2003). In addition to gut oedema, intestinal ischemia may play a significant role given 
the vulnerability of villous tips to ischemia and hypoxia (Riddington et al. 1996; 
Takala 1996) that occurs when blood flow is shunted away from the splanchnic 
region in heart failure (Parks & Jacobson 1985). Mucosal ischemia has been 
reported in patients on haemodialysis (Diebel et al. 1993) and ultrafiltration also 
reduces splanchnic blood volume (Yu et al. 1997). It is hypothesised that bacterial 
translocation across the gut wall could also be occurring in haemodialysis patients 
who frequently experience large blood volume changes during dialysis. McIntyre et 
al found that circulating levels of blood endotoxins rose markedly on initiation of 
haemodialysis (Christopher McIntyre 2011). But currently, there is lack of direct 
evidence of intestinal bacterial translocation in dialysis patients (Ritz 2011).   
2.2.3 : Periodontal disease and endotoxemia 
Periodontal disease embraces a spectrum of inflammatory disease affecting the 
tooth-supporting structures. The disease begins with the adherence of a bacterial 
biofilm on the surfaces of the teeth resulting in gingivitis which is potentially  
reversible on removal of the biofilm (Schaudinn et al. 2009). The disease can 
progress leading to destructive periodontitis and tooth loss. Periodontal disease is 
prevalent in CKD population (Dye et al. 2007) and a recent review found an 
association between periodontitis in haemodialysis patients with inflammation and 
malnutrition (Akar et al. 2011). Plaque samples from healthy individuals consist of 
mainly gram positive aerobic bacteria. With worsening severity of periodontal 
disease, there is a shift towards increasing numbers of gram negative anaerobic 
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species such as Actinobacillius actinomycetemcomitans, Campylobacter rectus and 
Porphyromonas gingivalis. In the non-CKD population, high antibody titres to 
periodontal pathogens was associated with high endotoxin levels and increased 
hazard risk for cardiovascular disease (Pussinen et al. 2007). Endotoxin levels 
increase after gentle mastication in patients with periodontitis (Geerts et al. 2002).  It 
is likely that chronic periodontal disease is a significant contributor to endotoxemia 
and inflammation in dialysis patients. Aggressive dental treatment of periodontitis 
reduces levels of high-sensitivity C-reactive protein in peritoneal dialysis patients 
(Siribamrungwong et al. 2013). Chronic periodontitis is associated with increased 
mortality in haemodialysis patients (de Souza et al. 2013), although whether 
aggressive treatment would improve long term outcome requires investigation. 
2.3 Problems with interpreting level of endotoxemia in the dialysis population 
Reported concentrations of blood endotoxin in both healthy and ESKD populations 
vary significantly with some studies detecting significant endotoxemia in only a small 
number of patients (Gnauck et al. 2016). In the CKD population, although most 
studies report a high prevalence of endotoxemia in dialysis population, there is  
inconsistency in the literature with some studies detecting endotoxemia in only a 
small proportion of patients (Markum 2004; Taniguchi et al. 1990), (Table 2-1). This 
is further complicated by the expression of endotoxin concentration in different units 
– usually in either weight or endotoxin units (EU).  Both of these issues make clinical 
interpretation of endotoxin levels difficult (Table 2-1). 
  
30 
 
Reference Population Method of endotoxin 
detection used 
Reported mean or 
median endotoxin 
concentration 
(Suzuki & Honda 2011) HD LAL turbidimetric 
 
 
 
Endotoxin Activity Assay (EAA) 
Detectable endotoxaemia 
in 8/58 patients (0.9-1.0 
pg/ml) 
 
0.17+/-0.11 to 0.45+/-0.16 
EAA units 
 
(Markum 2004) HD LAL chromogenic 4.63 pg/dL to 5.4 pg/dL 
 
(Christopher McIntyre 
2011) 
HD, PD, CKD LAL chromogenic PD - 0.56 EU/ml 
 
HD - 0.64 EU/ml 
 
CKD v - 0.11+/-0.68 EU/ml 
 
(El-Koraie & Naga 2013) HD LAL gel-clot assay 76.3+/-42.09 pg/ml 
 
(Szeto et al. 2010) PD LAL chromogenic 0.7 +/- 0.3 EU /ml 
 
(Kwan, Chow, Leung, et 
al. 2013) 
PD LAL chromogenic 1.95 +/- 0.63 EU/ml 
 
(D. Raj et al. 2009) HD LAL chromogenic 0.65 EU/ml 
 
(Terawaki et al. 2010) HD Endotoxin Scattering Photometry 0.23-0.37 pg/ml 
 
 
(Taniguchi et al. 1990) HD LAL chromogenic Significant endotoxemia 
detected in 6/87 patients 
 
Mean 27.6pg/ml 
 
(Kwan & Szeto 2013) HD LAL chromogenic 0.209+/-0.044 EU/ml 
 
(Szeto et al. 2008) PD , CKD, 
controls 
LAL chromogenic 
 
 
PD – 0.44+/-0.18 EU/ml 
 
CKD – 0.035+/-0.009  
EU/ml 
 
Control – 0.013 +/- 0.00 
EU/ml 
 
Table 2-1: Published levels of endotoxemia detected in dialysis patients. 1EU 
equates approximately to 100-120pg/ml depending on bacterial source (Stadlbauer et 
al. 2007) 
It is recommended that endotoxin concentration should be reported in endotoxin 
units (EU) rather than expressing the weight of endotoxin as a unit of measurement 
(Outschoorn 1982). This is because the potency of control standard endotoxins used 
in the LAL assay to generate the standard curve differs between manufacturers 
therefore expressing blood endotoxin levels in terms of weight makes it difficult to 
interpret. The potency of standard endotoxins are expressed in relation to a single 
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historical reference standard endotoxin derived from E.coli (EC-2) established by the 
United States Pharmacopoeia (Williams 2007). Earlier studies demonstrated that 
injecting 1ng/kg of EC-2 could trigger a pyrogenic response in man (Greisman & 
Hornick 1969). Therefore, one EU was defined as one-fifth of the amount of 
Escherichia coli (EC-2) endotoxin required to bring about a pyrogenic reaction in 
humans and reporting in EU is recommended since it reflects endotoxic activity of a 
sample relative to a reference standard endotoxin which would allow comparison of 
assay results obtained from different manufacturers.  
Although the vast majority of endotoxin studies in the dialysis population report 
detectable endotoxemia in apparently clinically stable non-infected dialysis patients, 
the levels reported appear unusually high, ranging from 0.209 to 1.95 EU/ml, which 
exceeds the pyrogenic threshold since it is well established that as little as 4.1-5 
EU/kg/hr is sufficient to trigger symptoms such as fever and hypotension in man 
(Greisman & Hornick 1969) (equivalent to approximately 0.12 EU/mL in an average 
man weighing 70kg with an average plasma volume of 3L).  
Several issues remain unclear: - 
 Why do levels of endotoxemia in the dialysis population vary so widely? 
 Why do studies report such apparently high levels of blood endotoxin in stable 
dialysis patients that exceed the pyrogenic threshold? 
 Why are some studies unable to detect endotoxemia in a significant 
proportion of their study cohort? 
If elevated blood endotoxin levels were a true and consistent phenomenon in the 
dialysis population it is unclear whether blood endotoxin level is persistently or only 
transiently elevated and the primary source of endotoxemia is unclear. In addition, it 
is unknown whether circulating endotoxemia directly contributes to unexplained 
inflammation that are commonly seen in dialysis patients since not all studies report 
an association between endotoxemia and inflammatory biomarkers (Gonçalves et al. 
2006). The conflicting data and literature reported may partly be due to 
methodological issues with the detection assays used to measure blood endotoxins 
– specifically the Limulus Amoebocyte Lysate (LAL) assay (see section 3.1). Before 
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embarking on interventional trials to examine the efficacy of endotoxin-lowering 
therapies it is important to clarify the phenomenon of endotoxemia in haemodialysis 
patients and to examine the reported associations with inflammation  
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 Chapter 3 
3. Methods of blood endotoxin detection 
 
The first method approved by the US Food and Drug Administration for endotoxin 
detection was the rabbit pyrogen test. This method was developed in the 1920s, and 
its basis was intravenous injection of a test solution into rabbits which were 
monitored for a rise in body temperature. Rabbits have similar endotoxin tolerance to 
humans and a rise in body temperature is used to indicate the presence of significant 
amounts of pyrogens or endotoxin in the injected test solution. This method was 
expensive and time consuming and was gradually replaced by the Limulus 
Amoebocyte Lysate (LAL) assay. Due to its high sensitivity and ability to quantify 
endotoxins, the LAL assay has been the most extensively used and researched 
method in blood endotoxin detection (Novitsky 1994).    
3.1 The Limulus Amoebocyte Lysate Assay 
During the 1960s, Levin and Bang observed that Limulus Polyphemus, the 
horseshoe crab, suffered from disseminated intravascular coagulation when infected 
with gram negative bacteria. In-vitro work demonstrated that this coagulation 
reaction was due to endotoxin-initiated activation of a cascade of enzymes present in 
primitive cells, called amoebocytes found in the haemolymph of the horseshoe crab 
(Young et al. 1972). The diagnostic potential of this reagent was realised and a 
purified enzyme system was produced that could be activated by picograms of 
endotoxin. The principle of the LAL assay is based on a gelation reaction resulting in 
the formation of a clot, following activation of a cascade of enzymes by endotoxin 
(Figure 3-1). 
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Figure 3-1: The LAL enzyme cascade (Wong et al 2014, reproduced with permission from John 
Wiley and Son publisher) 
 
Early attempts to detect endotoxins in substances using the gel clot assay involved 
incubating a test sample with LAL in an assay tube and then inverting the tube to see 
if the solution had clotted to form a firm gel. This method could only quantify 
endotoxin semi-quantitatively and is rarely used in practice, photometric methods 
such as the end-point and kinetic LAL assays are more commonly used.  
3.1.1 End-point LAL assay 
The end-point technique is an earlier photometric method used to measure and 
quantify endotoxin. The LAL is incubated with the test sample and observed for a 
period of time (usually around 10 minutes) using a spectrophotometer with a 405-
410 nm filter, during this time the LAL reacts with endotoxin present in the sample 
activating the coagulation cascade and increasing the optical density of the mixture. 
The reaction is then stopped with stop reagents such as acetic acid and the optical 
density of the mixture is recorded. Samples with highest concentration of endotoxin 
react quickly and achieving the highest optical density by the end of the incubation 
period. A standard curve is constructed based on the optical density recorded at the 
end of the incubation period for dilutions of control standard endotoxin. The main 
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advantage of end-point techniques is that results can be obtained relatively quickly, 
however the disadvantages are that it relies on the user being present to stop the 
reaction of all the samples at the same time before reading. This may introduce 
some variability in results. Since the optical density is used to construct the standard 
curve, the end-point method has a narrow range of sensitivity, this range is generally 
about a factor of 10, commonly referred to as 1 log (e.g. 0.1 to 1 EU/mL) (Nema & 
Ludwig 2010). This is because for samples with high endotoxin content, the solution 
would have fully coagulated already by the end of the incubation, making it difficult to 
accurately distinguish between samples that have similarly high levels of endotoxin. 
In samples with low endotoxin, the reaction would not have started after such a short 
incubation period (usually around 10 minutes), therefore the end-point method is not 
sufficiently sensitive to detect very low concentration endotoxin. 
3.1.2 Kinetic LAL assays 
The kinetic LAL assay is a more recent photometric method. In this assay, the 
reaction between LAL and the test sample is observed with a spectrophotometer 
using an incubating microplate reader. As the reaction progresses, the mixture starts 
to coagulate and the turbidity and optical density of the solution progressively 
increases. The change in optical density over time is used to quantify the 
concentration of endotoxin present in the sample (Figure 3-2). 
 
Figure 3-2: Typical optical density graph obtained from a sample containing endotoxin 
 
An alternative method using the same LAL cascade is the kinetic chromogenic 
assay, which replaces the coagulogen component of the cascade with a synthetic 
36 
 
chromogenic substrate that is linked to p-nitroaniline. Activation of the cascade 
cleaves p-nitroaniline from the colourless substrate to release a yellow colour 
(Cohen 2000). Both turbidimetric and chromogenic LAL assays are routinely used for 
endotoxin detection. The rate of increase in turbidity or intensity of the yellow colour 
is directly proportional to the concentration of endotoxin in the sample.   
Both kinetic methods quantify the endotoxin content of samples either by using the 
‘onset reaction time’ (time taken for the optical density of a mixture to reach a critical 
optical density) or Vmax (the maximum velocity of the reaction calculated using the 
linear component of the optical density graph). Different parameters derived from the 
optical density graph have also been used to calculate the endotoxin content 
previously (Gnauck et al. 2016) (see next Chapter: Validation of endotoxin detection 
methods). The kinetic LAL assays have significant advantages over the end-point 
methods including the benefit of automaticity, which reduces the variation introduced 
by operator technique and it also has a greater range of sensitivity, being able to 
quantify results over several logs compared to one log with the end-point method.  
3.1.3 : Problems with the LAL assay for blood endotoxin detection 
The LAL assay is licensed for the testing of pharmaceutical products and dialysis 
fluid for contamination (Glorieux et al. 2012). Testing non-biological samples with the 
LAL assay is sensitive and specific for endotoxin detection but testing biological 
samples such as blood is much more difficult. Several inherent problems with the 
LAL assay and some specific issues relating to its use in blood testing exist therefore 
testing for endotoxin in blood with the LAL assay is not validated. Despite this, the 
LAL assay is the most commonly used blood endotoxin detection method.  
3.1.3.1 Inherent variability of the LAL assay 
The LAL test is a biological assay and is a lysate that is extracted from the osmotic 
lysis of amoebocytes found in the horseshoe crab. The extract is a crude mixture 
and not a single purified enzyme and consequently, significant batch-to-batch 
variation exists in the potency of lysates. Lysate potency is determined by testing 
each batch against reference standard endotoxin (RSE) usually in serial two-fold 
dilutions, therefore potency is not determined precisely and may lead to some 
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variation between different batches. However, RSE is expensive and is an 
exhaustible supply therefore manufacturers use control standard endotoxin (CSE), 
whose potency is determined against RSE for every lot of lysate which introduces 
another potential source of variation (Kumar 2006). 
3.1.3.2 Specific issues with collection and processing of blood samples 
Meticulous attention to specimen collection, handling and storage is important when 
obtaining blood samples for endotoxin testing with the LAL assay since multiple 
factors can influence the accuracy of the result (Hurley 1995). Blood samples should 
be taken under sterile conditions and collected in endotoxin-free tubes. The blood 
collection apparatus should not contain polypropylene which can adsorb endotoxins 
and significantly reduce detection. In haemodialysis patients, blood collection from 
central venous catheters should be avoided due to the high likelihood of introducing 
endotoxin contamination into the sample from bacterial biofilms. If plasma is used for 
testing, the choice of anticoagulant used to obtain plasma is important.  Heparin is 
commonly used but doses as low as 10 IU/ml can be inhibitory to the LAL assay 
(Sturk et al. 1985). In addition, since heparin is derived from animal products, there 
is a risk of introducing endotoxin contamination into test samples. If EDTA is used as 
an anticoagulant this may cause sequestration of divalent cations which are 
necessary for optimal LAL enzyme activity. Cations may need to be added to 
compensate for the inhibition by EDTA (Dawson 2005). Processing time is also 
important since endotoxin is rapidly inactivated in untreated plasma. Samples should 
be collected and processed rapidly on ice, then frozen to preserve the stability of 
endotoxin (Hurley 1995). Additionally, a low centrifugal force should be used to 
obtain platelet-rich plasma since endotoxin can be bound to platelets (Peek et al. 
2004; Salden & Bas 1994). Thus, it is clear that the method of blood collection for 
endotoxin measurement and sample storage requires due consideration to avoid 
interference with the LAL assay, for many published studies of endotoxemia in the 
dialysis population it is unclear whether these pre-analytical factors have been 
considered.  
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3.1.3.3 Specific problems with measuring endotoxin in blood 
Components found in serum or plasma are known to affect the sensitivity of the LAL 
assay. The identity of many of these factors remain unknown but studies suggest 
that proteins in blood such as serine proteases (e.g. thrombin, plasmin) and serine 
protease inhibitors (e.g. anti-plasmin and anti-thrombin III) are components within 
blood that may non-specifically activate or inhibit the LAL assay (Fields 2006; Levin 
et al. 1970). The interaction between endotoxin and components of plasma and 
serum is complex. Components of plasma such as bile salts, proteins and 
lipoproteins can lead to binding and the formation of complexes or micelles resulting 
in the hydrophobic lipid A being ‘hidden’ from the aqueous environment, preventing 
its detection (Hurley 1995; Wang & Quinn 2010; Sandek et al. 2007). Endotoxin may 
also be removed from the blood by a number of different immune mechanisms 
including sequestration by immunoglobulins, antibacterial peptides such as bacterial 
permeability increasing protein, detoxification by macrophages via deacylation and 
binding by LPS-binding protein (LBP) leading to its transfer to HDL and other 
systemic lipoproteins (Gnauck et al. 2016). For dialysis patients, the effect of high 
level of uraemic solutes on the activity of LAL assay is also unclear and there is no 
published data which investigates this issue. The summation of these processes 
may lead to variability and difficulties in detecting endotoxin in blood especially in the 
dialysis population, for which the effect of uraemic solutes on LAL performance has 
never been investigated. 
Additionally, the LAL assay can be subject to interference by multiple substances 
that may be present in blood caused by medical treatment. These include antibiotics 
such as penicillin (McCullough & Scolnick 1976), aminoglycosides (Artenstein & 
Cross 1989) and blood from patients dialysing with cellulose membranes, the 
materials of which may contain traces of (1-3)-β-D-glucan which can  activate the 
LAL assay by an alternate enzymatic pathway (Taniguchi et al. 1990). It is therefore 
important to avoid sampling from patients who are treated with antibiotics or dialysis 
membranes with cellulose constituents.  
Historically, multiple methods have been devised to remove interfering factors 
present in blood and has been reviewed extensively (Hurley 1995), but the most 
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effective and simple method involves heating and dilution of the sample. However, 
diluting the sample significantly reduces the threshold of detection. The current limit 
of detection using kinetic techniques is 0.001EU/ml (Brade 1999), but blood samples 
are usually diluted by a ten-fold dilution, this reduces the limit of detection to 
0.01EU/ml. It is unclear if heating and dilution of the sample is sufficient to maximise 
recovery of endotoxin from blood samples, since recent work performed in healthy 
patients suggests that recovery of control standard endotoxin that has been spiked 
into raw plasma was poor despite dilution and heat treatment suggesting that any 
LPS sequestration process that occurs in plasma may not be easily removed 
(Gnauck et al. 2015). 
3.1.3.4 Interference of LAL by (1-3)-β-D glucan 
The LAL assay is not specific to endotoxin activation, it can also be activated by (1-
3)-β-D glucan (BG) via an alternative enzymatic pathway by factor G activation 
(Morita et al. 1981). BG are major carbohydrate constituents of cereal, yeast and 
fungal cell walls (Young & Vincent 2005) with a variable molecular weight ranging 
from thousands to millions of daltons depending on origin. Elevated blood BG has 
been used a serum marker for invasive fungal infection (Young & Vincent 2005; Rop 
et al. 2009). 
As discussed earlier, treatment with dialysis membranes composed of cellulose 
material are known to elevate blood BG levels in patients in the absence of invasive 
fungal infection. This could potentially lead to false activation of the LAL assay via 
factor G and artefactual elevation of blood endotoxin levels. A review of the reliability 
of BG detection assay in patients on renal replacement therapy concluded that 
treatment with modern non-cellulose haemodialysis membranes does not 
significantly alter serum BG levels (Prattes et al. 2015). However it was commented 
that in two studies that measured BG blood levels in lung transplant recipients to pre-
emptively diagnose invasive fungal infections found that treatment with 
haemodialysis was a significant predictor of false positive elevation in blood BG (i.e. 
raised BG but no evidence of systemic fungal infection). Both studies exclusively 
used polysulfone membranes which are not known to alter blood BG levels and the 
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authors were unable to explain the relationship between exposure to haemodialysis 
and raised BG in their cohort (Hanson et al. 2012; Alexander et al. 2010). 
Due to the significant methodological issues with the LAL assay for blood endotoxin 
detection assays, a number of alternative blood endotoxin detection assays have 
been developed.  
3.2 Alternative direct blood endotoxin detection methods 
3.2.1 Endotoxin Scattering Photometry (ESP) assay 
The ESP assay is a relatively novel endotoxin detection assay with a reported lower 
limit of detection of 0.01pg/mL (Terawaki et al. 2010), which is approximately ten 
times more sensitive than current kinetic LAL techniques. The assay also requires 
the use of LAL reagents, however the technique differs from the conventional kinetic 
LAL technique by using a light-scattering photometer to detect the formation of 
coagulin particles which are precursor gel clots formed during the early stages of the 
LAL coagulation cascade (Figure 3-3).  
 
Figure 3-3: Images of optical microscopic observations of aggregates formed by the LAL 
reaction with endotoxin at concentration of 0.05 EU/mL. (A) No aggregates at 8 minutes (B) 
Obscure aggregates at 12 minutes (C) Recognisable aggregates at 14 minutes (D & E) Snow-
like crystal aggregates at 20 and 30 minutes respectively. Scale bar denotes 100µm. 
Reproduced from (Mitsumoto et al. 2009) with permission from John Wiley and Sons publishers 
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The onset time of the rapid appearance of these coagulin particles is used to 
quantify endotoxin content. Since this method is based on the measurement of pre-
cursor gel clots from the early phase of the LAL reaction or coagulation cascade, it is 
able to detect small amounts of endotoxin more rapidly and with greater sensitivity. 
Use of the ESP assay in the clinical setting has been reported with some success. 
Endotoxin levels obtained from the ESP assay are higher in patients with septic 
shock (Kase & Obata 2010). The ESP assay was compared with the kinetic 
turbidimetric assay for discriminating patients who developed septic shock after 
emergency gastrointestinal surgery (Shimizu et al. 2013). In stable haemodialysis 
patients, blood endotoxin level quantified using the ESP assay correlated 
significantly with CRP (Terawaki et al. 2010).  
3.2.2 Recombinant factor C assay 
The zymogen factor C is the primer of the LAL coagulation cascade (see Figure 3-1). 
In vivo, factor C is a biosensor in the horseshoe crab and is activated by the 
presence of endotoxin. Efforts to conserve the population numbers of the horseshoe 
crab led to efforts to develop recombinant factor C as an endotoxin detection tool. 
This also eliminates the problem of batch-to-batch variation in sensitivity and 
specificity of the LAL assay (Ding & Ho 2010). Several commercial preparations of 
recombinant factor C are now available including PyrogeneTM Recombinant Factor C 
assay (Lonza) and the EndoLISA® assay (Hyglos), although currently both assays 
are slightly less sensitive than the kinetic LAL assays (lower limit of detection for 
both is 0.005 EU/mL). The recombinant factor C assay is recognised as an 
alternative method of endotoxin detection to the LAL assay in both the United States 
Pharmacopoeia (USP) (USP 28 NF 23) and European Pharmacopoeia (European 
Pharmacopoeia Chapter 5.1.10), however similar to the LAL assay, the recombinant 
factor C assay has not been validated for blood endotoxin detection. To date, no 
studies have been published on the use of the recombinant factor C assay for blood 
endotoxin detection. 
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3.2.3 Endotoxin detection methods under development 
There are a large number of direct endotoxin detection methods under development. 
Methods based on optical, electrochemical and mass based biosensors using 
sensing elements such as aptamers, synthetic peptides and antibodies and artificial 
materials such as gold nanoparticles are currently being explored as potential 
endotoxin detection methods (Su & Ding 2015). 
3.3 Surrogate measures of endotoxemia 
Due to the difficulties in measuring endotoxin in blood matrices directly, surrogate 
biomarkers have been used to estimate endotoxin activity in the blood. 
3.3.1 Endotoxin Activity Assay (EAA) 
The EAA is a bioassay which measures neutrophil activation by complement 
opsonised immune complexes of endotoxin as surrogate measure of endotoxemia. 
The assay is based on the binding of the lipid A region of endotoxin using a specific 
IgM antibody. This LPS-antibody complex is opsonised with complement and 
interacts with complement receptors (CR1 and CR3) on neutrophils priming the 
NADPH oxidase complex. Following priming, neutrophil respiratory burst is evoked 
using zymosan and detected as light release from the lumiphor, luminol, using a 
chemiluminometer. The magnitude of respiratory burst is proportional to the 
logarithmic concentration of endotoxin in the sample and is used to indicate the 
quantity of blood endotoxin present (Figure 3-4) (Romaschin et al. 2012). 
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Figure 3-4: Reaction mechanism for EAA utilising anti-LPS monoclonal antibody and 
neutrophils from whole blood (Romaschin et al. 2012) 
 
The EAA is a semi-quantitative test that will give an endotoxin activity (EA) result. 
The EA result will stratify patients into low (EA<0.4), intermediate (0.4-0.59) and high 
(EA>0.6) risk of developing septic shock. This assay has been approved by the US 
FDA and European regulatory agency in 2004 as a diagnostic tool to assess the risk 
of septic shock in human (Romaschin et al. 2012). The EAA can only be used as a 
semi quantitative indicator of endotoxemia because variations in chain length and 
the lipid structure of LPS can affect the relationship between EAA levels and the 
mass of LPS (Marshall et al. 2004). A previous study found a poor dose–response 
between blood spiked with control standard endotoxin and EA activity (Matsumoto et 
al. 2013). 
3.3.2 Lipopolysaccharide binding protein (LBP) 
LBP is a soluble acute phase protein synthesised and released by the liver in the 
presence of endotoxin. LBP binds and presents endotoxin to important cell surface 
pattern recognition receptors such as CD14 and TLR4 eliciting the release of pro-
inflammatory mediators. The level of LBP has been suggested to reflect the 
biological activity of circulating endotoxin in patient blood (Sun et al. 2010; Guerra 
Ruiz et al. 2007). LBP levels are elevated in those with non-alcoholic fatty liver 
disease (Guerra Ruiz et al. 2007), coronary artery disease (Lepper et al. 2007) and 
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sepsis (Opal et al. 1999). However, in a large cross-sectional study of 235 patients 
with septicaemia, the authors found no correlation between endotoxin measured 
using the LAL assay and LBP levels (Opal et al. 1999). 
3.3.3 Soluble CD14 
Soluble CD14 is a molecule which may also reflect endotoxin bioactivity. In blood, 
LBP protein forms a complex with endotoxin which is transferred to membrane-
bound CD14 (mCD14) resulting in cell activation. This LBP–LPS complex can also 
bind with soluble CD14 (sCD14), which can facilitate neutralization of endotoxin via 
HDL pathways or antagonize mCD14-positive cell activation by competitive binding 
(Seabra et al. 2009). Levels of soluble CD14 increase significantly post-dialysis 
(Mitzner et al. 1995; Nockher & Scherberich 1995). Two prospective observational 
cohort studies in haemodialysis patients have shown that blood concentrations of 
sCD14 correlated positively with inflammation and independently predicted mortality 
(D. Raj et al. 2009; D. S. C. Raj et al. 2009). One of these studies found that blood 
sCD14 concentration was significantly associated with endotoxemia (D. Raj et al. 
2009).  
3.4 Summary 
In summary, it is possible that endotoxemia is a major contributor to chronic 
inflammation in dialysis patients. However, the detection of blood endotoxin is 
complex with a multitude of assays available. To confirm or refute an association 
between endotoxemia and unexplained inflammation in dialysis patients, validation 
of an accurate and precise endotoxin detection assay for use in uraemic blood is 
required.  
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 Chapter 4 
4. Aims and General Methodology 
 
This chapter details the hypotheses and aims of this PhD thesis. Rationale for the 
design and general methodology for all studies in this thesis are summarised.  
4.1 Introduction 
Chapter 2 summarised the data that suggests endotoxemia as a potentially 
important mediator of inflammation in the dialysis population (Jefferies et al. 2014; 
Szeto et al. 2008; Terawaki et al. 2010). There may be multiple sources for 
endotoxemia but it has been suggested by others that the haemodialysis technique 
itself and the gastrointestinal tract are major contributory factors (Hauser et al. 2011; 
Christopher McIntyre 2011). Notably, increased gut permeability and endotoxemia 
has also been reported in healthy individuals undergoing intensive exercise who 
experience gastrointestinal complaints (van Wijck & Lenaerts 2011a). This occurs as 
a result of dehydration and reduced mesenteric blood flow during exercise (de 
Oliveira et al. 2014). A similar process may occur with patients during haemodialysis 
treatment and many often report nausea, vomiting, fatigue and a ‘washed-out’ feeling 
that can last hours to days post-dialysis. Recovery time after haemodialysis 
treatment can be variable and prolonged (Sklar et al. 1996). The cause of this 
phenomenon is unclear and contributes to poor quality of life. It may be possible that 
endotoxins are present in the blood of haemodialysis patients due to increased gut 
permeability, exacerbated by the haemodialysis procedure contributing to chronic 
unexplained inflammation and dialysis-related symptoms including prolonged 
recovery time. 
 
However as discussed in Chapter 2, there are conflicting data with regards to the 
level of endotoxemia in the dialysis population with some studies reporting a low 
prevalence of endotoxemia and others reporting unusually high blood endotoxin 
levels that is likely to exceed the pyrogenic threshold. There are also significant 
methodological issues with current endotoxin detection assays, none of which have 
been validated in uraemic blood. It is unclear whether current endotoxin detection 
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assays are able to accurately measure blood endotoxin in patients with kidney 
disease. 
4.2 Hypotheses and aims 
I. Endotoxins are present in the blood of haemodialysis patients. 
II. Blood endotoxin can be accurately measured using current available 
detection assays (such as the LAL assay – the most commonly used 
endotoxin detection assay). 
III. Endotoxemia is associated with chronic unexplained inflammation in 
haemodialysis patients. 
IV. The haemodialysis procedure itself increases gut permeability and blood 
endotoxin concentration. 
V. Gut permeability is increased in patients with end-stage kidney disease. 
VI. Endotoxemia is associated with haemodialysis-related symptoms. 
The overarching aim of this thesis is to study the role of endotoxin in chronic 
unexplained inflammation in haemodialysis patients. The studies reported in this 
thesis have been designed to meet the following objectives: - 
 To determine an optimum method of measuring blood endotoxin in ESKD and 
explore the accuracy of current available endotoxin detection assays.  
 To explore the association between endotoxemia and unexplained chronic 
inflammation in haemodialysis patients.  
 To determine the effect of haemodialysis on endotoxemia and inflammation.  
 To determine the impact of a single haemodialysis procedure on endotoxin 
levels and gut permeability.  
A roadmap of research studies conducted in this thesis is detailed in the Table 4-1. 
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Table 4-1: Roadmap of studies for thesis 
Aims and objectives Study description Section 
 
 
Scoping work to determine the 
prevalence of unexplained 
inflammation 
 
 
Cross-sectional survey to determine the 
prevalence of unexplained inflammation in 
haemodialysis patients 
 
 
4.3.1 
To determine the optimum method 
of measuring blood endotoxin in 
ESKD  
Comparative laboratory work to determine 
optimum LAL assay for endotoxin detection 
 
 
4.3.2 
 
4.3.3 
To explore the association 
between endotoxemia and 
unexplained chronic inflammation 
in haemodialysis patients 
Cross-sectional study in haemodialysis patients 
to determine the association between 
inflammation and blood endotoxin levels. Blood 
endotoxin levels were also compared with 
peritoneal dialysis patients and non-dialysed 
CKD patients  
 
4.3.4 
To determine the effect of 
haemodialysis on endotoxemia 
and inflammation  
 
Prospective study – CKD V patients not yet on 
dialysis were prospectively studied and sampled 
to measure the change in blood endotoxin 
levels with haemodialysis treatment over time. 
 
4.3.5 
To determine the impact of a 
single haemodialysis procedure on 
endotoxin levels and gut 
permeability 
Cross-sectional study to explore the acute effect 
of a single haemodialysis session on blood 
endotoxin and inflammatory biomarkers.  
 
Cross-sectional study to explore the impact of a 
single dialysis session on gut permeability and 
the relationship between increased gut 
permeability and endotoxemia 
 
4.3.6 
 
 
 
4.3.7  
 
If a firm association between endotoxemia and chronic unexplained inflammation in 
haemodialysis patients was demonstrated and the source of endotoxin established 
this would justify embarking on interventional trials to examine the efficacy of 
endotoxin-lowering strategies. 
A general overview of each individual study conducted as part of this PhD is 
described below. A detailed explanation of the methodologies is provided in the 
relevant chapters. 
4.3 Study population 
All participants were recruited from patients who were under the care of the Lister 
Renal Unit at the East and North Herts NHS Trust. Healthy controls for the study 
were recruited from volunteers and healthcare professionals working at the trust. 
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The haemodialysis programme at the East and North Herts NHS Trust covers a 
large number of patients in a wide geographical area covering Stevenage, Luton, 
Bedford, St. Albans and Harlow. There were approximately 500 prevalent 
haemodialysis patients at the time of the PhD studies. Patients at our centre are 
routinely treated with predominantly polysulphone membranes using either high-flux 
haemodialysis or haemodiafiltration. Water quality is regularly monitored to meet 
ultrapure standards as recommended in national and international guidelines. 
Dialysis is prescribed and monitored to achieve minimum target equilibrated Kt/V of 
1.2 per dialysis session. Blood tests for purposes of measurement of dialysis 
adequacy including C-reactive protein are monitored monthly. Residual renal 
function is monitored monthly with the use of inter-dialytic urine collections to allow 
estimation of renal urea clearance.  
4.3.1 : Retrospective cross-sectional study of the prevalence of unexplained 
inflammation in the haemodialysis population (see Chapter 5) 
 
Although the prevalence of general inflammation in haemodialysis population is well 
known (Owen & Lowrie 1998), the prevalence of chronic and unexplained 
inflammation is less clear and there are no published studies which documents this. 
To determine the extent of chronic unexplained inflammation in the haemodialysis 
population, a cross-sectional analysis of all prevalent haemodialysis population 
treated at the East and North Hertfordshire NHS Trust was carried out. Medical 
records and CRP levels of all haemodialysis patients were reviewed and categorised 
into those with chronic inflammation and those without inflammation. Patients with 
transient elevations in CRP were excluded from further analysis.  For patients with 
chronic inflammation, medical notes were reviewed to identify patients with an 
obvious cause of chronic elevated CRP (e.g. chronic leg ulcers, active vasculitis). If 
an identifiable cause could not be determined, patients were classified as having 
chronic unexplained inflammation.  
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4.3.2 : Studies to determine the optimum blood endotoxin detection assay in 
haemodialysis patients (see Chapter 6) 
To determine the optimum blood endotoxin detection assay, studies were carried 
over several phases as described below. 
4.3.2.1 Selection of phlebotomy apparatus 
Endotoxins are ubiquitous molecules, therefore precautions are necessary to avoid 
contaminating blood specimens during the sampling procedure to prevent reporting 
artificially high results of blood endotoxin levels (Redl et al. 1992). Blood collection 
tubes may introduce endotoxin contamination due to the additives used (Newhall et 
al. 2010). To reduce the risk of environmental contamination of blood samples, 
phlebotomy equipment and blood collection tubes were examined for endotoxin 
contamination using the standard method defined by the Association for 
Advancement of Medical Instrumentation (Bryans & Braithwaite 2004). Blood 
collection and storage tubes were additionally tested to ensure that the materials or 
additives within the tubes did not contain interfering factors that could significantly 
activate or inhibit the activity of the LAL assay. This study was conducted to facilitate 
the selection of phlebotomy equipment and blood collection for use in subsequent 
clinical studies.  
4.3.2.2 Optimisation of the LAL assay for blood endotoxin detection 
A review of endotoxemia studies in the dialysis literature showed that the LAL assay 
was the most commonly used method for blood endotoxin detection. The LAL assay 
is also frequently used for studies of populations with other disease states (Ronco et 
al. 2010; Brade 1999). The kinetic LAL assays have a much wider detection range 
and a lower limit of detection compared to end-point LAL assays. However, as 
discussed in Chapter 3, use of the LAL assay for blood endotoxin detection can be 
complex as samples require pre-treatment prior to analysis due to the presence of 
natural inhibitors and activating factors in blood. Dilution and heat treatment is the 
simplest and most commonly used pre-treatment method (Hurley 1995).  
The purpose of this phase was to determine the blood sample processing 
requirements to optimise LAL performance in uraemic blood. Once the optimum 
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methodology was established this was used to compare the LAL assay with 
alternative methods of blood endotoxin detection. 
Blood samples from 7 healthy controls and 7 haemodialysis patients were collected. 
Samples were spiked with different standards of control standard endotoxins (CSE) 
and then subjected to measurement to determine the percentage of the spiked 
endotoxin that could be recovered from the sample or “spike recovery”. On this 
basis, experiments were carried to determine the following: -  
 Is endotoxin spike recovery better in plasma or serum? 
 What is the optimum sample dilution factor? 
 Can spike recovery be improved with the use of detergents as a sample 
diluent? 
After the optimum blood sample processing conditions were determined. Optical 
density graphs were analysed to see if calculating the endotoxin content in samples 
using other parameters other than the onset reaction time such as slope of the 
optical density curve yielded more accurate spike recoveries (see chapter 6– Kinetic 
LAL assays). 
4.3.2.3 Comparison of the turbidimetric and chromogenic LAL assay (section 6.9) 
Using the optimum sample processing conditions and analytical methodology 
determined from the experiments carried out in section 4.3.2.2, studies were 
conducted to compare the performance of two commercially available variations of 
the kinetic LAL assay – the turbidimetric and the chromogenic assay. Both the kinetic 
turbidimetric and chromogenic methods are regularly used, but it is unclear which 
assay has better performance in uraemic blood. The best kinetic LAL assay was 
compared with an endpoint chromogenic LAL assay which has been commonly cited 
in the dialysis literature and also compared with an alternative novel endotoxin 
detection method - the Endotoxin Scattering Photometry (ESP) assay, due to its 
report of increased sensitivity compared to the traditional LAL assays and its 
success in diagnosing sepsis and correlation with inflammatory markers in 
haemodialysis patients (see chapter 3).  
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Blood samples from haemodialysis patients were spiked with different concentrations 
of CSE and measured to determine spike recovery for each assay. This was used to 
determine the accuracy and precision of all three assays to determine the best 
technique to use for blood endotoxin detection in subsequent clinical studies. The 
study was also repeated in blood samples collected from healthy controls to explore 
whether uraemia could affect the activity of the LAL assay. 
Other promising novel direct endotoxin measurement assays were available but 
have not been explored in this thesis. The recombinant factor C assay is not as 
sensitive as the kinetic LAL assays, and there are no reports of its use in blood. The 
Endotoxin Activity Assay (EAA) is also a promising assay since its use as a 
diagnostic aid in predicting severe sepsis in patients has received FDA-clearance. 
However it is semi-quantitative, and only provides surrogate measures of 
endotoxemia rather than direct measurement. Hence comparison of its performance 
with other direct endotoxin detection assays would be difficult, so the performance of 
this assay was not investigated. 
4.3.3 Determining the influence of (1→3)-β-D glucan on endotoxin 
measurements in haemodialysis patients (Chapter 8) 
Experiments carried out as described in section 4.3.2.3 showed that out of all three 
studied assays, the kinetic turbidimetric LAL assay was the most accurate and 
precise method. This assay was selected for subsequent clinical studies. However, 
the LAL assay can also be activated by (1→3)-β-D glucan (BG) via the factor G 
pathway, although this pathway can be blocked with the use of BG blocking buffers 
(Kambayashi et al. 1991; Tsuchiya et al. 1990). A review of endotoxin studies carried 
out in the dialysis population listed in Table 2-1, showed that with the exception of 
one study (Taniguchi et al. 1990), all studies were carried out using LAL assays that 
were not rendered insensitive to BG stimulation for measurement of endotoxin. This 
issue is significant due to the reported high levels of BG in the dialysis population 
(Prattes et al. 2015). Blocking the factor G pathway of LAL assay is associated with 
significant cost, therefore it is important to confirm the association of high BG levels 
in haemodialysis patients. A positive finding would suggest that steps should be 
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taken to remove BG interference when the LAL assay is used for blood endotoxin 
detection in haemodialysis patients to prevent false positive signals. 
Blood samples were collected from 50 stable, non-infected haemodialysis patients. 
All samples were measured with the LAL assay, with and without the use BG 
blocking buffers. The same samples were also measured for levels of BG using the 
Fungitell® assay, an FDA-cleared blood BG detection assay. The association 
between blood BG and blood endotoxin measurements derived from the LAL assay 
which did not block account for factor G activation was then determined. 
4.3.4 Cross-sectional study to examine the association between blood 
endotoxin levels and chronic unexplained inflammation in haemodialysis 
patients (see Chapter 5) 
A cross-sectional study was carried out to explore the association between 
endotoxemia and chronic unexplained inflammation. Sixty patients in-centre 
haemodialysis were recruited, consisting of 30 patients had chronic unexplained 
inflammation and 30 patients without inflammation (CRP consistently below the 
detection limit) were studied. Comparisons were made with healthy individuals and 
patients with less advanced stages of kidney diseases. The rest of the study cohort 
included 20 healthy controls, 20 patients with CKD stages 1-3, 20 patients with CKD 
stages 4-5 and 15 peritoneal dialysis patients. All participants were clinically stable 
and non-infected at the time of study. Blood samples were collected from all study 
participants and measured for: - 
1. Endotoxin  
2. (1→3)-β-D glucan 
3. IL-6 
4. TNF-α 
5. High sensitivity CRP 
The association between blood levels of endotoxin, (1→3)-β-D glucan and 
inflammatory biomarkers were explored by regression analysis. These parameters 
were also correlated with a number of quality of life outcome measures including 
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uraemia related symptoms, depression symptoms, level of fatigue and post-dialysis 
recovery time.  
Quality of life outcome measures 
Uraemia related symptoms: Symptoms related to kidney disease was assessed 
using Palliative Care Outcome Scale modified for renal disease (POS-S renal) 
(Murphy et al. 2009). This scale has been validated for the assessment of symptoms 
in populations with advanced kidney disease (Davison et al. 2015) [Appendix B – 
POS-S Renal] 
Fatigue: level of fatigue was captured using the Multidimensional Fatigue Inventory 
(MFI) (Smets et al. 1995), a 20 item self-report instrument designed to measure 
fatigue in five dimensions including general fatigue, physical fatigue, mental fatigue , 
reduced motivation and reduced activity. A global score combining results from each 
dimension ranges from 20 to 100. Higher scores demonstrate a higher level of 
fatigue. The MFI is a useful tool for the assessment of fatigue in chronically unwell 
patients (Lin et al. 2009). [Appendix C – Multidimensional fatigue inventory] 
Depression: patients were assessed for depressive symptoms using the Patient 
Health Questionnaire (PHQ-9). This questionnaire used for screening, diagnosing, 
monitoring and measuring the severity of depression. Depression severity is 
classified according to the score obtained: - 5-9, 10-14, 15-19 and >20 representing 
minimal, minor, moderately severe and severe depressive symptoms respectively. 
The PHQ-9 has been validated for use in dialysis patients (Watnick et al. 2005). 
[Appendix D – Patient health questionnaire 9] 
Post-dialysis recovery time: This was assessed by asking participants how long it 
takes to feel back to normal after a typical dialysis session (Lindsay et al. 2006). 
Prolonged recovery times are associated with worse quality of life, hospitalisation 
and mortality (Rayner et al. 2014). [Appendix E – Post dialysis recovery time] 
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4.3.5 Prospective longitudinal study to determine the effect of haemodialysis 
on blood endotoxin, (1→3)-β-D glucan and inflammation (Chapter 10) 
The effects of haemodialysis initiation on blood endotoxin, BG and markers of 
inflammation were studied. Thirty patients with CKD stage 5 within six months of 
starting haemodialysis were recruited. Blood samples and quality of life outcome 
measures as described above were collected up to 6 months prior to starting 
haemodialysis treatment. Blood samples were similarly analysed for endotoxin, BG, 
IL-6, TNF-α and hs-CRP. Participants were prospectively followed and repeat blood 
sampling and quality of life assessments were repeated within 1-3 months of starting 
haemodialysis to determine the effect of the haemodialysis process itself on blood 
levels of endotoxin and BG and on the markers of inflammation.  
4.3.6 Studies of the impact of intra-dialytic exercise and haemodialysis on 
endotoxemia and inflammation (Chapter 9) 
There are numerous reports of healthy individuals developing endotoxemia after 
intense exercise (Bosenberg et al. 1988; Ashton et al. 2003; Lambert 2008) possibly 
due to gut ischemia (Marshall 1998; ter Steege et al. 2012; van Wijck & Lenaerts 
2011a). Haemodialysis may also induce additional circulatory stress on the 
gastrointestinal tract since some studies suggest that the splanchnic and splenic 
vascular beds may contract during haemodialysis (Yu et al. 1997). It is possible that 
patients who undertake intra-dialytic exercise may risk exerting additional circulatory 
stress to gastrointestinal tract during haemodialysis sessions leading to acute 
endotoxemia and pro-inflammatory responses. To test this hypothesis, 10 
haemodialysis patients who regularly participate in intra-dialytic exercise were 
studied. Blood was collected from participants before and after haemodialysis on two 
separate sessions. Patients were asked to carry out their normal intra-dialytic 
exercise routine on one study day (exercise day) and to abstain from exercise on the 
second study day (non-exercise day). Differences in blood endotoxin, BG and 
inflammation levels were analysed before and after haemodialysis on an exercise 
and non-exercise day to ascertain the acute effect of haemodialysis and intra-dialytic 
exercise on inflammation and endotoxemia. 
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4.3.7 Studies of the impact of haemodialysis on gut permeability (Chapter 11) 
The gut may be a major source of endotoxin and other bacterial products such as 
bacterial DNA (Bossola et al. 2009). As discussed in chapter 2, gut permeability may 
be altered in uraemia and has been reported in animal and non-dialysed CKD 
patients (Magnusson et al. 1991). However, gut permeability has never been 
measured in haemodialysis patients.  
The conventional method of measuring gut permeability involves the oral 
administration of non-metabolised sugar probes and measuring their recovery in 
urine (Bjarnason et al. 1995). In normal circumstances most of the sugar probes are 
excreted in the stool, however if intestinal permeability is increased, these sugar 
probes are absorbed into the blood stream and excreted in the urine. The amount of 
sugars recovered in the urine can be used to assess the degree of gut permeability. 
Since most haemodialysis patients pass little or no urine, this technique cannot be 
used. Recently, a novel method of measuring gut permeability assay by measuring 
the recovery of sugar probes in plasma has been developed at the University of 
Maastricht (van Wijck & Lenaerts 2011a; van Wijck et al. 2014; van Wijck et al. 
2013).  
The conventional assays for gut permeability measurement are usually based on a 
difference in gut absorption of two orally-administered sugars. Under normal 
conditions, one of these sugars is unable to cross the intestinal barrier easily 
whereas the second sugar is able to do so freely. However, if gut permeability is 
increased both sugars are able to cross the intestinal barrier. Changes in the 
difference in absorption of these sugars can be used to assess changes in 
gastrointestinal permeability. However, a two sugar-probe test provides only limited 
information, whereas a multi-sugar probe could provide a more accurate picture. 
This technique utilises liquid chromatography mass spectrometry (LC-MS) which 
allows for sensitive measurement of sugars in plasma. As sensitivity is increased, 
more sugars at a lower dose can be administered so that total sugar load is not 
higher compared with the classical dual sugar assay. The sugar mixture contains 
lactulose, sucralose, rhamnose and erythritol.  Lactulose and rhamnose are often 
used as a marker for small intestinal permeability since they are degraded by the 
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microbiota in the colon (Fink 2002; Hietbrink et al. 2007). Sucralose and erythritol 
can be used as a marker for whole gut permeability since they resist colonic bacterial 
fermentation (Farhadi et al. 2003). The calculated plasma lactulose:rhamnose ratios 
(L/R) is used to assess small intestinal permeability and plasma sucralose:erythritol 
ratios (S/E) for whole gut permeability.  Area under curve was determined for L/R 
and S/E ratios and comparisons made using the Kruskal-Wallis test to ascertain 
differences in sugar ratios between dialysis and non-dialysis days. 
This novel gut permeability measurement technique was applied in a cross-sectional 
study of 10 haemodialysis patients. The effect of haemodialysis on gut permeability 
was determined by measurement of gut permeability on a dialysis and non-dialysis 
day. The study was also carried out in 5 healthy controls for comparison of gut 
permeability with non-uraemic subjects. 
4.4 Research Ethics 
All studies were reviewed and approved by the NHS Research Ethics committee and 
local Research and Development office. All study participants were given an 
information sheet to explain the study and informed written consents was obtained 
from all participants. Letters of approval are shown in Appendix A.  
The NHS Research Ethics committee for the studies are given below:- 
Studies to determine the optimum endotoxin detection assay in haemodialysis 
patients – 14/SC/0067 
Determining the influence of (1→3)-β-D glucan on endotoxin measurements in 
haemodialysis patients - 14/EM/1266 
Cross-sectional study to examine the association between blood endotoxin levels 
and chronic unexplained inflammation in haemodialysis patients – 15/EE/0019 
Prospective longitudinal study to determine the effect of haemodialysis on blood 
endotoxin, (1→3)-β-D glucan and inflammation – 15/NW/0192 
Studies of the impact of intra-dialytic exercise and haemodialysis on endotoxemia 
and inflammation – 15/EE/0267 
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Studies of the impact of haemodialysis on gut permeability – 15/EE/0379 
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 Chapter 5 
5. The prevalence of chronic unexplained inflammation in 
haemodialysis patients 
5.1 Introduction 
Chronic unexplained inflammation in the dialysis population is a well-recognised 
phenomenon (Kocyigit et al. 2014; Achinger & Ayus 2013). The prevalence of 
inflammation in the haemodialysis population is estimated to be 35% (Owen & 
Lowrie 1998), however the proportions of those with unexplained inflammation and 
those with obvious clinical causes of inflammation (e.g. chronic infected leg ulcers) is 
unclear. The prevalence of unexplained inflammation has not been reported. 
A cross-sectional study of all prevalent haemodialysis patients treated at the East 
and North Herts NHS Trust was carried out to determine the extent of unexplained 
inflammation in the haemodialysis population. Differences in demographic, clinical 
and dialysis-related parameters between patients with and without inflammation was 
studied to gain insight into potential implicating factors that may be associated with 
chronic unexplained inflammation in haemodialysis patients. 
5.2 Methods 
5.2.1 Definition of chronic inflammation 
One of the difficulties in studying inflammation is the lack of consensus on how to 
define inflammation in the dialysis population (KDOQI Workgroup 2005), despite the 
recognition that inflammatory biomarkers are persistently elevated in a significant 
proportion of patients (Santoro & Mancini 2002). Most studies use C-reactive protein 
(CRP) to identify inflamed individuals but the optimal cut-off CRP to diagnose 
inflammation is unclear (KDOQI Workgroup 2005). Haemodialysis patients at the 
East and North Herts NHS Trust have monthly blood tests to measure C-reactive 
protein (CRP) as part of routine clinical care, therefore CRP was the biomarker used 
to identify patients with inflammation in this study. Some authors have suggested 
that a CRP>10 mg/L indicates inflammation caused mainly by infection (Tsirpanlis et 
al. 2004), whilst others have set this cut-off at >15 mg/L (Stenvinkel et al. 2002). 
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Some studies have found that a cut-off level of 6 mg/L can accurately predict 
constant inflammatory state on follow-up (Ortega et al. 2002). In general, a CRP 
value between 0.1 to 15 mg/L has been suggested to reflect microinflammation 
(Tsirpanlis et al. 2005). CRP at the East and North Herts NHS was measured using 
Olympus Beckman-Coulter AU analyser and reagents and healthy individuals are 
expected have a CRP of ˂5mg/L using this assay. Therefore values >5mg/L are 
considered elevated.  
To define those with chronic inflammation in this study, patients with two measured 
levels of CRP >5mg/L at least one month apart within the last 3 months were 
considered as having chronic inflammation. CRP measurements have to be at least 
one month apart to avoid classifying patients with only transient rises in CRP as 
having chronic inflammation.  
5.2.2 Database search 
A database of all patients receiving haemodialysis treatment at the East and North 
Herts NHS Trust was generated in October 2013. Medical records and serial CRP 
measurements in the previous 3 months were reviewed for all patients. Patients with 
obvious causes for an elevated CRP such as active infection, recent hospitalisation 
or surgery were excluded from further analysis. 
Patients with persistently elevated CRP measurements using the criteria stated in 
section 5.2.1 but with no obvious clinical cause were classified as having chronic 
unexplained inflammation. The medical notes of this group were reviewed further to 
look for potential risk factors which may predispose to the development of 
inflammation including:- 
 Use of tunnelled dialysis catheters 
 Failed transplant allograft in-situ 
 History of gastrointestinal disease such as diverticulitis or colitis 
 History of foot or leg ulcers 
 History of recurrent urinary tract infections 
 Polycystic kidney disease  
 History of arthropathy 
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 History of bronchiectiasis or tuberculosis 
 Presence of eosinophilia 
 Positive HIV 
 Long term urinary catheter in-situ 
 Active malignancy 
 Active hepatitis 
Patients were then categorised into three groups:- 
1. No inflammation (CRP <5 mg/L) 
2. Chronic inflammation with potential underlying risk factors 
3. Chronic inflammation without potential underlying risk factors 
Demographic data (age, gender, weight), co-morbidity (underlying cause of kidney 
disease and Charlson Co-morbidity Index) and other relevant dialysis parameters 
were collected for all patients and compared between inflamed (Group 2 and 3) and 
non-inflamed patients (Group 1). Demographic data, co-morbidity, residual renal 
function and dialysis parameters were also compared between Groups 2 and 3. 
5.2.3 Dialysis parameters 
The following dialysis parameters were collected on all patients:- 
Dialysis time (Td): the duration of the most recent dialysis session in minutes 
Interdialytic weight gain as a percentage of dry weight (IDWG%): IDWG as a 
percentage of dry weight (kg). 
Access blood flow (Qb): vascular access blood flow (mL/min). 
Renal urea clearance (KRU): renal urea clearance was used to indicate the level of 
residual renal function present. To calculate KRU, blood was sampled for urea 
measurement at the end of the first dialysis session of the week and immediately 
before the next session. Between these samples, urine was collected over the whole 
inter-dialytic period. KRU was calculated using the formula:- 
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𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 (𝑚𝐿/𝑚𝑖𝑛)  =  
2 ∙ (𝑈𝐼𝐷 ∙ 𝑉𝐼𝐷)
𝑡𝐼𝐷 ∙ (𝐶𝑝𝑜𝑠𝑡 𝐻𝐷1 + 𝐶𝑝𝑟𝑒𝐻𝐷2)
 
Where UID = urinary urea concentration, VID = urine volume, tID = collection duration, 
CpostHD1 = serum urea concentration at the end of the first dialysis session, and CpreHD2 = 
serum urea concentration immediately before the start of the second dialysis 
session.  
Dialyser Kt/V: Dialysis adequacy was measured by calculating the single pool Kt/V 
urea (spKt/V) using the second generation Daugirdas equation (Daugirdas 1993) 
and then converted to equilibrated Kt/V using the Tattersall equation (Tattersall et al. 
1996). 
𝑠𝑝
𝐾𝑡
𝑉
=  −𝑙𝑛 (
𝐶𝑝𝑜𝑠𝑡 𝐻𝐷
𝐶𝑝𝑟𝑒 𝐻𝐷
− 0.008𝑡) + (4 − 3.5
𝐶𝑝𝑜𝑠𝑡 𝐻𝐷
𝐶𝑝𝑟𝑒 𝐻𝐷
) ×
𝑈𝐹
𝑃𝑜𝑠𝑡 𝐻𝐷 𝑤𝑒𝑖𝑔ℎ𝑡
 
 
Where Cpost HD and Cpre HD = post-dialysis and pre-dialysis serum urea concentration 
respectively, t = dialysis time, UF = ultrafiltration volume and Post HD weight = 
weight after dialysis (kg) 
𝐸𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑎𝑡𝑒𝑑 
𝐾𝑡
𝑉
=  𝑠𝑝
𝐾𝑡
𝑉
×
𝑡
𝑡 + 35
   
Where t = dialysis time (minutes) 
Renal Kt/V: KRU from residual renal function contributes to significant urea removal 
and can be combined with dialyser Kt/V to obtain total Kt/V provided by renal and 
dialyser urea clearance. KRU is converted to its equivalent intermittent clearance, 
renal Kt/V, using the equation: - 
𝑅𝑒𝑛𝑎𝑙 
𝐾𝑡
𝑉
=
𝐾𝑅𝑈 × 𝑓
𝑉
 
Where f is an inflation factor = 5500 for thrice weekly schedules or 9500 for twice 
weekly (Depner 2005) and V = volume of distribution of urea calculated using the 
Watson equation (Watson et al. 1980). 
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Total Kt/V is calculated by adding renal Kt/V to dialyser Kt/V. 
5.2.4  Statistical analysis 
Normally distributed data are presented as means ± standard deviation and non-
normally distributed data as medians and interquartile ranges. Differences between 
groups were compared using Student’s T-test or Mann-Whitney U test as 
appropriate. Categorical data between groups were compared using chi-square. A p 
value <0.05 was used to indicated statistical significance. 
5.3 Results 
There were 444 prevalent haemodialysis patients at the time of data extraction. 
64.8% (287/444) of patients had chronic inflammation as defined using the criteria 
stated in section 5.2.1. In this group, 183 patients had obvious clinical reasons (e.g. 
recent hospitalisation or active infection) for inflammation and were excluded from 
further analysis representing 41.2% of the study population. 104 patients (23.4% of 
the study population) had chronic unexplained inflammation and 157 patients 
(35.4%) did not have systemic inflammation. In patients with chronic unexplained 
inflammation, 62.5% (65/104) had potential risk factors that may predispose to 
inflammation and 37.5% (39/104) had no identifiable predisposing risk factor 
represent 9% and 15% of the whole study population respectively (Figure 5-1). 
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Figure 5-1: Proportion of haemodialysis patients with and without inflammation  
  
Clinical characteristics of patients with and without unexplained inflammation are 
shown in Table 5-1. Patients with inflammation were more likely to be older (67 vs. 
63), heavier (80kg vs. 71kg) and have lower dialysis adequacy (Kt/V 1.32 vs. 1.41) 
despite having a longer dialysis sessions (Td 202 minutes vs. 192 minutes). Both 
groups were similar with respect to residual renal function, co-morbidity, IDWG and 
access blood flow and dialysis catheter use.  Predisposing risk factors for 
inflammation were also similar between both groups. 
 
  
9% 
15% 
41% 
35% 
Proportion of haemodialysis patients with and without inflammation at 
the East & North Herts NHS Trust 
Unexplained inflammation without
obvious underlying risk factors
Unexplained inflammation with potential
underlying risk factors
Inflammation with obvious reasons
No inflammmation
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Table 5-1: Clinical characteristics of patients with and without unexplained inflammation 
 
 
Unexplained inflammation No inflammation P value 
Age 
 
67 ± 15 63 ± 16 0.045* 
Male (%) 
 
64 57 0.367 
Weight (kg) 
 
80 ± 22 71 ± 16 <0.001* 
CRP (mg/L) 
 
12.4 1.8 <0.001* 
KRU (mL/min) 
 
0 [IQR 0-1.6] 0.49 [IQR 0-2] 0.171 
Total Kt/V 
 
1.32 ± 0.28 1.41 ± 0.32 0.017* 
Td (min) 
 
202 ± 27 192 ± 45 0.038* 
Qb (mL/min) 
 
325 ± 60 327 ± 56 0.793 
IDWG (%) 
 
1.9 ± 1.1 1.9 ± 1.3 0.819 
Dialysis catheter use (%) 
 
31.7 24.2 0.131 
HDF (%) 
 
70.2 79.6 0.104 
CCI 
 
4 [IQR 2-6] 4 [IQR 2-5] 0.138 
Cause of kidney disease 
(% affected) 
 
   
Diabetes 23.1 27.4 0.435 
Glomerulonephritis 8.7 19.1 0.02* 
Polycystic kidney disease 9.6 7.6 0.575 
Tubulo-interstitial disease 8.7 5.7 0.362 
Hypertension or RVD 16.3 13.4 0.505 
Other 12.5 10.2 0.561 
Unknown aetiology 
 
21.2 15.9 0.282 
Predisposing risk factors 
for inflammation  
(% affected) 
   
Transplant graft in-situ 8.7 6.4 0.487 
GI pathology 6.7 6.4 0.908 
Hepatitis 2.9 0.6 0.148 
Leg ulcers 6.7 5.1 0.578 
Recurrent urinary tract 
infections 
5.8 2.5 0.184 
Malignancy 6.7 3.8 0.29 
Arthropathy 9.6 9.6 0.987 
Bronchiectasis 1.0 0 0.218 
Tuberculosis 1.0 0.6 0.768 
Eosinophilia 1.0 0 0.218 
Long term catheter in-situ 0 1.9 0.156 
HIV  0 0.6 0.415 
KRU, renal urea clearance; Td, dialysis session time; Qb, access blood flow; IDWG, inter-dialytic 
weight gain; HDF, haemodiafiltration; CCI, Charlson Co-morbidity index; RVD, renovascular disease; 
GI, gastrointestinal disease; HIV, human immunodeficiency virus; CRP < 5 was designated as ‘0’ for 
the analysis 
 
Comparison of clinical characteristics of patients with unexplained inflammation with 
and without predisposing risk factors for inflammation are shown in Table 5-2. Sub-
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group analysis of the cohort of patients with unexplained inflammation did not reveal 
any differences between those with and without predisposing risk factors in terms of 
demographic or clinical parameters. 
Table 5-2: Clinical characteristics of inflamed patients with and without potential predisposing 
risk factors for inflammation 
 
 
Unexplained inflammation 
with risk factors 
Unexplained 
inflammation without  
risk factors 
P value 
Age 
 
67 ± 15 67 ± 14 0.97 
Male (%) 
 
63.1 64.1 0.916 
Weight (kg) 
 
77 ± 20 84 ± 24 0.119 
CRP (mg/L) 
 
19.4 [IQR 8.7-19.4] 13 [IQR 10-20] 0.456 
KRU (mL/min) 
 
0.21 [0-1.9] 0 [0-1.2] 0.505 
Total Kt/V 
 
1.34 ± 0.04 1.28 ± 0.04 0.262 
Td (min) 
 
201 ± 28 204 ± 27 0.671 
Qb (mL/min) 
 
322 ± 64 330 ± 52 0.485 
IDWG (%) 
 
1.8 ± 1.2 1.9 ± 0.9 0.668 
HDF (%) 
 
66.2 76.9 0.245 
CCI 
 
4 [IQR 2-6] 4 [IQR 3-6] 0.818 
Cause of kidney 
disease (% affected) 
 
   
Diabetes 16.9 33.3 0.054 
Glomerulonephritis 12.3 2.6 0.087 
Polycystic kidney disease 13.8 2.6 0.059 
Tubulo-interstitial disease 9.2 7.7 0.787 
Hypertension or RVD 13.8 20.5 0.373 
Other 15.4 7.7 0.251 
Unknown aetiology 
 
18.5 25.6 0.385 
 
5.4 Conclusion 
This cross-sectional survey found that nearly a quarter of the prevalent 
haemodialysis population has chronic and unexplained inflammation. Inflamed 
patients were associated with older age, increased weight and lower dialysis 
adequacy despite having slightly longer session duration. There were no significant 
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differences in terms of vascular access type, flow, use of haemodiafiltration or 
residual renal function which could explain this observation. The association 
between older age and inflammation may be due to heavier co-morbidity, although 
the CCI scores were similar to those without inflammation. Inflamed patients tended 
to have lower Kt/V values, although these values still exceed dialysis adequacy 
targets set by national and international guidelines. These observations are similar to 
study in PD patients which found an inverse relationship between the pro-
inflammatory cytokine IL-6 and Kt/V that was independent of residual renal function 
(Milan Manani et al. 2016). A lower dialysis dose may result in reduced clearance of 
cytokines since dialysis membranes are capable of removing some pro-inflammatory 
cytokines (Tarakçioğlu et al. 2003). However it is difficult to establish direct causal 
relationship between reduced dialysis dose and inflammation based on observational 
studies only. A significant proportion of patients had unexplained inflammation 
despite having no obvious predisposing risk factor which would drive a continuous 
inflammatory process.  
In summary, the prevalence of inflammation is high in the dialysis population and in 
many instances without an obvious clinical cause. Further studies are needed to 
investigate the underlying cause of inflammation to help mitigate the poor prognostic 
outcomes in dialysis patients.  
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 Chapter 6 
 
6. Studies to determine the optimum blood endotoxin assay in 
haemodialysis patients 
 
6.1 Introduction 
Determining the optimum blood endotoxin detection assay in haemodialysis patients 
is necessary before studies can be carried out to determine the association between 
blood endotoxin and inflammation in haemodialysis patients. As discussed in 
Chapter 2, blood endotoxin detection is difficult and no assays have been validated 
for use in blood, although many of these assays are frequently utilised in the 
research setting. A major problem with the methodology of blood endotoxin 
measurement may occur during blood sampling phase. Since endotoxin is 
ubiquitous, contamination of phlebotomy equipment, blood tubes and storage vials 
may lead to contamination of blood samples and falsely raised blood endotoxin 
levels. Most blood collection tubes are sterile but are not certified to be endotoxin-
free and additives in blood collection tubes may also be a source of contamination 
(Redl et al. 1992). Conversely, certain additives used to obtain plasma such as 
ethylenediaminetetraacetic acid (EDTA) and citrate can bind calcium by chelation 
and inhibit LAL reactivity (Cooper 1990).  
Most published endotoxin studies carried out in dialysis patients do not report the 
methodology used for blood sampling in sufficient detail therefore it is unclear 
whether steps have been taken by authors to minimise risk of introducing 
contamination or exogenous factors into blood samples which may affect the 
accuracy of reported results. Compounding this methodological issue, different LAL 
techniques and novel assays have been used to measure endotoxin in the dialysis 
population with a wide range of blood endotoxin level results, some of these are in 
different units, making it difficult to interpret the results (Table 2-1). No studies that 
compare the performance of these assays in the uraemic setting have been 
published.   
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The principle of the LAL assay is to observe the test sample after the addition of LAL 
to determine the rate at which the mixture coagulates. This is achieved by observing 
the increase in optical density of the sample mixture over time. As reviewed recently 
(Gnauck et al. 2016) and discussed in Chapter 3.1, there are several methods of 
calculating endotoxin from the generated optical density graphs but it is unclear 
which method is better for calculating of endotoxin content in uraemic blood 
samples.  
Endotoxin release into the blood may interact with plasma components including bile 
salts, proteins, lipoproteins leading to binding and the formation of complexes or 
micelles resulting in the hydrophobic lipid A being hidden from the aqueous 
environment. These complex interactions may alter the sensitivity of the LAL assay 
(Hurley 1995; Wang & Quinn 2010; Sandek et al. 2007). Blood contains poorly 
understood factors that can activate or inhibit the LAL assay such as serine 
proteases (e.g. thrombin, plasmin) (Fields 2006) and serine protease inhibitors (e.g. 
anti-plasmin and anti-thrombin III) (Levin et al. 1970). Additionally, blood samples 
from haemodialysis patients contain high levels of different uraemic solutes, it is 
unclear whether these solutes would exert effects on LAL activity. Historically, 
multiple methods have been devised to remove interfering factors present in blood, 
but the most effective and simple methods involve heating and dilution of the sample 
and most authors typically use a 1:10 dilution followed by heating for 70°C for 10 
minutes prior to testing (Hurley 1995). However, diluting the sample significantly 
reduces the threshold of detection, therefore a minimum dilution factor that would 
sufficiently remove interfering factors without compromising sensitivity would be 
desirable. There have also been reports in studies of patients with liver disease that 
utilise detergents such as Tween 80 as a diluent have improved recovery of 
endotoxin (Bode et al. 1993; Fukui et al. 1993). Exploration of such methods may be 
useful in improving the sensitivity of the LAL assay. 
There are a number of different commercial variations of the LAL assay. Kinetic LAL 
assays are the most recent developments which have the advantages of 
automaticity, increased sensitivity and a wider detection range compared to the older 
end-point assays. LAL detection can utilise either turbidimetric or chromogenic 
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methods (see Chapter 3). The chromogenic LAL assay has been the most 
commonly used endotoxin detection method in previous human studies and dialysis 
literature (Ronco et al. 2010). However, in Japan, the turbidimetric LAL assay is 
routinely used and is covered by the Japanese national health insurance program 
(Matsumoto et al. 2013). The majority of endotoxin studies carried out in dialysis 
patients was carried out using an endpoint chromogenic LAL assay (see Table 6-12). 
No direct head to head comparison studies of chromogenic versus turbidimetric LAL 
have been published. 
There are also a number of emerging novel assays which may have better accuracy 
and sensitivity than the traditional LAL assays. From a review of current novel 
assays (see Chapter 3), the Endotoxin Scattering Photometry assay (ESP) appeared 
to be the most promising due to its reported higher sensitivity and its reports of an 
association between endotoxemia and inflammation in haemodialysis patients, 
although this requires further examination (Terawaki et al. 2010). 
6.2 Study aims 
The aims of these studies were to:- 
1. Identify phlebotomy equipment and blood storage devices that do not have 
detectable endotoxin or LAL interfering factors for use in blood collection. 
[Chapter 6.3] 
2. Determine the optimum parameters derived from optical density graph to 
calculate endotoxin content of blood samples using the LAL assay. [Chapter 
6.5 and 6.6] 
3. Investigate plasma pre-treatment methods to improve the recovery of 
endotoxin from blood samples from haemodialysis patients. [Chapter 6.7 and 
6.8] 
4. Compare the performance of kinetic chromogenic and kinetic turbidimetric 
LAL assays with the novel ESP assay [Chapter 6.9] and the commonly used 
endpoint chromogenic LAL assay for endotoxin detection in haemodialysis 
patients [Chapter 6.10] 
70 
 
This chapter consists of seven sub-sections, each sub-section describes the 
experiments carried to meet the objectives described above. 
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6.3 Testing phlebotomy equipment, blood collection tubes and storage vials 
for endotoxin contamination and interfering factors 
6.3.1 Method 
All components and apparatus used for blood collection was examined for endotoxin 
contamination using the method described by the Association for Advancement of 
Medical Instrumentation (AAMI) (Bryans & Braithwaite 2004). Medical devices are 
tested for endotoxin by soaking in pyrogen free water for 1 hour at 37°C followed by 
analysis of the solution for endotoxin contamination. For these studies, endotoxin 
extracting solution (Wako Chemicals, USA) was allowed to dwell in the lumen of 
needles, syringes and blood collection tubes rather than soaking the whole device 
since collected blood will only be exposed to the inner lumen of the device. 
Endotoxin extracting solution containing of 0.1% human serum albumin (Wako 
Chemicals, USA) was used in replacement of pyrogen free water as a rinsing 
solution because endotoxin recovery from devices using water may be less efficient 
(Tsuchiya et al. 1996). After the dwell period, the rinse solutions were tested for 
endotoxin using the kinetic turbidimetric LAL assay (Charles Rivers, Ecully, France). 
This assay is used by the Quality Control department at the Lister Hospital for testing 
endotoxin contamination in dialysis water at the East and North Herts NHS Trust. 
The Quality Control department is also contracted to test dialysis water for endotoxin 
contamination for renal services from other NHS trusts and is subject to regular 
audits and checks by the Medicines and Healthcare Products Regulatory Agency. 
 
Devices were randomly selected to test for endotoxin contamination. Any devices 
that tested positive for endotoxin contamination were no longer considered suitable 
for use in subsequent studies and no further testing was performed on devices with 
evidence of endotoxin contamination. For devices that passed the initial test for 
endotoxin contamination (i.e. endotoxin content in rinse solution below the detection 
limit), a second device (of the same type) was randomly selected from another batch 
and subjected to repeat measurement for endotoxin contamination.  
 
To ensure that blood collection and storage tubes do not contain any LAL interfering 
factors, devices that tested negative for endotoxin contamination were instilled with 
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pyrogen free water spiked with 1 EU/mL of control standard endotoxin (CSE) and 
allowed to dwell for 1 hour at 37°C. Following the dwell period the solution was 
tested for endotoxin to measure % spike recovery:-  
 
% 𝑠𝑝𝑖𝑘𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑠𝑎𝑚𝑝𝑙𝑒
×  100% 
The spike recovery is a common method of determining the ability of an assay to 
measure an analyte of interest. In brief, a known quantity of analyte is added (or 
used to spike) a sample which is subjected to analysis by the assay. An ideal assay 
is able to measure the exact quantity of analyte that is added to the sample, thus an 
ideal ‘spike recovery’ for an assay would be 100%. 
For the LAL assay, spike recoveries between 50–200% are considered acceptable. 
The wide acceptable range is due to the fact that the LAL test is a biological assay 
and thus inherent variability in LAL testing is a well-recognised phenomenon due to 
differences in assay sensitivity, manufacturer reagents and laboratory accessories 
(Kumar 2006). The sensitivity of each batch of commercial LAL formulations 
(originally gel clot formulations) is calibrated against Reference Standard Endotoxin 
(RSE) supplied by the Food and Drug Administration (FDA) or the United States 
Pharmacopoeia (USP). The concentration of endotoxin at which clot formation 
occurs is termed lambda. The USP states that the verification of a LAL test’s proper 
performance (i.e. lack of interference by the sample) is demonstrated by clot 
formation at ½ lambda, lambda, or twice lambda. This requirement gave rise to the 
50–200% recovery specification used to verify appropriate LAL test performance 
(Kumar 2006; United States Pharmacopoeia 2013). 
The following devices were tested for endotoxin contamination and LAL interfering 
factors using the method described above and a flow chart is illustrated below 
(Figure 6-1): - 
 Terumo 10mL syringe 
 Terumo 20mL syringe 
 Becton Dickinson serum tube (containing clot activator and gel for serum 
separation) 
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 Becton Dickinson tube containing lithium heparin and gel for plasma 
separation 
 Becton Dickinson tube containing liquid EDTA  
 Becton Dickinson tube containing buffer sodium citrate (0.109M) 
 Terumo Venoject II tubes containing heparin 
 Eppendorf Biopur safe-lock tubes  
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Figure 6-1: Flow chart to illustrate protocol for testing blood collection apparatus for 
contamination and LAL interfering factors  
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Endotoxin assay  
Rinse solutions from devices were tested for endotoxin contamination using a kinetic 
turbidimetric LAL assay (Endosafe KTA2, Charles Rivers, Ecully). Analysis of 
samples was carried out using manufacturer supplied equipment including 
depyrogenated glass tube, pipettes and Eppendorf Endosafe pipette tips. 100μL of 
sample was added to duplicate wells on 96-well microplates. Endosafe KTA2 
reagent was reconstituted with 5.2mL of LAL reagent water (pyrogen-free water). 
100μL of this mixture was added to each sample. Analysis of each microplate 
consisted of duplicate wells containing LAL reagent water to act as a negative 
control. Plates were analysed using a Biotek ELx808 absorbance microplate reader 
with Endoscan-V software (version 4.0; Charles River Laboratories, France) and 
observed at 340 nm. The optical density of each well is observed and the time taken 
for the optical density to increase by 0.03 units is recorded. This is known as the 
reaction time (Figure 6-2). The onset reaction time is extrapolated from a standard 
curve to calculate the endotoxin content of a sample. 
 
 
Figure 6-2: Optical density graph showing a sample containing 10 EU/mL of endotoxin 
reaching the onset optical density of 0.03 at 488.8 seconds 
 
During the initial phase of testing, standard curves were constructed using dilutions 
of control standard endotoxin ranging from 10 to 0.01 EU/mL as this was the 
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detection range used to test for endotoxin contamination in dialysis water. However, 
the lower limit of detection stated by the manufacturer is 0.001 EU/mL depending on 
laboratory conditions and equipment. To exclude the possibility of low level 
endotoxin contamination in devices, the standard curve was extended from 10 to 
0.001 EU/mL when examining devices for endotoxin contamination on the repeat 
test.  
The USP regulations stipulate that all constructed standard curves are required to 
have a correlation coefficient of >0.98 for valid extrapolation of reaction times. Each 
standard should be analysed in at least two replicates and the coefficient of variation 
for standards should be <10% or ˂20% depending on the manufacturer (Richardson 
& Novitsky 2002). The coefficient of variation (CV) is a measure of precision and is 
used to assess the degree of agreement among individual test results. The CV is 
calculated by expressing the standard deviation as a percentage of the mean. The 
higher the CV the less precise or agreement there are between results. A valid 
standard curve ranging from 10 to 0.001 EU/mL is illustrated below:- 
 
 
Figure 6-3: Standard curve from 10 to 0.001 EU/mL (X-axis) against reaction time (Y-axis). 
Logarithmic scales are used. Correlation coefficient (r) = 0.992. Equation for regression line 
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drawn through data points is shown and is used to calculate endotoxin content of samples 
using the onset reaction time 
However, the reaction times obtained with the lowest standard (0.001 EU/mL) was 
not precise and occasionally the CVs obtained were as high as 33.57% which 
invalidated the standard curve (see Table 6-1). Elevating threshold of the lowest 
standard from 0.001 to 0.0025 EU/mL produced much more precise values for 
reaction times and multiple runs obtained CV values ranging from 0 to 2.76%. 
Therefore in subsequent studies to compare the performance of the LAL assay with 
the ESP assay (Chapter 6.9 and 6.10) the lowest standard used was 0.0025 EU/mL, 
which represented the lower limit of detection. 
 
Concentration of 
CSE (EU/mL) 
Run number Reaction time 
(seconds) 
 
CV (%) 
0.001 1 4185 
3570 
7.93 
 2 3195 
2325 
15.76 
 3 7860 
5805 
21.2 
 4 6465 
6675 
1.6 
 5 5790 
7635 
13.74 
 6 8535 
4245 
33.57 
0.0025 1 4380 
4425 
0.51 
 2 4665 
4665 
0 
 3 4755 
5025 
2.76 
 4 4320 
4185 
1.59 
 5 4170 
4275 
1.24 
 6 4140 
4305 
1.95 
 
Table 6-1: Coefficient of variation (CV) and reaction times obtained for control standard 
endotoxin (CSE) concentrations at 0.001 and 0.0025 EU/mL on multiple runs 
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6.3.2 Results 
Endotoxin content from blood collection tubes are shown in Table 6-2. A number of 
blood collection tubes were found to have endotoxin contamination or contain factors 
that may activate the LAL assay. Rinse solution from serum tubes from Becton 
Dickinson, Terumo Venoject II heparinised tubes and Terumo syringes did not have 
any detectable endotoxin. Water containing 1 EU/mL of CSE used to rinse these 
devices were analysed for endotoxin to measure spike recovery. Spike recovery was 
within the 50-200% suggesting these devices (Becton Dickinson serum tubes, 
Terumo Venoject II tubes and syringes) do not contain any significant LAL activating 
or inhibiting factors. 
 
 
Device Endotoxin content (EU/mL) Spike recovery (%) 
Run #1 #2 #1 #2 
Terumo 10mL syringe <0.01 <0.001 94 - 
Terumo 20mL syringe <0.005 <0.001 129 140 
BD Serum tube <0.01 <0.001 78.1 76 
BD Li Heparin tube 0.352 - - - 
BD EDTA tube 0.048 - - - 
BD Sodium citrate tube 0.523 - - - 
Terumo Venoject II tube <0.01 <0.001 94 87.8 
Eppendorf Biopur tubes <0.001* 86.4 95 
 
Table 6-2: Endotoxin content of devices and spike recoveries obtained from water spiked with 
1 EU/mL control standard endotoxin solution used to rinse device.  
* - Eppendorf Biopur tubes are manufacturer certified to contain <0.001 EU/mL. 
 
6.3.3 Conclusion 
These series of experiments have determined suitable blood collection tubes and 
syringes to be used for blood sampling. Examination of a selection of blood 
collection tubes showed that most tubes contain significant endotoxin contamination. 
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From the blood collection tubes tested, only Becton Dickinson serum tubes and 
Terumo Venoject II heparinised tubes tested negative for endotoxin contamination. 
Becton Dickinson serum tubes contains a clot activating gel for separation of serum 
from blood and Terumo Venoject II tubes contain heparin as an anticoagulant which 
allows plasma to be separated from whole blood, these blood collection tubes were 
used in subsequent studies. A number of syringes (to be used for blood draw) were 
checked and did not demonstrate significant endotoxin contamination or contain LAL 
interfering factors. Eppendorf Biopur tubes are manufacturer certified to contain 
<0.001 EU/mL, spike recovery of 1 EU/mL CSE that were allowed to dwell within the 
tubes were between 86.4 to 95% suggesting that these storage tubes do not contain 
any LAL interfering factors.  
 
In conclusion, Becton Dickinson serum tubes, Terumo Venoject II tubes, Terumo 
syringes and Eppendorf Biopur tubes will be used for blood sampling and storage for 
subsequent studies. 
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6.4 Study population 
A number of studies were carried out and described in this chapter. The purpose of 
these studies was to investigate methods to optimise the accuracy of the LAL assay 
and to compare the performance of different variations of the LAL assays with the 
ESP assay. These series of experiments were carried out using blood specimens 
collected from seven haemodialysis patients and seven healthy individuals with no 
history of renal disease. All participants gave informed written consent. 
Inclusion criteria (Haemodialysis patients) 
 Adult patients on haemodialysis aged 18 years and above.  
 Adult patients dialysing through a functioning arteriovenous fistula. 
 Patients with at least two measurements of CRP < 5 mg/L carried at least one 
month apart within the last 3 months. 
Inclusion criteria (Healthy controls) 
 Healthy adults aged 18 years and above 
 No history of kidney disease 
Exclusion criteria 
 Anaemia (Hb < 100g/L) 
 Ongoing sepsis 
 HIV, Hepatitis B or C positive status 
 Current pregnancy 
 Active vasculitis or connective tissue disease 
 Active malignancy 
 Liver dysfunction 
 Right chamber heart failure  
 On oral steroids, NSAIDs or immunosuppressive medications 
 Any bowel pathology e.g. diverticulitis or inflammatory bowel disease 
 No capacity to consent for themselves 
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6.5 Determining the difference in spike recovery between plasma and serum 
6.5.1 Introduction 
Serum and plasma are both components of blood. Serum is the extracellular 
proportion of blood after coagulation and is devoid of clotting factors such as 
fibrinogen. Plasma is the liquid, extracellular component of blood that has been 
treated with anti-coagulants, composing of serum and clotting factors. Both serum 
and plasma have been used in previous studies for measurement of blood 
endotoxin. The pros and cons for using serum or plasma for endotoxin measurement 
has been previously discussed (Hurley 1995). The endotoxin inactivation capacity of 
serum has been reported to be higher than plasma by some authors, however others 
have found the opposite (Novitsky & Roslansky 1985). In general, experts consider 
plasma as the preferred blood component for measurement of endotoxin (Hurley 
1995).  
A number of studies have also investigated the difference in endotoxin recovery 
between platelet rich versus platelet poor plasma. Some authors advocate the use of 
platelet rich plasma due to the observation of endotoxin binding to platelets (Das et 
al. 1973), although this has been disputed by the lack of difference in the recovery of 
endotoxin from platelet rich, platelet poor plasma and whole blood (Sakon et al. 
1986). Despite the lack of strong evidence, and due to the possibility of platelet 
binding to endotoxin, many endotoxin studies have been conducted using platelet 
rich plasma [summarised in (Novitsky 1994)]. 
The studies carried out in section 6.3 showed that both Becton Dickinson serum 
tubes and Terumo Venoject II heparinised tubes (to produce plasma) could be used. 
Although the current literature suggests that plasma is preferred over serum for 
measuring endotoxin, a brief study was carried out to verify this. 
6.5.2 Methods 
Venesection and processing of samples 
Blood was drawn aseptically from one healthy individual and collected in Becton 
Dickinson serum tubes and Terumo Venoject II heparinised tubes. Blood collected in 
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the serum tubes were allowed to rest and fully coagulate prior to centrifuging at 
1500g for 10 minutes at 4°C. Serum samples were immediately placed in Eppendorf 
Biopur safe lock tubes and stored at -80°C. Blood collected using Terumo Venoject II 
heparinised tubes were centrifuged at 250g for 10 minutes at 4°C to produce platelet 
rich plasma and stored at -80°C. All blood samples were processed and stored 
within 30 minutes of collection. 
Endotoxin spiking procedure 
On the day of analysis, plasma and serum samples were thawed to room 
temperature (20-25°C) and spiked with 5 EU/mL of standard E.coli 055:B5 endotoxin 
Samples were vortexed and incubated at room temperature for 15 minutes. To 
remove potential LAL activating or inhibitory factors present in serum/plasma. 
Samples were diluted 1:10 with LAL reagent water and heated at 70°C for 10 
minutes. These heating and dilution conditions were recommended based on an 
extensive review of studies using different heating and dilution methods (Hurley 
1995). Samples were allowed to cool to room temperature prior to measurement for 
endotoxin. 
Endotoxin measurement 
Samples were measured using the kinetic turbidimetric LAL assay (Endosafe KTA2; 
Charles River, Ecully) as described above. Samples were analysed in duplicate on 
sterile 96 well microplates (manufacturer-certified to <0.001 EU/mL) and analysed 
using a Biotek ELx808 absorbance microplate reader with manufacturer supplied 
software (Endoscan-V version 4.0, Charles River, Ecully), reaction times were 
recorded at onset optical density of 0.03. A four point standard curve was 
constructed using control standard endotoxin with correlation coefficient >0.98 (10-
0.01 EU/mL). Coefficient of variation for reaction times for standards and samples 
was <20%. Spike recovery was calculated for all samples using the method as 
described in section 6.3. 
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6.5.3 Results 
Endotoxin measurements for plasma and serum samples are shown in Table 6-3. 
Endotoxin content in both plasma and serum was <0.01 EU/mL. Despite a relatively 
large spike of endotoxin (5 EU/mL), recovery of endotoxin from serum samples was 
low at 16.3%, consistent with previous reports of endotoxin neutralising properties of 
serum (Gnauck et al. 2016; Hurley 1995). Spike recovery from plasma was higher at 
58.1% which is within the 50-200% requirement (United States Pharmacopoeia 
2013) although considerable amount of spiked endotoxin was not retrieved despite 
dilution and heat treatment. 
Blood component Concentration of 
endotoxin spike (EU/mL) 
 
Endotoxin measured 
from sample (EU/mL) 
Spike recovery (%) 
Serum 0 
 
<0.01 - 
 5 
 
0.814 16.3 
Plasma 0 
 
<0.01 - 
 5 2.905 58.1 
 
Table 6-3: Endotoxin spike recovery from plasma and serum samples spiked with 5 EU/mL of 
control standard endotoxin 
6.5.4 Conclusion 
The finding from this study suggests that recovery of endotoxin from plasma is better 
than serum which is in agreement with previous reports (Hurley 1995). Both types of 
collection tubes were examined and did not contain any endotoxin contamination or 
LAL interfering factors. The inherent endotoxin neutralising properties of both serum 
and plasma is well known, although the molecular nature of these inhibitors remain 
to be fully understood, it appears to be heat-labile and the effects are partially 
removed by dilution and heat treatment (Novitsky & Roslansky 1985). The spike 
recovery from plasma was 58.1%, which is just within the 50-200% requirement, 
although the amount of spiked LPS retrieved is relatively low. Hence it is worthwhile 
exploring measures to improve the spike recovery such as using different dilutions 
and use of detergents to improve the recovery (see Chapter 6.7 and 6.8). A 
considerable large amount of LPS was used to spike the samples (5 EU/mL) 
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although it is unlikely that samples collected from non-septic haemodialysis patients 
would have such a high level of endotoxemia. It is unclear, if endotoxin spike 
recovery would still be in the acceptable range if lower concentrations of endotoxin 
are used to spike and further studies will be conducted to explore this. Further 
studies were conducted to determine the spike recovery from samples spiked with 
endotoxin in the range reported in the dialysis literature (see Table 2-1) (Chapter 
6.9). In conclusion, the study findings show that more endotoxin can be detected 
from plasma compared to serum. The reasons for this are unclear, although it has 
been reported that endotoxin may be associated with blood components such as 
platelets that are not found in serum (Das et al. 1973). In subsequent studies 
described in this thesis to investigate the association between endotoxemia and 
unexplained inflammation in haemodialysis patients, the plasma component of blood 
was used for the measurement of endotoxin. 
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6.6 Analysing the optical density graph - use of alternative methods to 
calculate endotoxin  
6.6.1 Introduction 
For kinetic LAL techniques, there are a number of different methods of calculating 
the endotoxin content using the generated optical density graphs. As discussed in 
Chapter 3, the most conventional method used by manufacturers is based on the 
time taken for the optical density to increase to a threshold optical density (typically 
ranging from 0.03 to 0.2) [Figure 6-4].  
 
 
Figure 6-4: Optical density graph showing reaction curve 
 
There is no guidance on the threshold optical density and manufacturers may 
recommend different threshold or onset optical densities, although it is generally 
recommended that a lower threshold should be used if low concentration standards 
are used or if a particular batch of LAL reagents reacts more slowly. 
The purpose of this study was to determine whether alternative parameters derived 
from the reaction curve of the optical density graph could better quantify endotoxin 
content of a sample compared to the conventional method.  
The optical density plot is typically a sigmoid curve consisting of a lag phase, 
followed by a period of rapid increase and ending with a terminal plateau phase. The 
rate of increase in optical density is a function of the concentration of endotoxin 
(Hurley et al. 1991). An alternative method of calculation is to calculate the maximum 
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velocity of the reaction (Vmax) by measuring the slope of the linear part of the 
reaction curve (Figure 6-5). This method requires the reaction in the sample to reach 
a plateau phase because most software are only able to determine Vmax from a 
reaction curve accurately that reaches a plateau  (Gnauck et al. 2016). 
 
Figure 6-5: Linear portion of reaction curve is used for calculation Vmax 
 
Other alternative parameters including using the reaction time taken for the sample 
to increase by 50% of the maximum optical density (LAL50%) [Figure 6-6]. 
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Figure 6-6: Optical density graph to show reaction time when 50% of the maximum optical 
density is reached 
The disadvantage of using the Vmax and the LAL50% parameters is the requirement 
for prolongation of the analytical period to allow the reaction curve to reach the 
plateau phase. Analytical periods may be significantly prolonged for samples with a 
low amount of endotoxin.  
As discussed earlier, the onset optical density threshold set by manufacturers is 
variable and can range from 0.03 to 0.2. A different onset reaction time was selected 
based on the point at which the reaction curve starts becomes linear rather than 
using a ‘fixed’ optical density which is arbitrarily set. This point was chosen since this 
represents the onset time for which the reaction curve achieves the most rapid rate 
of increase in optical density (‘onset time B’) [see Figure 6-7].  
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Figure 6-7: Onset time B – reaction time at onset of maximal rate of increase in optical density 
The accuracy of all four parameters including the conventional method, Vmax, 
LAL50% and onset time B to quantify endotoxin from plasma samples spiked with 
CSE were compared. 
6.6.2 Methods 
Blood samples were drawn from two healthy controls using the method already 
described in section 6.5.2, blood samples were processed to produce plasma and 
stored at -80ºC until analysis.  
Plasma samples were thawed on the day of analysis and spiked with CSE ranging 
from 0.05 to 5 EU/mL and incubated for 15-30 minutes. Samples were diluted 1:10 
and heated at 70ºC for 10 minutes followed by analysis using the kinetic turbidimetric 
LAL assay (Endosafe KTA2, Charles River, Ecully) as described in section 6.5.2. All 
samples were incubated at 37ºC and analysed using a Biotek ELx808 absorbance 
microplate reader. Optical density readings were measured every 30 seconds for 
9999 seconds which was the analytical time limit of the microplate reader. 
Data analysis 
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Data points from optical density graph for standards and samples were extracted 
from the microplate reader. An asymmetric sigmoidal 5 parameter logistic regression 
line was fitted through these data points using Graphpad Prism Software (version 
6.01, 2012), the regression line was used for calculation of Vmax, LAL50% and 
‘onset time B’. 
Vmax: was calculated by measuring the slope of the gradient of the linear portion of 
the sigmoid curve. 
LAL50%: the reaction time at the point for which the optical density was 50% of the 
maximum optical density reached by the end of the incubation period was recorded. 
Onset time B: this is the reaction time at the onset of the maximal rate of increase in 
the optical density of the sample. The second derivative of the regression line for 
each sample analysed was plotted and the reaction time for which the maximal rate 
of increase in optical density was recorded by manual inspection by identifying the 
first inflection point of the graph of the second derivative of the regression line (see 
Figure 6-8). 
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Figure 6-8: (A) Optical density curve of sample, (B) First derivative of curve A, (C) Second 
derivative of curve A. Onset time B was recorded at the first point of inflection for graph C (red 
vertical line – represents time of onset of maximal rate of increase in optical density) 
Standard curves were constructed using optical density readings from dilutions of 
CSE ranging from 10 to 0.005 EU/mL. Spike recovery for each spiked sample was 
recorded and comparisons made between each method. 
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6.6.3 Results 
Spike recovery from plasma samples calculated using all four parameters derived 
from the optical density graph is shown in Table 6-4. Using the conventional method 
of calculating endotoxin content (using the reaction time at a onset optical density of 
0.03) yielded the most accurate spike recoveries, ranging from 53.9 to 105%, in one 
sample spiked with 0.05 EU/mL, recovery was only 0%. This may have been due to 
the low level spike used since 0.05 EU/mL was the lowest limit of detection (the 
lowest standard used for this study was 0.005 EU/mL, dilution factor was 1:10). 
Spike recovery using the Vmax was poor ranging from 0 to 27.3%. The onset time B 
method generated a large variability in spike recovery ranging from -48 to 95.2% 
respectively. Spike recovery using was LAL50% was similar to that using the 
conventional method with recovery ranging from 57.9 to 69.8%, although in all 
plasma samples that were spiked with 0.05 EU/mL, spike recovery was 0%. This 
suggests that the conventional method of using the reaction time at a fixed optical 
density was the most accurate method of calculating endotoxin content in 
comparison to the other alternative methods. 
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Participant Concentration of 
endotoxin spike 
(EU/mL) 
 
Parameter Measured endotoxin 
(EU/mL) 
Spike recovery (%) 
1 0 (unspiked sample) Onset OD reaction time  <0.005 - 
  Vmax <0.005 - 
  LAL50% 0.052 - 
  Onset time B 0.086 - 
 0.05 Onset OD reaction time  0.053 105 
  Vmax <0.005 0 
  LAL50% <0.005 0 
  Onset time B 0.062 -48 
 0.5 Onset OD reaction time  0.375 75.1 
  Vmax 0.123 24.6 
  LAL50% 0.307 61.4 
  Onset time B 0.437 70.4 
 5 Onset OD reaction time  2.697 53.9 
  Vmax 0.378 7.6 
  LAL50% 2.95 57.9 
  Onset time B 4.266 83.6 
2 0 (unspiked sample) Onset OD reaction time  <0.005 - 
  Vmax <0.005 - 
  LAL50% <0.005 - 
  Onset time B 0.164 - 
 0.05 Onset OD reaction time  <0.005 0 
  Vmax <0.005 0 
  LAL50% <0.005 0 
  Onset time B 0.198 68.8 
 5 Onset OD reaction time  3.676 73.5 
  Vmax 1.364 27.3 
  LAL50% 3.49 69.8 
  Onset time B 4.922 95.2 
 
Table 6-4: Spike recovery from plasma samples spiked with different concentrations of control 
standard endotoxin. Spike recovery derived from using different parameters of optical density 
graph was compared. Onset OD reaction time, reaction time at onset OD 0.03; Vmax, slope of 
linear part of reaction curve; LAL 50%, reaction time at 50% of max OD, Onset time B, reaction 
time at onset of maximal rate of increase in OD 
6.6.4 Conclusion 
This study investigated alternative methods of calculating endotoxin content from the 
optical density graph. Alternative methods using Vmax, the LAL50% and onset time 
B were not superior to the conventional method of calculating endotoxin content. The 
Vmax and LAL50% method have the added disadvantage of requiring a prolonged 
analytical time to allow the reaction curves to reach the plateau phase. Using the 
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reaction time at the onset of maximal rate of increase in optical density (onset time 
B) yielded extremely variable spike recoveries and would not be suitable for use.  
In summary, using the reaction time at a fixed onset optical density was the optimum 
parameter for calculating endotoxin content. This method of calculation is built into 
most manufacturer software which enables automaticity for calculation of endotoxin 
content and results can be obtained without having to wait for the reaction curves to 
reach the plateau phase. One limitation of this study was that different threshold 
levels of optical density was not investigated and it may be possible that having a 
lower or high threshold optical density value may improve the accuracy of the results 
although using the standard value recommended by the manufacturer (onset optical 
density of 0.03), although the majority of spike recoveries was acceptable and within 
the 50-200% limit.  
In summary, using the reaction time at the onset of a fixed optical density provides 
the most accurate method of quantifying endotoxin content of a sample. This 
parameter from the optical density graph will be used for calculation of endotoxin in 
subsequent clinical studies. 
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6.7 Studies to determine optimum dilution factor for endotoxin detection 
using the LAL assay 
6.7.1 Introduction 
Blood consists of complex proteins such as endogenous amidases (e.g. plasmin and 
thrombin) that can activate the LAL assay and proteins such as anti-thrombin II (a 
serine protease inhibitor) that may inhibit the activity of the LAL assay (Webster 
1980). Inactivation of these plasma components is necessary prior to measurement 
for endotoxin using the LAL assay. Several historical methods for inactivation of 
these substances have been previously described including chloroform extraction, 
gel extraction, solid-phase binding and perchloric acid treatment. These techniques 
are complex and have largely been superseded by dilution and heat treatment for its 
simplicity and relative efficacy (Hurley 1995). Although simple, the necessity to dilute 
samples decreases the sensitivity of the assay. The current limit of detection using 
kinetic techniques is 0.001 EU/mL (Brade 1999), but blood samples are usually 
diluted by a ten-fold dilution, this would reduce the limit of detection to 0.01 EU/mL. 
Thus, a minimum dilution factor should be used to enable sufficient dilution of the 
interfering factor in the sample without compromising the sensitivity of the assay. 
The usual dilution factor is 1:10, however more recent endotoxin studies in the 
dialysis population have utilised a 1:5 dilution (Christopher McIntyre 2011; Jefferies 
et al. 2014). The studies described in section 0 and 0 were carried using a 1:10 
dilution factor for plasma and serum samples. These preliminary studies show that in 
general, spike recovery from plasma was within the acceptable limit of 50-200%, 
however there was a general trend for samples spiked with large amounts of 
endotoxin to achieve lower spike recoveries compared to samples spiked with 
smaller quantities of endotoxin (see Table 6-4, spike recoveries for samples spiked 
with 0.05 EU/mL ranged from 75.1 to 105%; spike recoveries for samples spiked 
with 5 EU/mL ranged from 57.9 to 73.5%). It is possible that for samples with known 
large quantities of endotoxin, further dilution is necessary to improve recovery. It 
would also be desirable to investigate if using 1:5 dilution could adequately remove 
the effects of any activators or inhibitors in plasma since this would the sensitivity of 
the assay to be increased. 
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The purpose of this study was to investigate optimal dilution factors for pre-treatment 
of uraemic plasma for endotoxin detection.  
6.7.2 Method 
Blood samples were drawn from one healthy control and processed to produce 
platelet rich plasma using the method as described in section 6.5.2. Samples were 
stored at -80°C. 
On the day of analysis, samples was thawed to room temperature (20-25°C) and 
divided into aliquots. Samples were spiked with different concentrations of control 
standard endotoxin (CSE) ranging 0.05, 0.1, 0.25, 0.5, 1, 2.5 and 5 EU/mL. Samples 
were incubated for 15 to 30 minutes and diluted 1:5 and 1:10 and subjected to dry 
heat at 70°C for 10 minutes prior to analysis for endotoxin to calculate spike recovery 
using the kinetic turbidimetric LAL assay (Endosafe KTA2, Charles Rivers). Standard 
curves were constructed for each plate from 10 to 0.005 EU/mL. Spike recovery for 
each spiked sample was calculated. Spike recovery was initially compared between 
1:5 and 1:10 dilutions. For samples with a spike recovery ≤60%, samples were 
further diluted to 1:20 to determine if spike recovery could be improved with a greater 
dilution factor. 
6.7.3 Results 
Endotoxin spike recovery for samples diluted using different dilution factors are 
shown in Table 6-5. In general, a 1:5 dilution yielded relatively poor spike recoveries 
ranging from 0-60%, suggesting that a 1:5 dilution was insufficient to remove the 
inhibitory effects of plasma on the LAL assay. Using a higher dilution factor of 1:10 
revealed similar findings to the results from studies carried out in section 0. Spike 
recovery was reasonable and within the acceptable limits, ranging from 93.6 to 
144%, but recovery progressively reduced with increasing concentration of the 
endotoxin spike. Samples with 1 to 5 EU/mL of added endotoxin resulted in relatively 
modest spike recoveries (41.3 to 62.9%). However, diluting the same samples using 
a 1:20 improved the spike recovery to between 79.3 to 124.9%. 
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 Concentration of endotoxin spike (EU/mL) 
Dilution factor 
 
0 0.05 0.1 0.25 0.5 1 2.5 5 
1:5 dilution         
         
Endotoxin 
(EU/mL) 
 
<0.005 <0.005 0.083 0.147 0.245 0.629 1.486 2.063 
Spike recovery 
(%) 
 
 0 55 49 45 60 58 41 
1:10 dilution         
         
Endotoxin 
(EU/mL) 
 
<0.005 0.072 0.134 0.234 0.47 0.629 1.486 2.063 
Spike recovery 
(%) 
 
 144 134 93.6 94 62.9 59.4 41.3 
1:20 dilution         
         
Endotoxin 
(EU/mL) 
 
<0.005 - - - - 1.249 2.79 3.96 
Spike recovery 
(%) 
 - - - - 124.9 111.6 79.2 
 
Table 6-5: Spike recoveries for plasma samples diluted using 1:5, 1:10 and 1:20 dilution factor 
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6.7.4 Conclusion 
This study was in agreement with previous observations that sufficient dilution and 
heat treatment of plasma is necessary for adequate retrieval of endotoxin. Use of 1:5 
dilution factor was borderline sufficient to recover some endotoxin from plasma 
however in some cases, spike recovery was below the 50% criteria. This is contrary 
to studies conducted by other investigators (Jefferies et al. 2014; Szeto et al. 2010; 
Kwan, Chow, Leung, et al. 2013) who used a 1:5 dilution and found elevated blood 
endotoxin levels (mean endotoxin levels ranged from 0.65-1.95 EU/mL) in dialysis 
patients. However, these studies were performed using an end-point LAL detection 
method.  
The minimum dilution factor necessary was 1:10 for more accurate endotoxin spike 
recoveries. However, although spike recovery was accurate for samples containing 
lower amounts of endotoxin (0.05-0.5 EU/mL), in agreement with the studies 
described in Chapter 6.5, spike recovery progressively reduced with higher 
concentrations of endotoxin spike. The reason for this observation is unclear 
however it is known that the aggregative state of the endotoxin molecule may have 
differential effects biologically and on the LAL assay itself. Naturally occurring 
endotoxin are usually in an aggregated state, it has been proposed that endotoxin 
aggregation is necessary for biological and LAL activity. Ribi et al showed that 
endotoxin derived from three species of gram negative bacteria was rendered non-
pyrogenic using the rabbit pyrogen test when the endotoxin was dissociated using 
sodium deoxycholate. Removal of sodium deoxycholate with dialysis allowed the 
subunits to re-aggregate and restored its pyrogenic activity in rabbits (Ribi et al. 
1966). Mueller et al examined the biological activity of aggregated and monomeric 
forms of endotoxin and found that aggregates are more biologically active in terms of 
cytokine inducing effects on human mononuclear cells and on the LAL assay 
(Mueller et al. 2004). However, other authors have found the opposite and described 
increased activity of the LAL assay with monomeric forms LPS (Takayama et al. 
1994a; Shnyra et al. 1993). Detergents and surfactants are known to alter the 
aggregative state of the endotoxin molecule thus altering their biological activity and 
its subsequent detection by the LAL assay. Increased endotoxin detection from 
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blood of patients with liver disease using surfactants has been previously reported 
(Bode et al. 1993), although the mechanism for this have not been elucidated..  
This small study suggests that retrieval of endotoxin from plasma in the range 0.05 
to 0.5 EU/mL, is possible using current blood sampling methods with a 1:10 dilution 
and heat treatment. Recovery of endotoxin in samples with higher amounts of 
endotoxin (>0.5 EU/mL) is not as successful and may need further dilution to obtain 
a more accurate result. However, this approach would be cumbersome as samples 
may need to be measured twice although it would be unlikely for many samples from 
our clinically stable non-infected haemodialysis population to have such high level of 
endotoxin. Given the success reported by Bode et al, the use of surfactants to 
improve spike recovery was investigated (see section 6.8). 
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6.8 Studies to investigate the use of surfactants to optimise endotoxin 
detection using the LAL assay  
6.8.1 Introduction 
Endotoxins are lipopolysaccharides comprising of three distinct components (Figure 
6-9). The O antigen consists of a polysaccharide region which is variable between 
species. This is attached to a more conserved core region and lipid A antigen. The 
lipid A antigen is highly conserved among different species of bacteria and is 
responsible for the pro-inflammatory and toxic effects of endotoxin. The lipid A region 
is the component that reacts with biological assays enabling its detection (Williams 
2007). 
 
 
Figure 6-9: Schematic diagram of endotoxin structure 
Endotoxin is an amphipathic molecule and can form aggregates and micelles in 
aqueous form. It has been hypothesised that highly aggregated forms of endotoxin 
may ‘hide’ the endotoxin from detection (Bode et al. 1993; Fukui et al. 1993). 
However, most consider the endotoxin aggregates are more active biologically and 
reactive with detection assays (Tsuchiya 2014; Mueller et al. 2004; Ribi et al. 1966). 
Although some studies have found have found the opposite is true and have shown 
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that monomeric forms of endotoxin are more active (Din et al. 1993a; Takayama et 
al. 1994b). Thus chemicals that can alter the aggregative state of an endotoxin 
molecule may be able to improve its reactivity with detection assays. 
Some authors have found that use of Tween 80 (polysorbate 80), a non-ionic 
surfactant, improved the recovery of endotoxin from plasma of patients with liver 
disease (Fukui et al. 1993; Bode et al. 1993). Use of other surfactants such as 
Tween 20 (polysorbate 20) and Triton X-100 to improve recovery of endotoxin from 
plasma has also been reported (Katsuya et al. 1992). Surfactants are known to alter 
the aggregative state of endotoxin by dissociating them into their monomeric forms 
(Jang et al. 2009). Due to the reduced spike recovery observed with blood 
specimens spiked with high amounts of endotoxin (see section 6.8), the use of two 
surfactants – Triton X-100 and Tween 80, to improve spike recovery from plasma 
samples was investigated. 
6.8.2 Methods 
Concentrations of Triton X-100 (Sigma-Aldrich, United Kingdom) and Tween-80 
(Merck Chemicals, Germancy) similar to those used in previous studies (Bode et al. 
1993; Katsuya et al. 1992) were made by dilution with LAL reagent water. Triton X-
100 at concentrations of 0.02% and Tween 80 at 0.1% were tested for endotoxin 
contamination using the kinetic turbidimetric LAL assay (Endosafe KTA2, Charles 
River, France) to ensure that both surfactants were not contaminated with endotoxin. 
Samples were analysed in duplicate and positive control wells were spiked with 0.1 
EU/mL for measurement of spike recovery to ensure there were no significant LAL 
interfering factors present in the surfactant. LAL reagent water was used as negative 
control and standard curve ranging from 10-0.005 EU/mL was constructed. 
Endotoxin results were extrapolated from the standard curve using reaction time at 
an onset optical density of 0.03. 
6.8.2.1 Determining the optimum surfactant 
Studies were carried out to determine the optimum surfactant to use as a diluent 
since both Tween 80 and Triton X-100 have been used previously. Blood samples 
were collected from one healthy control and processed to produce plasma and 
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stored as previously described (section 6.5.2). Samples were thawed on the day of 
analysis, aliquoted and spiked with 0.05, 0.5 and 2.5 EU/mL. Endotoxin spiked 
samples were diluted in either 0.02% Triton X-100 or 0.1% Tween 80 using a 1:10 
dilution factor followed by heat treatment at 70°C for 10 minutes. Samples were 
analysed using Endosafe KTA2 LAL assay to assess spike recovery. 
6.8.2.2 Determining the effect of surfactants on endotoxin spike recovery from 
plasma 
The optimum surfactant determined from the study performed in section 6.8.2.1 was 
further explored measuring its effect on spike recovery from samples from five 
healthy controls and five haemodialysis patients to ensure that any potential 
efficacious effect of surfactants on spike recovery could be replicated in uraemic 
plasma. Blood samples were collected and processed as described above, aliquots 
of plasma were spiked with 0.1 and 2.5 EU/mL. Samples were diluted 1:10 using 
water or the optimum surfactant determined from section 6.8.2.1 and heat treated as 
described above. All samples were analysed using the kinetic turbidimetric LAL 
assay (Endosafe KTA2, Charles River, France) to compare the difference in spike 
recovery achieved with using water or detergent as a diluent. Standard curves from 
10-0.0025 EU/mL was constructed, endotoxin results were extrapolated from the 
standard curve using the reaction time at onset optical density of 0.03. 
Due to the viscous nature of plasma and surfactants, occasionally bubbles in the 
samples caused artefacts in the optical density graphs. These artefacts can lead to 
imprecision in the calculation of endotoxin content in the sample (Figure 6-10). 
Optical density graphs for all samples were inspected and those containing artefacts 
were discarded from the analysis and the sample measurement was repeated. 
Artefacts occurred rarely but was a result of inadequate pipetting which created 
bubbles in the sample. 
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Figure 6-10: Bubbles in the samples introducing artefact in the optical density graph.  
Statistical analysis 
Differences in spike recovery between samples diluted in surfactant and LAL reagent 
water were compared using paired t test. Endotoxin concentration between groups 
was compared using the Wilcoxon signed-rank test or Mann–Whitney U test as 
appropriate. 
 
6.8.3 Results 
Dilutions of Triton X-100 and Tween 80 did not have any detectable endotoxin. Spike 
recovery for positive product controls for both surfactants was within the 50-200% 
range (Table 6-6).  
 
Surfactant Endotoxin (EU/mL) Spike recovery (%) 
 
Triton 0.02% 
 
<0.005 
 
59 
Tween80 0.1% <0.005 102 
 
Table 6-6: Endotoxin content of detergents and respective spike recovery from positive 
product control 
LAL reagent water and both surfactants were used to dilute endotoxin spiked plasma 
samples (Table 6-7), similar to previous findings, spike recovery using water as a 
diluent was within the 50-200% valid range, however a progressive reduction in 
spike recovery was observed in samples with progressively higher concentrations of 
103 
 
endotoxin. Spike recovery was not improved with the use of Triton X-100 with spike 
recovery ranging from 0 to 67%. Spike recovery using Tween 80 was improved 
compared to both Triton X-100 and water with recoveries ranging from 92 to 188%.  
Diluent Concentration of 
endotoxin spike 
(EU/mL) 
Endotoxin (EU/mL) Spike recovery (%) 
LAL reagent water 0 
0.05 
0.5 
2.5 
<0.005 
0.054 
0.393 
1.368 
- 
108 
78.6 
54.7 
Triton 0.02% 0 
0.05 
0.5 
2.5 
0.089 
0.079 
0.424 
1.67 
- 
0 
67 
63.2 
Tween80 0.1% 0 
0.05 
0.5 
2.5 
<0.005 
0.094 
0.52 
2.30 
- 
188 
104 
92 
Table 6-7: Comparison of spike recovery from plasma samples between detergents and water 
as a diluent 
These initial findings suggest that at the concentrations tested, greater improvement 
in endotoxin recovery could be achieved with Tween 80 compared to Triton X-100. 
The efficacy of 0.1% Tween 80 was further examined by repeating in a study 
comprising of five haemodialysis patients (mean age 58) and five healthy adults 
(mean age 44). 
Endotoxin recovery was similar in both haemodialysis patients and healthy subjects 
spiked with a low concentration of endotoxin (0.1EU/ml). In plasma spiked with high 
concentration of endotoxin (2.5 EU/ml), use of Tween 80 significantly improved 
recovery in both haemodialysis patients (100.1% vs. 70.4%; p < 0.001) [Figure 6-11] 
and healthy controls (90.4% vs. 59.8%; p = 0.002) [Figure 6-12].   
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Figure 6-11: Mean endotoxin spike recovery from haemodialysis patients. Plasma samples 
diluted with 0.1% Tween 80 and water. Reproduced from (Wong et al. 2015) BMJ publishing 
group with permission. 
 
 
Figure 6-12: Mean endotoxin spike recovery in healthy plasma diluted with 0.1% Tween 80 and 
water. Reproduced from (Wong et al. 2015) BMJ publishing group with permission. 
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In unspiked plasma samples, dilution with 0.1% Tween 80 yielded a higher 
concentration of endotoxin content than in plasma samples diluted with water only 
(0.04 EU/ml vs. 0.036 EU/ml; p = 0.046) (Figure 6-13).  
 
Figure 6-13: Baseline endotoxin content in plasma of haemodialysis patients diluted with 0.1% 
Tween 80 and water. Reproduced from (Wong et al. 2015) BMJ publishing group with 
permission. 
 
Endotoxemia was detected in 4 out of 5 haemodialysis patients and the median 
endotoxin level was 0.041 EU/ml [95% CI 0 to 0.1 EU/ml]. In healthy controls, low 
level endotoxemia was detected in only one subject (0.027 EU/ml).     
6.8.4 Conclusion 
Valid spike recovery of between 50-200% was obtained using both Tween 80 and 
water. Spike recovery was reduced in samples containing a high quantity of 
endotoxin when water was used as a diluent. This was improved with the use of 
0.1% Tween 80 suggesting it improves detection if samples contain a large quantity 
of endotoxin. Baseline endotoxin content was also significantly higher in plasma 
diluted with Tween 80 compared to dilution in water only, further supporting this 
notion and in agreement with previous studies (Bode et al. 1993; Fukui et al. 1993). 
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The underlying mechanistic effect which could explain the improved endotoxin 
detection using detergents is unclear. In general, industry experts consider that the 
aggregated form of endotoxin molecule is more biologically active (Tsuchiya 2014), 
although findings from some studies are in conflict with this opinion (Takayama et al. 
1994b; Din et al. 1993b). Pharmaceutical products containing surfactants or 
detergents such as polysorbate have recently been identified as a cause of the 
phenomenon of ‘low endotoxin recovery’ in products such as vaccines which have 
been directly spiked with endotoxin (Reich et al. 2016). Dissociation of endotoxin 
aggregates will only occur in the presence of chelating agent such as sodium citrate. 
It has been suggested that increasing the concentration of chelating agents disturbs 
the ionic interactions between endotoxin molecules, reducing the rigidity of 
aggregates. This allows surfactants such as polysorbate, to intercalate into the 
destabilized aggregates and forming micelles with endotoxin ‘masking’ the molecule 
from detection (Reich et al. 2016). Thus, the finding of improved endotoxin detection 
from blood specimens with surfactants conflicts with the observations noted in the 
pharmaceutical industry. One hypothesis is that surfactants at a lower threshold 
concentration causes only partial breakdown of the endotoxin aggregate, allowing 
the structure to exist as partial aggregates. This better exposes the lipid molecules to 
Factor C and leads to an increase in the efficiency of endotoxin detection (Wimbish 
& Reich 2016; Nakamura et al. 1988).  
Due to the finding of improved endotoxin detection from plasma samples with the 
use of 0.1% Tween 80, this was used as a diluent in subsequent studies. The series 
of studies described in 6.3, 6.5, 6.6 and 6.7 have enabled the optimisation of the 
kinetic turbidimetric LAL assay with reasonable spike recoveries achieved. However, 
as discussed in Chapter 3, a number of alternative detection assays are available 
including the kinetic chromogenic LAL assay and the Endotoxin Scattering 
Photometry assay. Using the kinetic turbidimetric LAL assay with the methodology 
defined by the studies so far, comparative studies to evaluate the performance of 
these assays will be described in the next section. 
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6.9 Comparative study of blood endotoxin detection methods in 
haemodialysis patients 
6.9.1 Introduction 
Endotoxemia is a widely reported phenomenon in haemodialysis patients 
(Gonçalves et al. 2006), however endotoxin detection in blood is difficult and the 
optimal assay for use in haemodialysis patients is unknown. Many different 
endotoxin detection assays have been employed in previous studies in dialysis 
patients, including the turbidimetric LAL assay, chromogenic LAL assay, Endotoxin 
Scattering Photometry (ESP) and Endotoxin Activity Assay (EAA). It is important to 
determine the optimum detection assay for use in patients with end-stage kidney 
disease since endotoxemia is reported to be associated with chronic inflammation 
(Hauser et al. 2011) – a poor prognostic marker (Carrero & Stenvinkel 2010). 
Accurate endotoxin measurements are essential to further understanding of the 
sequela of endotoxemia in this population and to facilitate the development of 
potential endotoxin-lowering strategies.  
The LAL assay is the most commonly used endotoxin detection assay. LAL is 
derived from extracts of primitive amoebocytes present in the haemolymph of the 
horseshoe crab. The lipid A component of endotoxin interacts with pro-clotting 
enzymes present in LAL activating a coagulation cascade resulting in gelation and 
eventual clot formation (Williams 2007). High endotoxin content samples lead to 
rapid gelation. The rate of increase in turbidity can be measured using a 
spectrophotometer to quantify the endotoxin content of a sample. This technique is 
known as the turbidimetric LAL assay. A variation of this technique involves the 
addition of chromogenic substrates to LAL which undergoes a colour change in the 
presence of endotoxin. The chromogenic LAL assay has been the most commonly 
used endotoxin detection method in previous human studies and dialysis literature 
(Ronco et al. 2010). However in Japan, the turbidimetric LAL assay is routinely used 
and is covered by the Japanese national health insurance program (Matsumoto et al. 
2013). It is not know which variation of the LAL assay has better performance since 
direct comparative studies in haemodialysis patients have not been published. 
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A series of studies were determined from sections 6.3, 6.5, 6.6, 6.7 and 6.8 to 
determine appropriate blood sampling methodology and optimising the kinetic LAL 
assay. Using the methodology determined from these preliminary studies, both 
variations of the LAL assay was compared with the novel Endotoxin Scattering 
Photometry assay (ESP). The ESP assay is a novel method of endotoxin detection 
has been developed capable of detecting very low levels of endotoxins in biological 
samples.  The ESP assay uses an alternative method of detecting LAL activation by 
using laser photometry to detect the appearance of small particles formed early in 
the activation of the coagulation cascade.  Validation studies have demonstrated its 
ability to detect levels as a low as 0.01pg/mL or 0.048mEU/ml (Obata et al. 2008).  A 
few clinical studies have demonstrated a superior predictive power of the ESP assay 
over the LAL assay in the diagnosis of intra-abdominal sepsis (Shimizu et al. 2013) 
and a small study using the ESP assay detected a strong association between CRP 
and low level endotoxemia in haemodialysis patients although direct comparison with 
the LAL assay was not performed (Terawaki et al. 2010).  
Endotoxin spike recovery experiments were carried out to directly compare the 
accuracy and precision of the both variations of the LAL assay with the ESP assay. 
6.9.2 Methods 
Participant selection 
The whole study cohort consisted of 7 clinically stable patients undergoing outpatient 
haemodialysis (mean age 63) at the Lister Renal Unit (Hertfordshire, UK) and 7 
healthy controls (mean age 47) recruited from volunteers and healthcare workers at 
the Lister Hospital (Hertfordshire, UK). To minimise the possibility of high amounts of 
native endotoxin present in plasma samples which would interfere with endotoxin 
spike recovery experiments. Only subjects who were clinically well with no evidence 
of sepsis were recruited to the study. Additionally, HD patients were required to have 
a C-reactive protein measurement of <5mg/L within the last month to be eligible for 
recruitment. Patients with a venous catheter in-situ, liver dysfunction, congestive 
cardiac failure and active gastrointestinal or inflammatory diseases were not eligible 
for recruitment.  
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Blood collection  
Blood collection was performed as described in section 6.3 and processed to 
produce plasma, all samples were stored at -80ºC prior to analysis.  
Plasma pre-treatment for the LAL assay 
Plasma samples that were used for analysis with the turbidimetric and chromogenic 
LAL assay was processed identically. Plasma samples were diluted 1:10 in 0.1% 
Tween 80 (Merck Chemicals, Darmstadt, Germany) and heated at 70°C for 10 
minutes to denature plasma proteins and proteases which may interfere with 
endotoxin detection by the LAL assay (Hurley 1995; Dawson 2005). Batches of 0.1% 
Tween 80 were consistently found to have no detectable endotoxin and were free of 
interfering factors (endotoxin spike recoveries ranged from 94% to 106%). Samples 
were cooled to room temperature (20-25°C) prior to endotoxin measurements. 
Assessment of assay accuracy 
Plasma samples from five haemodialysis patients and five healthy controls were 
divided into aliquots and directly spiked with five different concentrations of control 
standard E.coli 055:B55 endotoxin (0 [unspiked sample], 0.05, 0.1, 0.5 and 2.5 
EU/ml) and then diluted in 0.1% Tween 80 and subjected to heat treatment as 
described above. Each sample was tested for endotoxin content in sextuplicate 
using both the kinetic chromogenic and kinetic turbidimetric LAL assay. Samples that 
contained bubbles introducing artefact into optical density graphs were discarded 
from the analysis. All samples had between four to six repeated measurements. 
Percentage spike recovery was calculated for each spiked plasma sample using the 
formula:-  
 
% 𝑠𝑝𝑖𝑘𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑠𝑝𝑖𝑘𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 −  𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑢𝑛𝑠𝑝𝑖𝑘𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑑𝑑𝑒𝑑 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛
×  100% 
 
The optimal spike recovery is 100%, although a spike recovery between 50 and 
200% is considered valid (United States Pharmacopoeia 2013). Assay accuracy was 
110 
 
assessed by comparing differences in spike recovery between all three assays. 
Measured endotoxin content was compared with expected endotoxin content in 
spiked samples using Bland-Altman analysis (Bland & Altman 1986) and linear 
regression analysis was used to calculate slope and y-intercept of the line of best fit 
to estimate magnitude of proportional and constant error (Westgard & Hunt 1973).  
Assessment of assay precision 
Samples from two haemodialysis patients and two healthy controls were pooled 
separately. Pooled uraemic and pooled healthy control plasma were spiked with two 
different concentrations of control standard endotoxin (0.05 and 0.5 EU/ml), diluted 
and heat treated as described earlier and subjected to ten repeated assay 
measurements for endotoxin using the kinetic chromogenic and kinetic turbidimetric 
LAL assay to calculate a coefficient of variation (CV). The CV is used to assess 
assay precision (Richardson & Novitsky 2002) but there is no industry guidance on a 
maximum acceptable CV, although most LAL manufacturers impose a CV <10-20% 
for results to be considered valid (Richardson & Novitsky 2002). CV was calculated 
using the formula: - 
𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 =  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑛𝑠𝑒𝑡 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝑀𝑒𝑎𝑛 𝑜𝑛𝑠𝑒𝑡 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 𝑜𝑓𝑠𝑎𝑚𝑝𝑙𝑒𝑠
× 100% 
Endotoxin assays 
Kinetic turbidimetric LAL assay: samples were assayed using Endosafe KTA2 lysate 
(Charles River Laboratories, France) on sterile 96-well microplates (manufacturer 
certified to <0.001EU/ml). Assays were carried out using manufacturer supplied 
equipment including depyrogenated glass tube, pipettes and Eppendorf Endosafe 
pipette tips (certified <0.005 EU/ml). Analysis of each microplate consisted of 
duplicate wells containing endotoxin-free water to act as a negative control. Plates 
were analysed using a Biotek ELx808 absorbance microplate reader with Endoscan-
V software (version 4.0; Charles River Laboratories, France) and observed at 340nm 
with an onset optical density value set at 0.03 as per manufacturer’s 
recommendations. Six-point standard curves were constructed using onset reaction 
times from standard dilutions of control standard endotoxin (E.coli 055: B5) ranging 
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from 10-0.0025 EU/ml. All standard curves constructed had a correlation coefficient 
of >0.98. Due to the ten-fold dilution used for plasma, the lower limit of detection was 
0.025 EU/ml. 
Kinetic chromogenic LAL assay: samples were assayed using Endochrome-K lysate 
(Charles River Laboratories, France) with manufacturer supplied depyrogenated 
glass tubes, pipettes and pipette tips as described above. Microplates were analysed 
using FLUOstar Omega microplate reader with MARS data analysis software (BMG 
Labtech, Offenburg, Germany) and observed at 405nm with an optical density value 
of 0.1 as per manufacturer’s recommendations. The same concentrations of control 
standard endotoxin were used to construct standard curves as described for the 
kinetic turbidimetric LAL assay. 
Endotoxin Scattering Photometry assay: assays were carried out on plasma samples 
using the technique as described by Obata et al (Obata et al. 2008). The principle of 
the assay is based on the detection of coagulin particles formed by the interaction 
between endotoxin and LAL reagent early in the coagulation cascade. The 
appearance of these small particles means that the influence of endotoxins has 
stimulated activation of the clotting enzyme across the LAL cascade and the timing 
of their appearance is related to endotoxin concentration. The reaction time of 
appearance of these coagulin particles are used to calculate the endotoxin content of 
a sample, rather than the traditional method of using the reaction time at the onset of 
a set optical density. The ESP assay has a reported lower limit of detection of 0.01 
pg/mL (approximately 0.048 milli EU/mL) (Terawaki et al. 2010). 
Plasma samples (0.1mL) were diluted in distilled water (0.9mL) containing 0.02% 
Triton-X and 0.02% denatured human albumin. Samples were vortexed and heated 
for 10 minutes at 70ºC on a dry block heater. After cooling on ice for 5 min, an 
aliquot (0.62 ml) was mixed with LAL lyophilized powder (Single-Test-Wako ES; 
Wako Pure Chemical Industries, Tokyo, Japan) in a test tube with a flash mixer for 
30 seconds, and 300-μl aliquot was moved to a photometric cuvette for laser 
scattering photometry. The reaction mixture was observed by laser scattering 
photometry at 37 °C (model PA-200 or PA-20, analytical software, version 3; Kowa, 
Nagoya, Japan). A light source is transmitted to the solution and the transparency 
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and relative particle size count is measured every 5 minutes. At the onset of the 
coagulation, the formation of coagulin particles is detected by a sharp increase in the 
particle count of small particles ranging from (1-10um) [Figure 6-14].   
 
Figure 6-14: Gelation process using ESP assay at 10pg/mL. The red arrow indicates time of 
appearance of small particles in the solution and the reaction time is recorded and used to 
calculate the endotoxin content. (Obata et al. 2008) [with permission from Analytical 
Biochemistry] 
The time at point of inflection is recorded and extrapolated to a standard curve 
constructed using dilutions of standard endotoxin (Wako Pure Chemical Industries, 
Tokyo, Japan) ranging from 0.01 pg/mL to 10000 pg/mL (0.000048 to 48 EU/mL).  
6.9.3 Results 
Comparison of assay accuracy  
This sub-study consisted of five haemodialysis patients and five healthy controls. In 
unspiked plasma samples, the ESP assay reported the highest level of blood 
endotoxin out of all three assays (0.272 EU/mL). Endotoxemia was detectable in all 
subjects using the ESP assay. The kinetic turbidimetric LAL assay detected 
endotoxemia in four out of five haemodialysis patients whereas the kinetic 
chromogenic LAL assay detected endotoxemia in one out of five haemodialysis 
patients (Table 6-8). In healthy controls, the ESP assay detected blood endotoxin in 
all patients with a median endotoxin level of 0.117 EU/mL (interquartile range 0.068-
0.54 EU/mL). The kinetic turbidimetric LAL assay detected endotoxin in one patient 
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only (0.027 EU/mL). No healthy subjects had detectable endotoxemia using the 
kinetic chromogenic LAL assay. 
 Endotoxin (EU/mL)  
 
Assay Turbidimetric LAL 
(A) 
Chromogenic LAL 
(B) 
ESP 
(C) 
P 
Haemodialysis 
patients 
 
0.041 [IQR 0.016-
0.081] 
0 [0-0.017] 0.272 [0.132-0.321] A vs. B = 0.068 
A vs. C = 0.08 
B vs. C = <0.05* 
Healthy controls 0 [0-0.013] 
 
0 0.117 [0.068-0.54] A vs. B = <0.05* 
A vs. C = 0.317 
B vs. C = <0.05* 
 
Table 6-8: Median endotoxin levels from the kinetic turbidimetric LAL, kinetic chromogenic 
LAL and ESP assay 
 
Spike recovery for all three assays is shown in Table 6-9. The kinetic turbidimetric 
assay was the most accurate assay, spike recovery for each level of endotoxin spike 
was within the 50-200% acceptable limit for both haemodialysis patients and healthy 
controls. Spike recovery for the kinetic chromogenic assay was frequently below the 
50% suggesting persistent inhibition of the kinetic chromogenic LAL assay by 
interfering factors present in plasma despite dilution and heat-treatment. The 
accuracy for the ESP assay was poor with wide ranging spike recoveries obtained. 
For haemodialysis patients, sample spiked with low concentration endotoxin (0.05 to 
0.1 EU/mL), yielded highly variable recoveries with interquartile ranges from -56.9% 
to 677% and -49.3% to 272% respectively. Samples spiked with larger quantities of 
endotoxin (0.5 to 2.5 EU/mL) were slightly less variable with less wide interquartile 
ranges [IQR 97.2% to 219.9% and 47.8% to 206.1% respectively]. These results 
suggest a high degree of inaccuracy with the ESP assay. For healthy controls, 
similar observations were found with highly variable and inaccurate spike recoveries 
obtained (overall spike recovery 147.7% [IQR 35.8-353.9]). Due to the highly 
variable spike recoveries obtained using the ESP assay, use of linear regression 
analysis to estimate proportional and constant error was not possible.  
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Concentration of endotoxin spike 
(EU/ml) 
 0.05 0.1 0.5 2.5 Overall 
Population  
HD patients 
(n = 5) 
Chromogenic assay 
 Spike recovery (%)  15.3 [-7.3-97.6]  
 
40.2 [32.8-
100.4] 
 
46.4 [39.6-
63.8] 
 
67.6 [59.7-
73.7] 
 
53.8 [34.0-78.9] 
 
 Turbidimetric assay  
 Spike recovery (%)  125.3 [74.1-
142.6] 
 
129.9 [99.1-
137] 
 
96.7 [78.3-
147.1] 
 
108.6 [85.9-
121.7] 
 
113.8 [85.6-
133.5] 
 
 ESP assay       
 Spike recovery (%) 
 
 144.5 [-56.9-
677] 
56 [-49.3-272] 190.8 [97.2-
219.9] 
170.5 [47.8-
206.1] 
181.1 [78.2-
234.8] 
Healthy 
(n = 5) 
Chromogenic assay 
 Spike recovery (%)  0 [0-60.8] 
 
31.5 [0-40.0] 
 
51.5 [21.8-
53.4] 
 
37.7 [25.4-
57.4] 
 
34.0 [4.7-53.9] 
 Turbidimetric assay 
 Spike recovery (%)  142.4 [95.1-
212.5] 
 
146.4 [127-
173.4] 
 
102.2 [99.9-
123] 
 
84.2 [82.6-
101.3] 
 
114.0 [98.3-
145.4] 
 
 ESP assay       
 Spike recovery (%) 
 
 21.8 [-411.8-
414.4] 
77.5 [-240.5-
144.7] 
99.9 [-1.85-
370.9] 
176.1 [150.9-
294.8] 
147.7 [35.8-
353.9] 
 
Table 6-9: Median spike recovery from kinetic turbidimetric, kinetic chromogenic and ESP 
assay. HD, haemodialysis; EU/mL, endotoxin units per millilitre. Numbers in brackets 
represent interquartile ranges 
 
Comparison of assay error and bias 
Bland-Altman analysis was used to assess assay bias (Bland & Altman 1986). 
Bland-Altman plots for measured and expected endotoxin spike recovery all three 
assays are shown in Figure 6-15. Overall mean bias was lowest for the turbidimetric 
assay mean bias at 0.011 EU/ml (95% CI 0.079 to -0.057). For the chromogenic 
assay was -0.384 EU/ml (95% CI -0.219 to -0.549) and assay bias for the ESP was 
the highest at -0.689 EU/mL (95% CI -3.84 to 2.47). Sub-analysis of the HD cohort 
revealed mean bias for the turbidimetric assay was 0.049 EU/mL (95% CI 0.162 to -
0.064) and significantly lower than both the chromogenic and ESP assay (both 
p<0.05).  
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Similarly, in healthy subjects, bias with the chromogenic and ESP assay were both 
significantly higher than the turbidimetric assay (-0.478 vs. -0.021EU/ml and -0.771 
vs. 0.021 EU/mL respectively, both p<0.05). [Data points in the Bland-Altman plots 
align in a straight line because the expected values were ‘fixed’ e.g. 0.05, 0.1, 0.5 
etc.] 
 
Figure 6-15: Bland-Altman analysis of measured versus expected spike recovery  
 
Linear regression analysis was used to estimate constant and proportional error 
(Westgard & Hunt 1973). Due to the high inaccuracy of the ESP assay, this method 
was used to compare the kinetic chromogenic and kinetic turbidimetric assay only. 
Comparison plots of measured versus expected endotoxin content in spiked samples 
were constructed (Figure 6-16). Correlation between measured and expected 
endotoxin was higher for the turbidimetric assay compared to the chromogenic assay 
for both haemodialysis patients (r = 0.962 vs. 0.939) and healthy subjects (r = 0.954 
vs. 0.922). For haemodialysis patients, estimates of proportional error and constant 
error were lower for the turbidimetric assay (4.2% and 0.016 EU/ml [-0.13 to 0.162]) 
compared to the chromogenic assay (32.2% and -0.027 EU/ml [-0.094 to -0.041]). In 
healthy subjects, overall assay error was similarly lower in the turbidimetric assay 
compared to the chromogenic assay (proportional error, 11.8% vs. 59.0%; constant 
error, 0.067 EU/ml [-0.011 to 0.145] vs. -0.011 EU/ml [-0.128 to 0.102]) [Table 6-10 
and Figure 6-16].  
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Figure 6-16: Comparison plots showing linear regression lines (hashed lines) for 
measured versus expected endotoxin content in spiked samples for haemodialysis 
patients and healthy controls with the chromogenic and turbidimetric assay. Dotted 
lines represent 95 % confidence intervals for linear regression lines. Each data point 
represents a mean of 4–6 measurements for one subject). Black reference line indicates 
perfect agreement between measured and expected endotoxin content 
Population Assay Slope  Proportional 
error (%) 
Y-intercept (constant error) 
[EU/mL] 
Correlation 
coefficient 
 
HD 
(n = 5) 
 
Turbidimetric 
 
1.042 [0.927-1.157] 
 
4.2 
 
0.016 [-0.130-0.162] 
 
 
0.962 
 Chromogenic 0.678  [0.625-0.731] 
 
32.2 -0.027  [-0.094-0.041] 0.939 
 
Healthy 
(n = 5) 
 
Turbidimetric 
 
0.882 [0.821-0.943] 
 
 
11.8 
 
0.067 [-0.011-0.145] 
 
 
0.954 
 Chromogenic 0.41 [0.320-0.500] 
 
59 -0.011 [-0.128-0.102] 
 
0.922 
 
Table 6-10: Comparison of assay error of turbidimetric and chromogenic LAL assay using 
linear regression analyses 
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Comparison of assay precision 
The coefficient of variation (CV) calculated using the onset reaction time for both 
cohorts was <10% for both chromogenic and turbidimetric assays. For the ESP 
assay, imprecision was high for the ESP assay, with CV for reaction times ranging 
from 9.5% to 22.6%.  
CV calculated using the actual endotoxin content of the sample was <10% for the 
turbidimetric LAL assay in pooled uraemic plasma samples spiked with high 
concentration of endotoxin (0.5 EU/ml), however in samples spiked with low 
concentration of endotoxin (0.05 EU/ml), CV was higher at 24.1% suggesting 
imprecision of the turbidimetric assay at this low endotoxin concentration in HD 
patients. With the chromogenic assay, for samples spiked with high concentration of 
endotoxin (0.5 EU/ml), CV for HD patients and healthy subjects was ranged from 
25.8 to 26.5% suggesting high imprecision, CV for samples spiked with low amounts 
of endotoxin (0.05 EU/ml) could not be defined because spike recovery was 0%. 
Imprecision was highest for the ESP assay with CV ranging from 33.9 to 66.9% 
(Table 6-11). 
  
118 
 
  CV - onset reaction time (%) 
 
CV - EU/ml (%) 
Concentration of endotoxin spike 
(EU/mL)  
 
0.05 0.5 0.05 0.5 
Population Assay 
 
    
HD 
(n = 2) 
Turbidimetric 4.6 2.5 24.1 8.9 
 
 Chromogenic 2.4 3.8 Undefined 25.8 
 
 ESP 22.6 14.6 59.0 66.9 
 
Healthy 
(n = 2) 
Turbidimetric 2.8 1.3 9.3 4.5 
 
 Chromogenic 5.4 4.6 Undefined 26.5 
 
 ESP 20.8 9.5 63.9 33.7 
Table 6-11: Coefficient of variation for all three assays in pooled uraemic and non-uraemic 
plasma 
 
6.9.4 Discussion 
This is the first comparative study of the ESP assay and two commonly used LAL 
detection techniques in haemodialysis patients. The accuracy and precision of the 
ESP assay and two kinetic LAL assays utilising chromogenic and turbidimetric 
methods were studied. 
The ESP assay is a novel method of endotoxin detection assay which relies on the 
detection of coagulin particles formed earlier in the LAL cascade. Its reported 
advantages include its increased sensitivity and speed of detection compared to the 
LAL assay. The LAL reagent used in the ESP assay is also insensitive to (1→3)-β-D 
glucan (BG) stimulation making it specific to endotoxin activation only. BGs are 
carbohydrate constituents of cereal, yeast and fungal cell walls (Young & Vincent 
2005) and are capable of activating the LAL assay via an alternate enzymatic 
pathway mediated by factor G activation (Morita et al. 1981) [Figure 3-1]. However, 
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despite the reported advantages of the ESP assay, recovery experiments from 
plasma spiked with endotoxin using this assay was inaccurate and imprecision was 
high. The coefficient of variation obtained from this assay varied from 9.5 to as high 
as 66.9%. The high degree of inaccuracy and imprecision of the ESP assay 
suggests that it would not be suitable for blood endotoxin measurement. 
Only kinetic LAL assays were compared in this study since kinetic techniques have 
significant advantages over older LAL techniques including the gel-clot and end-point 
method. Kinetic assays are more sensitive, able to quantify results over a wider 
range of endotoxin concentrations and benefits from having an automated process of 
analysis reducing the variation due to user technique (Williams 2007). However, from 
the dialysis literature, only one study utilised a kinetic assay (Suzuki & Honda 2011), 
the remaining studies employed either the end-point techniques (Markum 2004; D. 
Raj et al. 2009; Szeto et al. 2010; Kwan, Chow & Leung 2013; Christopher McIntyre 
2011; Szeto et al. 2008; Jefferies et al. 2014) or the gel-point method (El-Koraie & 
Naga 2013; Taniguchi et al. 1990). Despite their widespread availability and use, it is 
not known whether the turbidimetric or the chromogenic assay has superior 
performance in patients with end-stage kidney disease.  
This study, using LAL reagents from the same manufacturer, has shown that the 
kinetic turbidimetric LAL assay is a more accurate and precise endotoxin detection 
tool compared to the chromogenic assay in haemodialysis patients and is able to 
detect endotoxin over a wide range of different endotoxin concentrations (0.05-2.5 
EU/ml). Additionally, this investigation showed that uraemic solutes that accumulate 
in patients with kidney failure do not appear to have any greater significant 
interference on the LAL assay than non-uraemic plasma.  
Endotoxin spike recovery with the chromogenic assay was significantly inhibited by 
plasma from haemodialysis patients and healthy controls despite attempts to remove 
interfering factors from samples with dilution and heat treatment. Spike recoveries 
with the chromogenic were consistently below the minimum requirement of 50% for 
healthy controls and overall median spike recovery was borderline acceptable at 
53.8% for the haemodialysis cohort. In comparison, median spike recovery for the 
turbidimetric assay was 113.8%, well within the industry specified 50-200% 
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requirement (United States Pharmacopoeia 2013). The magnitude of assay error 
and bias was also greater for the chromogenic assay for both haemodialysis and 
healthy control subjects. Assay precision in this study was assessed using the 
coefficient of variation calculated from both the onset reaction time and the endotoxin 
content of the sample. There is a lack of industry guidance on which variable should 
be used to calculate the CV, depending on the manufacturer either the onset 
reaction time or the endotoxin read-out measurement can be used (Richardson & 
Novitsky 2002). It has been suggested that CV calculated using the endotoxin 
content of samples is a more rigorous measure of assay precision (Richardson & 
Novitsky 2002). Using the onset reaction time, CV was <10% for both the 
turbidimetric and chromogenic LAL assay. However, CV calculated using the 
endotoxin content of the sample showed that the turbidimetric assay was more 
precise than the chromogenic assay. But in low levels of endotoxemia (≤0.05 EU/ml), 
assay imprecision was higher (CV - 9.3 to 24.1%) and care should be taken at 
interpreting samples containing low concentration of endotoxins.  
Turbidimetric assays have the advantage of being more economical and a historical 
comparative study in non-uraemic plasma favoured the turbidimetric over the 
chromogenic assay because of the interfering effect of chromogenic substrates on 
the kinetics of the LAL reaction (Hurley et al. 1991). For end-point LAL assays, the 
chromogenic assay may suffer from interference as plasma and serum samples can 
absorb light at the measured 405nm wavelength, potentially interfering with the 
results (Fields 2006). 
The LAL assay has been extensively used for the detection of endotoxin in 
pharmaceutical products, however its use in blood has been a matter of intense 
debate (Novitsky 1994; Cohen 2000). Currently the LAL assay is not licensed by the 
Food and Drug Administration for ‘detecting endotoxemia in man’. This decision was 
heavily influenced by studies conducted by Stumacher (Stumacher et al. 1973) in 
1973 and Elin in 1975 (Elin et al. 1975) demonstrating lack of concordance between 
endotoxemia and bacteraemia (Novitsky 1994). However, others have debated the 
validity of trials which measured the correlation of the LAL assay with positive culture 
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bacteraemia as a ‘gold-standard’ (Novitsky 1994), which is well known to have a low 
sensitivity for identifying patients with sepsis (Lee et al. 2007).  
Due to current limitations with the LAL assay, a number of different novel detection 
assays have evolved over the last few decades including the recombinant factor C 
assay (rFC), the ESP assay and the Endotoxin Activity Assay (EAA) – a bioassay 
based on neutrophil activation by complement opsonised immune complexes of LPS 
(Romaschin et al. 2012). No studies on the use of the rFC assay in human blood 
have been published to date. The EAA is an FDA-approved blood endotoxin 
detection assay, however the EAA provides a read-out of a patient’s neutrophil 
oxidative chemi-luminescent response to LPS-antibody complexes rather than the 
direct endotoxin content present in the sample (Romaschin et al. 2012). A recent 
investigation found a poor dose-response between blood spiked with control 
standard endotoxin and EAA activity (Matsumoto et al. 2013). It is noteworthy that 
most studies in the dialysis literature utilised the end-point chromogenic assay 
supplied by Cambrex (End-point chromogenic LAL QCL-1000). This assay is now 
being manufactured by Lonza and further comparison with this specific assay may 
be useful. 
The strengths of this study includes the meticulous attention to pre-analytical factors 
such as careful selection of blood sampling accessories by testing apparatus for 
contamination and interfering factors. No blood samples were obtained from 
tunnelled dialysis catheters to reduce the risk of contamination by bacterial biofilms 
(Dasgupta 2002). Blood sampling and processing was performed rapidly to reduce 
the risk of endotoxin inactivation in untreated plasma (Hurley 1995). The United 
States Pharmacopoeia states that in kinetic LAL testing, test samples need to be 
verified to be free of assay interfering factors by obtaining a spike recovery between 
50-200% from a positive product control (PPC) for an endotoxin measurement from 
a sample to be considered valid (United States Pharmacopoeia 2013). The PPC is a 
duplicate of the sample spiked with LPS at a concentration that lies near the mid-
point of the standard curve after dilution and heat treatment. In this study, plasma 
samples were spiked with several different quantities of LPS prior to dilution and 
heat treatment which allowed examination of the ability of the assays to retrieve LPS 
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from plasma containing wide range of different concentrations of endotoxin. Spiking 
samples before dilution and heat treatment to measure spike recovery also more 
closely resemble the process experienced by naturally occurring endotoxins present 
in the sample.  
The limitations of this study include the relatively small number of participants and 
the use of control standard endotoxin derived to assess spike recovery. Standard 
endotoxins are derived from E.coli and are usually stabilised in preservatives such 
as lactulose and polyethylene glycol which may behave differently in vivo compared 
to naturally occurring endotoxin. However, natural endotoxins are difficult to 
standardise and many other published studies also use control standard endotoxin to 
assess recovery or immune response (Hurley 1995; Sturk et al. 1985; Hurley et al. 
1991; Peek et al. 2004; Sharma et al. 2005; Fukui et al. 1993). The incubation times 
for samples spiked with endotoxin were not controlled due to the large number of 
samples that were processed, although laboratory analyses of spiked samples was 
carried out as soon as possible. It is unclear whether different incubation times can 
affect spike recovery. However since the same spiking procedure was used 
throughout the whole study, incubation times would have been broadly similar 
between samples. The LAL assays used in this study have not been modified to be 
insensitive to BG, thus it unclear whether the endotoxin measured in some of the 
baseline samples may have been due to BG interference. Further study on this issue 
is warranted, however, the LAL is reported to be nearly 1000-times more sensitive to 
endotoxins than BG (Roslansky & Novitsky 1991) and contamination with BG can 
usually be recognised by significant enhancement of spike recoveries (Cooper et al. 
1997), which was not seen in this study. Optimal heat treatment conditions were not 
investigated in this study, however the plasma pre-treatment conditions selected for 
this study were based on an extensive review by Hurley (Hurley 1995) and it is likely 
that the pre-treatment process for removal of interfering factors was sufficient since 
the overall spike recovery for the turbidimetric assay was >100%. The findings could 
also be criticised in that, since that comparisons were made between chromogenic 
and turbidimetric assays using LAL reagent from one manufacturer only (Charles 
Rivers). The conclusions may not apply with use of reagents from other 
manufacturers, therefore further comparisons with assays from other manufacturers 
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may be useful particularly the end-point chromogenic assay by Cambrex and Lonza 
which has been cited in many dialysis studies (see 6.10).  
In summary, this study suggests that the kinetic turbidimetric LAL assay is an 
accurate blood endotoxin detection method in haemodialysis patients. The kinetic 
chromogenic assay is prone to significant inhibition by the uraemic plasma despite 
dilution and heat treatment and the ESP assay has poor accuracy and high 
imprecision. The kinetic turbidimetric LAL assay could be utilised to determine the 
relationship between endotoxemia with inflammation in dialysis patients. This assay 
was used in subsequent studies in this thesis for the measurement of blood 
endotoxin. 
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6.10 Measurement of blood endotoxin in haemodialysis patients using the 
kinetic turbidimetric LAL assay and end-point chromogenic assay 
6.10.1 Introduction 
The studies described in the previous section suggest superior accuracy of the 
kinetic turbidimetric LAL assay. However, a review of endotoxin studies carried out in 
the dialysis population showed that the majority of these studies utilised an end-point 
chromogenic LAL assay. The end-point techniques have significant disadvantages 
compared to the kinetic methods due to, 1) a narrower range of detection, 2) the 
necessity for the user to stop the reaction of all sample wells at the same time, thus 
introducing the problem of intra- and inter-user variability and 3) end-point 
chromogenic assays may suffer from interference since plasma and serum samples 
also absorb light at the measured 405nm wavelength potentially interfering with the 
results. A summary of endotoxin studies carried out in the dialysis population is 
summarised in Table 6-12 below:- 
Study Population Assay method Manufacturer (1→3)-β-D glucan 
insensitive? 
 
(Suzuki & Honda 
2011) 
 
Haemodialysis 
 
 
Kinetic turbidimetric 
Endpoint chromogenic 
 
Pyrostar; Wako 
Endospecy; Seikagaku 
 
Yes 
Yes 
(Markum 2004) Haemodialysis Endpoint chromogenic Endospecy; Seikagaku Yes 
(C McIntyre 2011) Haemodialysis 
CKD 
Peritoneal dialysis 
Endpoint chromogenic QCL1000; Cambrex No 
(El-Koraie & Naga 
2013) 
Haemodialysis Gel-clot Pyrotell; Associates of 
Cape Cod 
No 
(Kwan, Chow, Leung, 
et al. 2013) 
Peritoneal dialysis Endpoint chromogenic QCL1000; Cambrex No 
(Szeto et al. 2008) Peritoneal dialysis Endpoint chromogenic QCL1000; Cambrex No 
(Szeto et al. 2010) Peritoneal dialysis Endpoint chromogenic QCL1000; Cambrex No 
(Wu et al. 2014) Peritoneal dialysis Endpoint chromogenic QCL1000; Lonza No 
(Harrison et al. 2012) Haemodialysis Endpoint chromogenic QCL1000; Lonza No 
(Taniguchi et al. 1990) Haemodialysis Endpoint chromogenic 
Endpoint chromogenic 
 
Endospecy; Seikagaku 
Toxicolor Test; 
Seikagaku 
Yes 
No 
(Kwan & Szeto 2013) Haemodialysis Endpoint chromogenic QCL1000; Cambrex No 
(Gonçalves et al. 
2006) 
CKD Endpoint chromogenic Hycult No 
(D. S. C. Raj et al. 
2009) 
Haemodialysis Endpoint chromogenic QCL1000; Cambrex No 
Table 6-12: Characteristics of endotoxin assays used in patients with kidney disease 
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The majority of studies utilised an end-point chromogenic assay manufactured by 
Cambrex. The production of this assay has recently been overtaken by Lonza. As 
discussed previously, most studies that use the end-point chromogenic assay which 
report unusually high blood endotoxin levels that exceed the expected pyrogenic 
threshold of 5 EU/kg (Greisman & Hornick 1969). Endotoxin measurements of blood 
samples that are known to contain detectable endotoxin using the kinetic 
turbidimetric assay (Endosafe KTA2, Charles Rivers) were subjected to repeat 
measurement using the end-point chromogenic LAL assay (QCL1000, Lonza) to 
determine the correlation between endotoxin measurements obtained from both 
assays 
6.10.2 Methods 
Patient population 
Plasma samples from twenty haemodialysis patients that were known to contain 
endotoxin measured using the kinetic turbidimetric LAL assay were selected for 
study. Inclusion and exclusion criteria for participants are described in section 6.4. All 
patients were clinically well and did not have any active infection at the time of the 
study.  
Blood sampling and processing 
Blood samples from all participants were collected either through an arterio-venous 
fistula or from a peripheral vein pre-dialysis and processed to produce plasma. The 
same blood collection and processing method was used as described in section 6.3. 
Plasma samples were stored at -80ºC until analysis. Each plasma sample was 
analysed twice – once using the kinetic turbidimetric LAL assay (Endosafe KTA2, 
Charles Rivers) and once using the endpoint chromogenic LAL assay (QCL1000, 
Lonza) 
Endotoxin measurement 
Kinetic turbidimetric LAL assay: samples were measured for endotoxin using the 
kinetic turbidimetric LAL assay by Charles Rivers using the same procedure as 
described in section 6.9. 
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Endpoint chromogenic LAL assay: samples were measured for endotoxin using an 
endpoint chromogenic LAL assay (QCL1000; Lonza) as per manufacturer’s 
instructions.  
Samples were thawed on the day of analysis and diluted 1:10 in LAL reagent water 
and heated at 70ºC for 10 minutes to denature plasma proteins and proteases that 
may interfere with the LAL reagent. Samples were cooled to room temperature (20-
25ºC) and transferred to quadruplicate wells on a 96 well microplate (manufacturer 
certified <0.001 EU/mL) equilibrated at 37ºC on a heating block adapter. Two wells 
of each sample were directly spiked with 0.4 EU/mL to act as positive product 
controls. A four point standard curve was constructed using standards control 
endotoxin from 1 to 0.1 EU/mL with LAL reagent water acting as a blank. Fifty 
microliters of LAL reagent was added to each well using a multichannel pipette and 
incubated for 10 minutes at 37ºC. After 10 minutes, 100µL of chromogenic substrate 
was added to each well and samples were incubated for a further 6 minutes. After 
incubation for a total of 16 minutes, the LAL reaction was stopped using a 10% 
sodium dodecyl sulfate and the microplate was read at 405nm using a 
spectrophotometer. Mean change in optical density was determined for each well 
and endotoxin content of each well was calculated by extrapolation from the 
standard curve (1-0.1 EU/mL; r >0.98). 
Statistical analysis 
Correlation between endotoxin measurements obtained from the kinetic turbidimetric 
and end-point chromogenic method was measured using Pearson correlation 
coefficient. Positive product controls for each sample were required to be within the 
50-200% for endotoxin read-out measurements to be valid. 
6.10.3 Results 
Endotoxin measurements for both assays are shown in  
Table 6-13. Mean endotoxin measurements obtained using the endpoint 
chromogenic method was almost one hundred fold higher than the kinetic 
turbidimetric assay (4.55 EU/mL [95% CI 3.83-5.28] vs 0.051 EU/mL [95% CI 0.037-
0.065], p<0.001).  
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Sample Endpoint chromogenic 
(EU/mL) 
PPC (%) Kinetic turbidimetric 
(EU/mL) 
PPC (%) 
1 3.49 -16 0.05 109 
2 3.62 -32 0.033 98 
3 3.93 32 0.106 86 
4 2.60 16 0.028 98 
5 3.24 16 0.039 72 
6 3.05 111 0.039 98 
7 5.45 0 0.095 88 
8 2.98 47 0.039 71 
9 2.79 47 0.053 68 
10 5.95 63 0.079 71 
11 3.17 63 0.035 84 
12 7.35 158 0.03 79 
13 5.95 32 0.068 103 
14 6.59 79 0.051 81 
15 5.51 -158 0.045 72 
16 6.90 142 0.105 95 
17 4.50 79 0.082 64 
18 2.98 16 0.047 63 
19 5.95 0 <0.0025 64 
20 5.07 32 <0.0025 74 
 
Table 6-13: Endotoxin measurements obtained from the same plasma samples using the 
kinetic turbidimetric LAL assay (Charles Rivers) and endpoint chromogenic LAL assay (Lonza) 
 
The majority of endotoxin measurements obtained from the end point method were 
not valid, positive product controls for 13/20 (65%) samples did not have valid spike 
recovery suggesting that the end-point assay is prone to significant interference from 
substances present in plasma sample despite dilution and heat treatment. All 
endotoxin measurements obtained from the kinetic turbidimetric LAL assay were 
valid, and all samples had valid PPC with spike recoveries within the 50-200% limit. 
There was no significant correlation between the two assays (r value, 0.196; 
p=0.408).  
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6.10.4 Conclusion 
No correlation was found between both assays with a nearly 100-fold difference in 
endotoxin levels between the two assays. PPC for all samples measured using the 
kinetic turbidimetric LAL assay had valid spike recoveries. The majority of endotoxin 
measurements obtained using the endpoint chromogenic LAL assay was invalid. 
However, endotoxin measurements from the seven samples with valid positive 
product controls measurements were still extremely high with a mean endotoxin 
content of 5.36 EU/mL. These measurements appear high considering all 
participants were non-infected and clinically stable at the time of blood sampling. 
Given that 5 EU/kg is sufficient to induce pyrogenic symptoms in humans and 
assuming an average 70kg human with approximately 3L of circulating plasma 
volume, it would be expected that as little as 0.12 EU/mL would be sufficient to 
trigger pyrogenic symptoms. The measurements obtained using the endpoint 
chromogenic method greatly exceeds this pyrogenic threshold. Notably, the 
endotoxin measurements obtained using the QCL1000 assay in this study are similar 
to the values reported in published studies using the same assay (Kang et al. 2013; 
Lira et al. 2010; Harte et al. 2010). 
In conclusion, this specific chromogenic endpoint assay appears to give unreliable 
results with extremely high endotoxin results. The significant majority of samples 
despite dilution and heat treatment did not yield valid PPCs. For the kinetic 
turbidimetric LAL assay, all samples had valid PPC with adequate spike recoveries 
and yielded lower levels blood endotoxin levels in the range which appear to be 
more biologically plausible. 
The reasons for the lack of correlation between the results obtained from both 
assays are unclear since all LAL reagents are FDA approved for testing of endotoxin 
prior to product release. Each batch of LAL is assessed and certified by its 
manufacturer and should be broadly comparable to similar products from other 
manufacturers. It is likely that these conditions apply only to testing endotoxin in non-
biological pharmaceutical or aqueous products such as dialysis fluid and not to 
complex substances such as blood and plasma.  
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6.11 Summary 
In summary, the association of endotoxemia with inflammation in dialysis patients 
needs to be confirmed with an accurate endotoxin detection assay to increase 
understanding of the potential harmful effects of chronic endotoxemia in this 
population and to develop endotoxin-lowering interventions.  
A series of studies were described in this chapter to determine the optimum method 
of endotoxin detection specifically for patients with kidney disease. Pre-analytical 
factors were considered including selection of appropriate blood sampling apparatus, 
collection and storage tubes (described in section 6.3) to avoid interfering factors 
from affecting the accuracy of results. The optimum blood component to test for 
endotoxin was investigated in section 6.5. Current kinetic LAL methods were 
optimised by exploring alternative means of calculating endotoxin from the optical 
density graphs (section 6.6), using optimal dilution factors (section 6.7) and 
alternative diluents such as surfactants (6.8). Optimised variations of the 
chromogenic and turbidimetric kinetic LAL assays were compared with the novel 
ESP endotoxin detection assay (section 6.9) and the commonly used endpoint 
chromogenic assay (section 6.10). 
These series of studies found that the kinetic turbidimetric LAL assay was the most 
accurate and precise assay for endotoxin detection from uraemic blood. This assay 
will be used in subsequent studies documented in this thesis for the investigation of 
the association of endotoxemia with inflammation in haemodialysis patients. 
However, the kinetic LAL reagents used in the studies carried out so far have not 
been modified to be insensitive to (1→3)-β-D glucan (BG) stimulation. Elevated BG 
levels have been described in haemodialysis patients particularly in those treated 
with cellulose dialysis membranes (Kanda et al. 2001). It is important to clarify 
whether the low level blood endotoxin found in the patients studied described in 
sections 6.9 and 6.10, is due to BG interference before embarking on larger studies 
to use this specific assay to determine the association between inflammation and 
endotoxemia. This issue is further explored in Chapter 7. 
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Although, a series of experiments have been carried out to determine an optimum 
method of blood collection and analysis for endotoxin detection. There are several 
limitations with these studies, firstly the sample size for these studies were small, 
secondly the endotoxin used to spike samples were derived from control standard 
endotoxin, ideally the experiments should be repeated using native endotoxin from 
different bacterial species to ensure that similarly adequate level of spike recoveries 
are obtained. Finally, although an experiment was carried which found that plasma 
was the ideal blood component to use for endotoxin detection, these tests were 
carried out using blood from healthy controls. It is unclear whether observation could 
be applied to dialysis patients with significant uraemia due to the ‘matrix effect’ – a 
phenomenon in which undefined plasma proteins, phospholipids and other 
components interfering with the ability of the LAL assay to detect endotoxin 
(Rosenberg-Hasson et al. 2014).  
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 Chapter 7 
7.  (1→3)-β-D glucan in kidney disease 
 
7.1 Introduction 
Beta-glucans are polysaccharides that contain D-glucose as a sole monomer unit 
linked by (1-3)-beta glycosidic bonds. They are structurally diverse and can vary in 
length and branching of side chains which results in differences in solubility and 
biological activity (Barton et al. 2016) [Figure 7-1].  
 
Figure 7-1: Beta glucan composed of D-glucose monomers linked by (1-3) beta-glycosidic 
bonds. A linear 1,3 glycosidic chain with a single 1,6 glycosidic chain is shown (reproduced 
with permission from Barton et al 2016, http://creativecommons.org/licenses/by/4.0/) 
  
(1→3)-β-D glucan (BG) are the most common type of beta-glucans found in fungal 
cell walls, yeast and seeds of some cereals such as barley and oats (1 (Rop et al. 
2009). The molecular weight of beta-glucans can vary from thousands to millions of 
daltons depending on its origin (Young & Vincent 2005). Cellular components of 
most pathogenic fungi such as candida and aspergillus contain BG, thus levels of 
BG in bodily fluids such as serum, broncho-alveolar lavage fluid and cerebrospinal 
fluid have been used as a pan-fungal cell marker to diagnose invasive fungal 
infections (Ostrosky-Zeichner et al. 2012).  
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7.2 Use of blood levels of (1→3)-β-D glucan as a pan-fungal diagnostic 
marker 
In 1968, during the evaluation of a carboxy-methylated beta-glucan as an anti-
tumour agent, this was found to induce clotting of the coagulation cascade of 
amoebocytes of the horseshoe crab despite the absence of endotoxin contamination 
(Marty & Koo 2009). Further work confirmed that the LAL cascade was activated via 
the interaction of BG with an alternative serine protease zymogen, factor G (Morita et 
al. 1981) [see Figure 7-2].  
 
Figure 7-2: The LAL enzyme cascade (Wong et al 2014, reproduced with permission from John 
Wiley and Son publisher) 
 
Activation of factor G activates pro-clotting enzymes which cleave a chromogenic 
substrate, p-nitroanilide from a synthetic peptide in the beta-glucan LAL that replaces 
the original clot forming coagulogen protein (Wright et al. 2011). Unlike the 
conventional LAL assays which can range from gel-clot, end-point and kinetic 
techniques, currently all BG detection assays utilise end-point techniques by 
measuring the absorbance at 450nm (Novitsky 2009). There are five serum BG 
detection assays available commercially (Table 7-1): - 
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Assay Manufacturer Type of assay and 
crab species 
Cut-off value for 
positive result 
(pg/mL) 
Fungitell Associates of Cape 
Cod 
Limulus Polyphemus 
(chromogenic) 
60-80 
Endosafe-PTS glucan Charles River 
Laboratories 
Limulus Polyphemus 
(chromogenic) 
10-1000 
Fungitec G-MK Seikagaku 
Biobusiness 
Tachypleus 
Tridentalus 
(chromogenic) 
20 
β-glucan test Wako pure chemical 
industries 
Tachypleus 
Tridentalus 
(turbidimetric) 
11 
BGSTAR Maruha Nichiro 
Corporation 
Tachypleus 
Tridentalus 
(chromogenic) 
11 
Table 7-1: Beta glucan assays (adapted from Wright et al 2011) 
 
Evaluation of BG assays as a diagnostic marker of invasive fungal infection was 
initially carried out in Japan which demonstrated the usefulness of blood BG 
detection assays to identify patients with invasive fungal infections (Obayashi et al. 
2008). Sensitivity and specificity of BG detection assays to detect invasive fungal 
infections based on autopsy material (using Fungitec-G) was reported to be 90% and 
100% respectively, with positive and negative predictive values of 59% and 85% 
respectively (Obayashi et al. 1995).  
Subsequently, a large number of studies have been carried out to examine the 
diagnostic potential of the BG assay to identify fungal infection. Although cut-off 
values for a positive result vary depending on the manufacturer and assay used, 
equivalent diagnostic ability have been reported between assays from different 
manufacturers (Odabasi et al. 2004). Out of all five assays, the Fungitell assay 
(Associates of Cape Cod inc.) is the most studied BG detection assay (He et al. 
2015). The first multi-centre study to evaluate BG detection assays was carried out 
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in USA using the Fungitell assay which reported sensitivity and specificity of 69.9% 
and 87.1% respectively (Ostrosky-Zeichner et al. 2005). A recent meta-analysis 
involving 4214 patients found that the pooled sensitivity, specificity, diagnostic odds 
ratio and area under summary receiver operating characteristic for BG detection 
assays were 0.78 [95% confidence interval (CI), 0.75-0.81], 0.81 (95% CI, 0.80-
0.83), 21.88 (95% CI, 12.62-37.93), and 0.8855, respectively, suggesting a high 
diagnostic accuracy for invasive fungal infections (He et al. 2015). The Fungitell 
assay has received FDA clearance for use as an adjunct in the diagnosis of invasive 
fungal infections (Wright et al. 2011) and high plasma or serum levels of BG are now 
considered as alternative microbiological evidence of fungal infection in the 
European Organization for Treatment and Research of Cancer/Mycosis Study Group 
criteria for diagnosis of fungal infection (Ostrosky-Zeichner et al. 2012; De Pauw et 
al. 2008). 
7.3 Causes of false positive and negative results for BG detection assays 
False positive (elevated blood BG levels in the absence of fungal infection) and false 
negative results for BG detection assays may occur due to several reasons (Table 
7-2):- 
False positive  False negative 
Haemodialysis or haemofiltration Lipemic blood samples 
Broad spectrum antibiotics Haemolysed blood samples 
Severe bacterial infections  Infection with fungi lacking in 
(1→3)-β-D glucan e.g. 
Cryptococcus, Mucorales, 
Zygomycetes 
Major surgery  
Administration of blood products  
Table 7-2: Causes of false positive and negative results for BG detection assays 
 
The observation that fluid extracts that had been exposed to dialyser membranes 
used for haemodialysis and haemofiltration are able to activate the LAL assay but 
without inducing pyrogenicity was reported in the 1980s (Henne et al. 1984; Pearson 
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et al. 1984). This “LAL-reactive” material was subsequently found to be BG which 
were derived from cellulose materials used for construction of the dialyser 
membranes and activates the LAL assay via the alternative zymogen factor G 
(Yamagami et al. 1986). Venous injection of cellulose dialyser wash solution into 
healthy subjects increased blood LAL-reactive material and levels of this substance 
increased ten-fold after dialysis (Kato et al. 2001; Yamagami et al. 1986).  
Blood levels of BG increase significantly after dialysis with cellulose membranes, 
although the phenomenon does not seem to occur if synthetic membranes such as 
polysulfone are used for dialysis instead (see section 7.4).  
Other causes of elevated blood BG in the absence of fungal infection includes 
treatment with some antibiotics which may contain BG (Marty & Koo 2009). 
Administration of blood products, albumin and immunoglobulins may also lead to 
false positive results since BG from cellulose filters may be eluted into blood 
components by filtration during the manufacturing process (Nagasawa et al. 2003). 
Major surgery can lead to elevations in blood BG levels due to the absorption of BG 
released from surgical gauze (Nakao et al. 1997). Severe bacterial infections may 
also lead to false positive results and some species of streptococcus are known to 
produce glucan or glucan-like polymers (Pickering et al. 2005; Digby et al. 2003). 
False negative results may occur if samples are very haemolysed or lipaemic. BG 
detection assays are unable to detect fungal infections caused by species such as 
Cryptococcus, Zygomyctes and Blastomyces dermatidis as these fungi lack or have 
low amounts of BG in their structure leading to false negative results (Wright et al. 
2011).  
7.4 Serum (1→3)-β-D glucan levels in kidney disease 
7.4.1 Non-dialysed chronic kidney disease patients 
No studies published to date looks specifically at the effect of reduced kidney 
function on levels of serum BG or its effect on BG detection assay. It is unlikely that 
reduced kidney function or clearance would significantly affect BG levels since 
animal studies demonstrate that the primary route of removal of BG is by the liver 
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and reticulo-endothelial system via oxidative degradative mechanisms (Young & 
Vincent 2005). Currently, there are no studies that have been published which 
examines whether uraemic substances may cross-react with BG detection assays 
(Kato et al. 2001). 
7.4.2 Haemodialysis and haemofiltration 
In the early era of haemodialysis, dialysers were constructed mainly from cellulose-
containing products, these have largely been replaced by more biocompatible 
synthetic membranes such as polysulfone, polycarbonate and polymethyl 
methylacrylate dialysers. Studies of blood BG levels in haemodialysis patients are 
summarised in Table 7-3: - 
Membrane 
material 
Population Average BG levels Reference 
Unmodified 
cellulose 
 
Stable haemodialysis 
patients 
330±80 pg/mL increased by 
70.6±20.7 pg/mL after dialysis 
(Yoshioka et al. 1989) 
Stable haemodialysis 
patients 
9.4 pg/mL (range 1.2-39.1) pre-
dialysis; 332 pg/mL (range 108.2-
2200) post-dialysis 
(Kanda et al. 2001) 
Modified cellulose 
 
Stable haemodialysis 
patients 
7.9 pg/mL (range 1-27.2) pre-
dialysis; 9 pg/mL  (range 1-29.5) 
post-dialysis 
(Kanda et al. 2001) 
Stable haemodialysis 
patients 
2778±549 pg/mL pre-dialysis; 
5561±722 pg/mL post-dialysis 
(Kato et al. 2001) 
Polysulfone or 
polymethyl 
methacrylate 
(PMMA) 
 
Stable haemodialysis 
patients 
18.8±3.7 pg/mL pre-dialysis; 
16.0±3.9 pg/mL post-dialysis 
(Kato et al. 2001) 
Stable haemodialysis 
patients 
Levels not stated but no 
significant change in BG level 
before and after dialysis 
(Kanda et al. 2001) 
Patients with active 
Pneumocystis Jiroveci 
pneumonia 
Levels not stated but no 
significant change in BG level 
before and after dialysis 
(Held & Wagner 2011) 
Lung transplant 
recipients 
383pg/mL dialysed patients; 
107.3pg/mL non-dialysed patients 
(Alexander et al. 2010) 
Critically ill patients on 
intensive care unit 
Levels not stated but exposure to 
haemodialysis was associated 
with raised BG levels 
(Hanson et al. 2012) 
Table 7-3: BG studies in patients treated with haemodialysis or haemofiltration 
Haemodialysis using cellulose membranes can raise blood BG levels by 100-200 
pg/mL (Yoshioka et al. 1989; Kanda et al. 2001). For modified cellulose membranes, 
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there are conflicting reports with one study reporting significant elevation of blood BG 
levels (Kato et al. 2001) and another study finding no effect of modified cellulose 
membranes on BG levels (Kanda et al. 2001). Most studies have found that synthetic 
membranes do not significantly influence blood levels of BG. Kanda et al found no 
difference in BG levels before and after dialysis with polymethyl methacrylate 
membranes (Kanda et al. 2001). Similarly, Kato et al reported that in patients who 
had been previously treated with cellulose dialysers, switching to polysulfone 
membranes led to a sustained reduction in blood levels of BG (Kato et al. 2001). 
However, an investigation in lung transplant recipients found that blood BG levels 
were increased for up to 7 days after exposure to haemodialysis despite use of 
biocompatible polysulfone membranes (Alexander et al. 2010). Another study in 
critically ill patients found that haemodialysis treatment with polysulfone membranes 
was a significant determinant of elevated blood BG in the absence of fungal infection 
(Hanson et al. 2012). Thus, it is unclear whether exposure to haemodialysis 
membranes regardless of the membrane material, does contribute to elevated blood 
levels of BG. However, most studies and a recent review on the reliability of blood 
BG testing in dialysis patients suggest that the impact of dialysis with synthetic 
membranes on blood BG levels are likely to be negligible (Prattes et al. 2015).  
7.4.3  Peritoneal dialysis 
There are a very limited number of studies that investigate blood BG levels in 
peritoneal dialysis patients – all of which are limited to case studies (Ginocchio et al. 
2012; Ates et al. 2013). Both studies report elevated blood BG as a useful marker of 
fungal peritonitis and for monitoring of response to treatment with antifungals. Since 
there is no exposure of blood to dialyser membranes with peritoneal dialysis, it is 
anticipated that this modality of dialysis would not significantly raise blood BG levels 
(Prattes et al. 2015). Currently, there are no published studies that report the level of 
blood BG in peritoneal dialysis patients without fungal infection. 
7.5 Summary 
Studies documented in this thesis were carried out on haemodialysis patients treated 
with biocompatible, synthetic dialyser membranes, although the small number of 
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published investigations suggest that treatment with synthetic dialyser membranes 
are unlikely to have any significant effect on blood BG, this finding is not consistent 
in all studies (Hanson et al. 2012; Alexander et al. 2010). As discussed in Chapter 3, 
since the LAL assay is not specific for endotoxin and may also be activated by BG 
via the factor G pathway, it is important to clarify if BG is significantly elevated in the 
blood of haemodialysis patients and if blood BG present in haemodialysis patients 
could be responsible for the apparent elevated blood endotoxin levels reported in the 
literature. This issue is further investigated in chapter 8.  
Additionally, there is a significant variation in blood levels of BG in the haemodialysis 
population (Table 7-3), differences in assay may partly explain this, however other 
clinical factors may be contributory such as diet, medications, co-existing conditions 
especially liver and gastrointestinal disease and dialysis factors. The influence of 
these factors on blood BG in haemodialysis patients (without fungal infection) has 
not been explored in the current literature and warrants further investigation. 
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 Chapter 8 
8. Influence of (1→3)-β-D glucan on endotoxin detection in end-
stage kidney disease 
 
8.1 Introduction 
As discussed in Chapter 2, endotoxemia is commonly reported in the dialysis 
population and has been associated with systemic inflammation – a strong 
prognostic of poor outcome (Carrero & Stenvinkel 2010). Endotoxins are implicated 
in the pathogenesis of sepsis syndrome and are potent mediators of inflammation. 
The levels of endotoxemia reported in the dialysis population range from 0.209 to 
2.31 endotoxin units/mL (EU/mL) (see Table 2-1). This appears high since it is well 
established that 4.1-5 EU/kg/hr is sufficient to induce pyrogenic symptoms such as 
rigor, nausea and hypotension in humans (Greisman & Hornick 1969; Hochstein 
1994). Nearly all studies in the dialysis population have employed the use of the LAL 
assay to detect endotoxin. Due to differences in the types of available LAL assay 
and sample preparation methods reported in these studies, a number of experiments 
were carried out to determine the most accurate and precise among LAL assays 
most commonly used in the dialysis population, further work was carried out to 
optimise the kinetic turbidimetric LAL assay which showed sufficient accuracy and 
precision to detect endotoxin from samples that had been spiked with control 
endotoxin (see section 6.9). However, although LAL is a very sensitive biological 
assay, capable of detecting sub-picogram/mL levels of endotoxin. LAL is not specific 
to endotoxin but can also be activated by (13)-β-D-glucan (BG) via an alternate 
enzymatic pathway mediated by factor G activation (see Chapter 3). Given the 
frequently reported association between elevated BG and exposure to 
haemodialysis, it is important to ensure that endotoxin ‘signal’ detected using the 
LAL assay is truly due to endotoxin itself rather than false positive activation by co-
existing elevated BG. Taniguchi et al found that endotoxin levels were much lower in 
hemodialysis patients when blood samples were assayed using LAL devoid of factor 
G compared with standard unmodified LAL, although they did not measure BG levels 
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in their study (Taniguchi et al. 1990). It is important to clarify whether blood 
endotoxin levels are truly raised in dialysis patients since emerging therapies such 
as extracorporeal endotoxin are in development and their efficacy in the treatment of 
sepsis syndrome has been reported  (Klein et al. 2014).  
LAL assay reactivity to BG can be prevented by either using LAL reagent that lacks 
factor G or by rendering the factor G component of the LAL assay unreactive to BG 
using BG-blocking buffers. Nearly all endotoxin studies in dialysis population, with 
one notable exception (Taniguchi et al. 1990), did not use LAL that was rendered 
insensitive to BG activation. Hence it is unclear whether reported high levels of 
endotoxemia are truly due to endotoxin or due to false positive interference from BG.  
Using the kinetic turbidimetric LAL assay as described in Chapter 8, the influence of 
BG on endotoxin read-out measurements was investigated by measuring endotoxin 
in haemodialysis patients with and without the use of a BG-blocking buffer. In a 
separate experiment, in order to determine whether use of BG-blocking buffers 
interfered with the detection of true endotoxemia, plasma samples were spiked with 
known amounts of endotoxin, and measured endotoxin levels with and without the 
blocking buffer. BG was measured in plasma samples to determine its association 
with endotoxin.  
8.2 Methods 
Study design 
This was a single centre cross-sectional study of prevalent haemodialysis patients 
treated at the East and North Herts NHS Trust. Ethical approval was obtained from 
the Northampton NHS Research Ethics Committee. Written informed consent was 
obtained from all participants. All patients dialysed using an arterio-venous fistula 
and were clinically stable at the time of study.  All were treated by on-line 
hemodiafiltration using ultrapure water. Exclusion criteria were HIV infection, viral 
hepatitis, abnormal liver function and active gastrointestinal disease. 
The study was divided into two phases. The first phase compared the difference in 
endotoxin read-out measurements between standard LAL (without BG-blocking 
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buffer [LAL(-)]) and LAL reconstituted with manufacturer supplied BG-blocking buffer 
(Charles Rivers® ES-buffer [LAL(+)]) to render the LAL insensitive to further 
stimulation by BG. The second phase of the study was carried out to ensure that BG-
blocking buffers themselves do not affect the accuracy or interfere with the sensitivity 
of LAL to detect endotoxin. 
8.2.1 Phase 1: Comparison of endotoxin measurements between LAL(-) and 
LAL(+) 
Fifty patients were recruited. For each subject, plasma samples were assayed for 
endotoxin using both LAL(-) and LAL(+). Samples were also measured for IL-6, TNF-
α and BG. Correlation between BG, markers of inflammation, demographic and 
clinical factors was explored. 
Blood sampling and processing 
Blood samples were collected pre-dialysis through the arterio-venous fistula using 
aseptic technique as described in Chapter 6. Briefly, blood samples for endotoxin 
and BG measurements were collected in Terumo Venoject II heparinised tubes 
(Project KBG, Tokyo). Blood samples for cytokine measurements were collected in 
S-monovette Z-gel tubes (Sarsedt, Germany). Plasma for endotoxin and BG 
measurements were prepared by centrifugation at 250g for 10min and serum for 
cytokine measurements were prepared by centrifugation at 1500g for 10min. Plasma 
and serum samples were immediately frozen and stored at -80°C. Blood collection, 
processing and storage were completed within 30 minutes for all samples. 
Phlebotomy equipment including syringes and blood collection tubes were batch 
checked for endotoxin contamination. Washout from the apparatus were consistently 
found to have undetectable endotoxin (<0.0025 EU/mL).  
Laboratory measurements 
Endotoxin assay using standard LAL without BG-blocking buffer [LAL(-)]: 
Endotoxin measurements were performed using the kinetic turbidimetric LAL assay 
(Endosafe KTA2, Charles River Laboratories, Ecully). Plasma samples were diluted 
1:10 with 0.1% Tween80 (Merck Chemicals, Darmstadt) and heated to 70°C for 
10min and cooled to room temperature (20-25ºC) prior to analysis. 100µL of diluted 
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plasma was added to duplicate wells on 96-well microplates. Endosafe KTA2 
reagent was reconstituted with 5.2mL LAL reagent water. 100µL of this mixture was 
added to each sample. The plate was monitored at 340nm using a Biotek ELx808 
absorbance microplate reader with Endoscan-V software (version 4.0; Charles River) 
with an onset optical density set at 0.03. Six-point standard curves were constructed 
using standard dilutions of control standard endotoxin (E.coli 055:B5) ranging from 
10-0.0025 EU/mL. All standard curves had a correlation coefficient >0.98. Coefficient 
of variation (CV) for onset reaction times for each assay was <20%.  
Endotoxin assay using LAL reconstituted with BG-blocking buffer [LAL(+)]: To 
block the factor G pathway, Endosafe KTA2 reagent was reconstituted with 5.2mL 
BG-blocking buffer (Charles River ES-Buffer) containing 1mg/mL carboxymethylated 
curdlan(Tsuchiya et al. 1990; Kambayashi et al. 1991). Endotoxin measurements 
were carried out using the same procedure as described above. For each patient, 
samples were analysed with LAL(-) and LAL(+) simultaneously on the same 
microplate. The same batch of LAL reagent was used throughout the study. 
(1-3)-β-D glucan assay: BG measurements was carried out using the Fungitell 
assay (Associates of Cape Cod, Inc.) as per manufacturer’s instructions (Associates 
of Cape Cod 2011; Petraitiene et al. 2008). In brief, 5µL of sample was mixed with 
20µL pre-treatment buffer (0.125M KOH/6M KCl), in microplate wells, and incubated 
at 37ºC for 10min. Fungitell reagent, reconstituted in 0.1M Tris HCl, pH 7.4, was 
added to sample and standard curve wells (7.8–500pg/mL, Pachyman). The 
reactions were read kinetically, at 405nm minus 490nm at 37ºC, for 40min.  Vmean 
values (milliabsorbance units/min) were calculated for standards and samples and 
sample titres interpolated from the standard curve. CV for all assays was <20%. 
Normal human serum contains low levels of BG, typically 10-40pg/mL(Odabasi et al. 
2004). Levels <60pg/mL are interpreted as negative and between 60-80pg/mL is 
interpreted as indeterminate. Levels >80pg/mL is interpreted as positive and in at-
risk patients is considered a marker of invasive fungal infection (Associates of Cape 
Cod 2011; He et al. 2015).  
Cytokine measurements and C-reactive protein measurements: serum was 
measured for IL-6 and TNF-α using enzyme-linked immunosorbent assays (Human 
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Quantikine ELISA, R&D systems). For IL-6, intra- and inter-assay CV was 1.6-4.2% 
and 2.0-3.7% respectively. For TNF-α, intra- and inter-assay CV was 4.2-5.2% and 
4.6-7.4% respectively. All haemodialysis patients at the East and North Herts NHS 
trust have monthly CRP measurements (Olympus AU2700, Beckman-Coulter) as 
part of routine clinical care. Monthly CRP measurements for all patients were 
collected in the preceding 3 months of the study to determine the chronic 
inflammatory status of subjects.  
Measurement of BG in dialysis fluid: Dialyzers were investigated for BG 
contamination. Dialysis priming fluid from 12 randomly selected dialyzers (10 
Fresenius FX and 2 Gambro Evodial dialyzers) was measured for BG as described 
above. The limit of detection of BG in aqueous solutions is 7.8pg/mL.  
8.2.2 Phase 2: Investigating the effect of BG-blocking buffers on endotoxin 
spike recovery 
To ensure that BG-blocking buffers themselves do not interfere with endotoxin 
detection, the ability of LAL reconstituted with different doses of BG-blocking buffers 
to detect endotoxin from plasma samples spiked with control standard endotoxin 
(lipopolysaccharide; LPS) was explored (Figure 8-1). 
 
 
Figure 8-1: Schematic presentation of spiking experiments—plasma from each patient was aliquoted 
and spiked with three different concentrations of control standard endotoxin (LPS) and each spiked 
sample was assayed using LAL reconstituted with different doses of glucan blocking buffer to 
calculate % spike recovery. * denotes manufacturer recommended dose of glucan blocking buffer 
(Charles Rivers ES-buffer 
®
; Endotoxin-Specific buffer) containing 1 mg/mL of carboxymethylated 
curdlan. 
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Eight patients with undetectable endotoxemia were recruited for this sub-study. 
Plasma from each subject was aliquoted and spiked with three different 
concentrations of LPS (0.05, 0.1 and 1EU/mL). Each spiked sample was diluted, 
heat-treated as described above and assayed with LAL(-) and LAL reconstituted with 
different concentrations of BG-blocking buffer. The standard inhibitor concentration 
of Charles River ES-buffer used to render LAL unreactive to BG stimulation is 1 
mg/mL carboxymethylated curdlan (Tsuchiya et al. 1990). Each LPS-spiked plasma 
sample was assayed with LAL reconstituted with progressively diluted 
concentrations of carboxymethylated curdlan ranging from 0.01-1mg/mL to calculate 
percentage spike recovery. Spike recovery was calculated using the following 
formula: - 
 
% 𝑠𝑝𝑖𝑘𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑠𝑎𝑚𝑝𝑙𝑒
×  100% 
 
Spike recoveries between 50-200% are considered acceptable as discussed in 
6.3.1. 
8.2.3 Statistical analysis 
Data are presented as means and medians with respective 95% confidence intervals 
and interquartile ranges. Paired and non-paired data were compared using 
Wilcoxon-signed rank and Mann-Whitney U test respectively.  Ordinal data between 
multiple groups was compared using Kruskal-Wallis test. Correlation was compared 
using Spearman’s correlation coefficient. ROC analysis was used to identify optimum 
cut-off levels of BG to identify patients with detectable endotoxemia using the LAL(-). 
Level of agreement between patients with detectable endotoxemia and those with 
elevated BG levels was analysed using the kappa statistic. 
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8.3 Results 
8.3.1 Patient characteristics 
Patient characteristics are listed in Table 8-1. Mean age was 64 and median dialysis 
vintage was 2.8 years. With the exception of one patient who dialyzed using 
synthetic polycarbonate heparin-grafted dialyzer (Gambro, Evodial), all were treated 
with synthetic polysulfone dialyzer (Fresenius, FX high-flux). Most had evidence of 
inflammation, with elevated IL-6 and TNF-α. 58% of patients had evidence of chronic 
inflammation with median CRP >5mg/L in the three months preceding the study. 
Parameter 
N = 50 
Value 
Age (years) 64 [95% CI, 60-69] 
Male gender (%) 74 
Weight (kg) 78.2 [95% CI, 73.1-83.3] 
CCI 3.8 [95% CI, 3.1-4.5] 4 [IQR 2-5] 
Diabetes (%)  30  
Previous gastrointestinal disease (%)  14 
KRU (ml/min) 0.1 [IQR 0-2.0] 
Kt/V 1.44 [95% CI, 1.36-1.51] 
Dialysis vintage (years) 2.8 [IQR 1.8-7.8] 
Convective volume (L)  18.8 [95% CI, 16.6-23.0] 
CRP (mg/L) 7.0  [IQR  5-11.3] 
High CRP ≥ 5 mg/L (%) 58% 
Albumin (g/L)  38.4 [95% CI,  37.4-39.4] 
TNF-α (pg/mL) 13.6 [IQR 11.6-17.7] 
IL-6 (pg/mL) 7.7 [IQR 4.6- 14.8] 
PTH (pmol/L) 38.6 [IQR 29.0-54.5] 
Dialyzer surface area (m
2
) 1.8 [IQR 1.8-2.2] 
Table 8-1: Patient characteristics 
CCI, Charlson co-morbidity index; KRU, residual urea clearance; CRP, median C-reactive protein over the previous 3 months; 
PTH, parathyroid hormone; TNF-α, tumour necrosis factor-α; IL-6, interleukin-6 (values quoted for healthy controls for IL-6 and 
TNF-α are <3.1pg/mL and <2.8pg/mL respectively); Kt/V, combined dialyser and renal urea clearance normalised to body 
volume 
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8.3.2 Effect of BG-blocking buffers on plasma endotoxin detection 
Using LAL(-), 50% of patients had detectable endotoxemia with median endotoxin 
level of 0.038EU/mL, however on repeat measurement with LAL(+), no subjects had 
detectable endotoxemia (Table 8-2).  
Population Plasma endotoxin (EU/mL) 
 
Plasma BG  
 
(pg/mL) LAL(-) (No BG 
blocker) 
LAL(+) (with BG 
blocker) 
Detectable endotoxemia  0.038   
[IQR 0.031-0.043] 
 
Undetectable 
(<0.025) 
78 [IQR 59-117] 
(n = 25) 
No endotoxemia  Undetectable 
(<0.025) 
 
Undetectable 
(<0.025) 
54 [IQR 36-65] 
(n = 25) 
p-value   <0.001 
Table 8-2: Plasma endotoxin and (1-3)-β-D-glucan levels in patients with and without 
endotoxemia 
8.3.3 Association between endotoxin signals detected using LAL(-) and (1-3)-β-
D-glucan  
Apparent endotoxin signals detected using LAL(-) was higher in patients with BG 
levels >80pg/mL (positive test) compared to those with BG levels <60pg/mL 
(negative test) [0.034 vs. 0EU/mL; p=0.02] (Figure 8-2) 
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Figure 8-2: Endotoxin signal detected using standard LAL without BG blocking buffer 
displayed by tertiles of (1–3)-β-D glucan. 
Endotoxin signals in patients with BG levels >80pg/mL also tended to be higher than 
those with BG levels between 60-80pg/mL (indeterminate result) although this did 
not reach statistical significance [0.034 vs. 0.028 EU/mL; p=0.09]. Elevated BG 
(>60pg/mL) were found in 58% of patients and BG levels was significantly higher in 
those with detectable endotoxemia compared to those with undetectable 
endotoxemia (78 vs. 54pg/mL, p<0.001, [Table 8-2]). These findings lend support to 
the notion that the ‘endotoxin’ signals detected using LAL(-) are false positives due 
to interference from BG. ROC analyses revealed a strong relationship between high 
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BG levels and apparent endotoxemia using LAL(-) (AUC=0.79 [0.66, 0.92]; p<0.001) 
[Figure 8-3].  
 
 
Figure 8-3: Receiver operative curve (ROC) analysis using (1→3)-β-D glucan at cut-off level 62 
pg/mL to predict those with detectable endotoxin signals using LAL(-) 
 
The optimum cut-off levels for identifying patients with apparent detectable 
endotoxemia were between 60-70pg/mL. BG levels >62pg/mL identified apparent 
endotoxemia with sensitivity of 72% and specificity of 76%. Level of agreement 
between patients with apparent detectable endotoxemia and those with elevated BG 
levels (>62pg/mL) was moderate (kappa=0.48, p=0.001).  
8.3.4 Effect of BG-blocking buffers on endotoxin spike recovery 
Endotoxin spike recovery for samples spiked with 0.05 EU/mL and 0.1 EU/ml was 
elevated at 172% and 130% respectively using LAL(-), suggesting enhancement of 
the LAL assay. However, this enhancement was abolished on repeat measurement 
with BG-blocking buffers [LAL(+)], with spike recoveries falling closer to the expected 
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value of 100% (106% and 97.5% for samples spiked with 0.05 EU/mL and 0.1 EU/ml 
respectively; p<0.05) [Figure 8-4].  
 
Figure 8-4:  Comparison of median spike recovery between LAL(-) and LAL(+) in plasma 
samples spiked with endotoxin (box plots represent median values with interquartile range, 
hashed horizontal line denotes the expected optimum spike recovery). LAL(-), standard LAL 
with no glucan blocking buffer; LAL(+), LAL reconstituted with Charles River® ES-buffer 
containing 1mg/mL carboxymethylated curdlan. 
For samples spiked with high concentrations of endotoxin (1 EU/mL), spike recovery 
was broadly reduced for both LAL(-) and LAL(+), with no significant differences in 
spike recovery. Despite this, all spike recoveries were within industry-accepted limits 
of 50-200%(United States Pharmacopoeia 2013) [Table 8-3].  
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Concentration of carboxymethylated 
curdlan (mg/mL) 
 
(n=8) 
0  1  0.5 0.1 0.01 
Standard LAL 
(no glucan 
blocking 
buffer) 
(Manufacturer 
recommended 
dose) 
Concentration of endotoxin 
spike  
0.05      
(Expected endotoxin 
content) [EU/mL] 
 
Spike recovery (%)  172  
[108.5-210] 
 
106  
[80.5-122.5] 
149  
[97.5-206] 
220  
[134.5-343.5] 
 
848  
[271-1798] 
P   0.028* 0.574 0.036* 0.012* 0.012* 
 
Concentration of endotoxin 
spike  
0.1      
(Expected endotoxin 
content) [EU/mL] 
 
Spike recovery (%)  130  
[102.5-142.5] 
 
97.5  
[69-124] 
120.5  
[73.8-202.3] 
160.5  
[105.5-274.3] 
665.5  
[170.3-1391] 
P  0.063 0.674 0.362 0.036* 0.012* 
       
Concentration of endotoxin 
spike  
1      
(Expected endotoxin 
content) [EU/mL] 
 
Spike recovery (%)  62.1  
[37.6-69.5] 
 
60.1  
[46.8-67] 
64.9  
[44.4-85.8] 
67.8 
[46.2-89]  
99.7  
[57.8-190.5] 
P   0.012* 0.012* 0.036* 0.05 0.575 
       
Table 8-3: Spike recovery from plasma samples with undetectable endotoxin using different concentrations of glucan blocking 
buffers. Median spike recovery with interquartile ranges presented. Spike recoveries of 50-200% are considered acceptable. 
Significant P values (*) indicates spike recovery significantly different from expected % spike recovery 
Assay measurements using LAL re-constituted with increasingly dilute amounts of 
carboxymethylated curdlan resulted in progressive enhancement of spike recovery 
(Table 8-3, Figure 8-5).  Lower doses of BG-blocking buffer (0.01-0.1 mg/mL ES 
buffer) caused activation of the LAL reagent almost immediately upon reconstitution 
resulting in wide variability of spike recoveries obtained using lower doses of BG-
blocking buffer. 
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Figure 8-5:  Comparison of median spike recovery between LAL and LAL 
reconstituted with different doses of BG blocking buffer (ES buffer). Spike recoveries 
of 50–200% are considered acceptable. Box plots represent median spike recovery 
with interquartile range, hashed horizontal line denotes the expected optimum spike 
recovery. 
8.3.5 Measurement of BG in dialysis fluid 
High levels of BG were observed in a significant proportion of patients and since BG 
leaching from cellulose-based HD membranes have been reported (Kanda et al. 
2001), dialysers were examined for BG contamination. Pre- and post-dialyser saline 
washout from the blood compartment of dialysers revealed very low level 
contamination. Post-dialyser washout tested positive for BG in 6/12 dialysers (range 
8-22pg/mL). Median BG levels in post-dialyser washout were 4.8 pg/mL (Table 8-4).  
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 Pre-dialyzer  Post-dialyzer P 
(n =12) (n=12) 
(1-3)-β-D-glucan 
(pg/mL) 
Below detection 
limit 
4.8  [IQR 0-9.8] 0.046* 
Table 8-4: BG measurements of saline washout pre- and post-dialyzer. Limit of 
detection was 7.8pg/mL, values <7.8pg/ml was designated as 0.  
 
8.3.6 Clinical correlates of (1-3)-β-D-glucan 
Weight and residual urea clearance correlated negatively with plasma BG levels (r=-
0.33 and -0.31 respectively; p<0.05). Plasma BG correlated positively with endotoxin 
signals detected using LAL[-] (r=0.55, p<0.01) but did not correlate significantly with 
markers of inflammation including TNF-α, IL-6, albumin or CRP. There was no 
relationship between BG and age, co-morbidity, dialysis vintage, dialysis adequacy 
as determined by Kt/V, convective volume or dialyser surface area (Table 8-5).  
 
Table 8-5: Clinical correlates of (1-3)-β-D glucan, endotoxin signals detected using LAL[-] and 
markers of inflammation 
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8.4 Discussion 
The levels of endotoxemia reported in the dialysis population are high and often 
appear close to or exceed the pyrogenic threshold of 4.1-5 EU/kg in humans 
(Greisman & Hornick 1969; Hochstein 1994). Contrary to the high blood endotoxin 
levels reported in the literature, the apparent level of endotoxemia detected using 
LAL(-) in our population was low with a median level of 0.038-0.041 EU/mL. These 
low levels do not appear to be due to sub-optimal pre-treatment of plasma to remove 
inhibitory plasma components since spike recovery from all samples was sufficient 
and well within the 50-200% limit (Figure 8-4). The plasma dilution and heat 
treatment conditions used in this study was similar to those used by many other 
authors (Hurley 1995). It is possible that the high endotoxin levels reported in the 
literature are due to pre-analytical factors such as contamination of phlebotomy and 
laboratory apparatus. All phlebotomy apparatus used in this study was tested for 
endotoxin contamination and interfering factors. Only manufacturer-certified 
endotoxin free laboratory apparatus was used for the analysis. 
False positive activation of the LAL from BG may also be partly responsible for the 
apparently high ‘endotoxin’ levels reported in dialysis patients. The apparent 
endotoxin signals detected in 50% of the study cohort using LAL(-) became 
undetectable when the assay was repeated with LAL(+) to block factor G activation. 
Furthermore, endotoxin signals detected using LAL(-) were significantly higher in 
those with the highest blood BG levels. These finding suggest that endotoxin signals 
in this study detected using standard LAL are likely to be false positives due to 
interference from BG.  
The factor G pathway of LAL was inhibited using highly concentrated 
carboxymethylated curdlan (Kambayashi et al. 1991; Tanaka et al. 1993) – itself a 
BG. The interaction between BG and factor G is complex (Ohno et al. 1990). Lower 
molecular weight BG structures such as laminarin and curdlan degradation products 
have factor G activating properties at low concentrations, but become inhibitory at 
high concentrations. Consistent with this, there was a progressive increase in 
endotoxin spike recovery as the concentration of the BG-blocking buffer was 
progressively reduced and very dilute concentrations of BG-blocking buffer caused 
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coagulation of the LAL reagent almost immediately upon reconstitution. This peculiar 
phenomenon is the basis of commercial BG-blocking agents used to eliminate BG 
interference in LAL endotoxin detection (Young & Vincent 2005) and BG-blocking 
agents typically consist of solutions containing highly concentrated BG. 
Highly concentrated carboxymethylated curdlan used as a BG-blocking buffer does 
not appear to affect the ability of LAL to detect endotoxin (Kambayashi et al. 1991), 
although previous studies have tested this in plasma samples spiked with relatively 
high concentrations of LPS. Since endotoxin content in the current study cohort with 
detectable endotoxemia was relatively low (median 0.038 EU/ml), and to ensure that 
the BG-blocking buffer used in this study did not interfere with true endotoxin 
detection at this level of endotoxemia, the effect of the BG-blocking buffer on the LAL 
assay’s ability to recover endotoxin from plasma spiked with lower amounts of 
endotoxin (0.05-0.1EU/mL) was examined.  
Spike recovery was enhanced (130-172%) using LAL(-), however on repeat 
measurement using LAL(+), this enhancement was abolished with spike recoveries 
falling closer to expected values (97.5-106%). This suggests that within this range of 
endotoxemia, there could be enhancement of the LAL assay by BG present in the 
blood, supporting the hypothesis that ‘endotoxemia’ detected in haemodialysis 
patients may be artefactual due to BG interference. This also demonstrates that BG-
blocking buffers used in this study do not interfere with the sensitivity of the LAL 
assay to detect endotoxin since spike recovery using LAL(+) was close to 100%. All 
spike recoveries obtained were within the industry-specified limits of 50-200%. As 
the LAL test is a biological assay and is subject to inherent variability, wide-ranging 
spike recoveries are permitted (United States Pharmacopoeia 2013), therefore this 
may lead to LAL users accepting results of endotoxin measurement and not taking 
steps to rule out BG positive interference. 
In samples spiked with a high concentration of endotoxin (1 EU/mL), spike recovery 
was broadly reduced and there was no significant difference in spike recovery 
between LAL(-) and LAL(+), possibly reflecting that the contribution of residual BG 
signal was only a small proportion of the overall signal when higher concentration of 
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LPS is used. Thus BG blocking buffers are more important and necessary when 
measuring endotoxin in patients with low level endotoxemia.  
Elevated levels of blood BG were found in a large proportion of patients. The clinical 
significance of high blood BG levels in-vivo is unclear. There was no relationship 
between BG with markers of inflammation in this study although only two pro-
inflammatory cytokines were studied. A broader inflammatory profile may have been 
useful as BG has been shown to stimulate release of a number of other pro-
inflammatory cytokines such as IL-8 (T. Suzuki et al. 2002; Kubala et al. 2003). 
Different cut-off levels of BG are used as a diagnostic marker in invasive fungal 
infections and in-vitro evidence suggests that BG may potentiate enhanced Toll-like 
receptor-induced cytokine production (Kikkert et al. 2007). However, the use of BG 
as adjunctive therapies for treatment of malignancies has been reported (Young & 
Vincent 2005; Rop et al. 2009; Yin et al. 2015; Lemieszek & Rzeski 2012). The 
source of high BG in this study is unknown. Though there was no evidence from 
single-pass experiments that the dialysis membranes were involved in significant BG 
generation, it is possible that cumulative treatments over many years may increase 
BG levels, although there was no correlation between BG levels and dialysis vintage. 
The gut is a potential source of high BG levels given reports of translocation of 
intestinal luminal contents due to disturbed gut permeability in uraemia (Wang, 
Zhang, et al. 2012; Hauser et al. 2011; Vaziri 2012), although there was no 
relationship between BG levels and history of gastrointestinal disease. There was an 
inverse relationship between BG with weight and residual kidney function. Animal 
studies suggest that BG are cleared mainly by the liver (Yoshida et al. 1997; Yoshida 
et al. 1996) and degraded oxidatively in the reticuloendothelial system(Hong et al. 
2004; Young & Vincent 2005), with minimal excretion by the kidney. The role of 
kidney function in BG excretion is poorly understood (Yoshida et al. 1997) and 
requires further investigation.  
The limitations of this study include the relatively small sample size and the use of 
reagents from only one manufacturer. It is unclear whether a similar conclusion 
would be reached if LAL reagents and BG-blocking buffers from other manufacturers 
were used. However, a previous study similarly found a low prevalence of detectable 
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endotoxemia in haemodialysis patients when measurements were carried out using 
LAL devoid of factor G (Taniguchi et al. 1990). As discussed previously, natural 
endotoxin should ideally additionally be used for assessment of spike recovery 
although natural endotoxin is difficult to standardise which precluded its use in this 
study. Furthermore, the efficacy of BG blocking buffers should be confirmed by 
spiking samples with BG to ensure that BG-blocking buffers are able to prevent any 
false positive activation of the LAL assay.  
In conclusion, BG presence represents a significant limitation of the LAL assay for 
endotoxin detection in dialysis patients. This data demonstrates that endotoxin 
measurement, in a setting free of BG contribution from dialyzer equipment or dialysis 
fluids, suffers from significant, positive BG interference, especially at very low levels 
of reported endotoxin. Accordingly, endotoxin measurements in dialysis patients 
should be carried out with LAL rendered insensitive to BG.  
This study raises several unexplored issues, firstly although no endotoxin was 
detected in this unselected group of patients (after accounting for false positive 
actions of BG), it is unclear whether patients at high risk of death (e.g. those with 
significant systemic inflammation) may have truly detectable endotoxin since the 
patients in this study population were relatively well and only mildly inflamed (median 
CRP 7mg/L). Elevated blood endotoxins may also be transient and detectable only 
under explicit physiological scenarios such as after exercise or haemodialysis due to 
the hypothesised ill-effects of exercise and haemodialysis on gastrointestinal 
vascular system. These issues are further investigated in Chapter 9. Secondly, 
raised BG levels were found in a significant proportion of haemodialysis patients in 
this study, the source and clinical significance of raised blood BG is unclear. As 
discussed in chapter 7, there are a limited number of studies of BG levels in the CKD 
population and it is difficult to draw any firm conclusions on the consequences of 
raised BG in the CKD population. Curiously, both potential beneficial and harmful 
effects of BG have been reported, BG have been suggested to be effective in the 
treatment of diseases such as cancer, microbial infections, hypercholesterolemia 
and diabetes (Chen & Seviour 2007), on the other hand, BG can be recognised as 
non-self-molecules and may activate the immune system via a number of different 
157 
 
mechanisms including the dectin-1, toll-like receptor 2 and complement system 
leading to the production of cytokines and an inflammatory response (Chen & 
Seviour 2007). In-vitro studies have reported the ability of BG to potentiate the 
cytokine response of toll-like receptor responses (Kikkert et al. 2007). To further 
elucidate the effects of endotoxin and BG in the CKD population, blood endotoxin 
and BG were measured in non-dialysed CKD patients, peritoneal dialysis patients 
and haemodialysis patients. The long term effects of raised BG and endotoxin in 
haemodialysis patients were also studied by a prospective, longitudinal follow-up of 
patients embarking on a haemodialysis treatment (see Chapter 10). 
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 Chapter 9 
 
9. Studies to determine the acute effect of haemodialysis and 
intra-dialytic exercise on blood endotoxin levels 
 
9.1 Introduction 
In the study described in Chapter 8, a sample of an unselected group of prevalent 
haemodialysis patients with relatively low levels of inflammation did not have any 
detectable blood endotoxin after accounting for false positive activation by BG. It is 
possible that blood endotoxin levels were not detected due to the relatively ‘non-
inflamed’ status of this study cohort. Blood endotoxin levels may be increased 
acutely by specific procedures which exert haemodynamic stress such as 
haemodialysis or exercise (Yu et al. 1997). An acute inflammatory response after 
intense exercise has been frequently observed in healthy individuals and elite 
athletes (K. Suzuki et al. 2002). This is purported to be due to the leakage of 
bacterial endotoxin – potent mediators of inflammation, into the systemic circulation 
from the gastrointestinal tract due to exercise-induced gut permeability and barrier 
dysfunction (Lim & Mackinnon 2006). Increased gut permeability related to intense 
exercise is thought to occur due to a combination of fluid depletion, hyperthermia, 
ischemia and free radical stress (Pals et al. 1997). Ischaemia occurs due to 
decreased blood flow to the splanchnic circulation during exercise and many athletes 
report gastrointestinal symptoms such as abdominal pain, nausea and vomiting 
during and after exercise(ter Steege & Kolkman 2012). Similarly, many 
haemodialysis patients experience gastrointestinal complaints after dialysis and also 
suffer from intestinal ischemia and contraction of the splanchnic circulation during 
dialysis and ultrafiltration (Yu et al. 1997). In this chapter, studies were carried out to 
explore blood endotoxin levels in haemodialysis patients during these situations. 
However, there is increasing interest to promote the use of intra-dialytic exercise due 
to a host of possible benefits including improved muscle power, fatigability, cardiac 
function, blood pressure control, reduction in depression and anxiety and for its anti-
inflammatory potential (Parker 2016). Additionally, the haemodialysis procedure itself 
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can induce an inflammatory response (Bitla et al. 2010) and some studies report 
increased oxidative stress with a single bout of intra-dialytic exercise (Esgalhado et 
al. 2015), whereas others have found upregulation of anti-inflammatory cytokines 
after intra-dialytic exercise(Peres et al. 2015). Given the increasing use of intra-
dialytic exercise in haemodialysis units, it is important to determine whether there are 
any harmful effects from this procedure given that endotoxin levels may be increased 
after exercise. Although bacterial endotoxin translocation after intense exercise is 
well reported in healthy individuals (Bosenberg et al. 1988), there is no published 
data on the effect of intra-dialytic exercise on blood endotoxin levels in 
haemodialysis patients.  
The objective of this study was to determine the acute effect of haemodialysis and 
intra-dialytic exercise on blood endotoxin levels and markers of inflammation. 
9.2 Methods 
Study population 
This is a single centre study of 10 chronic haemodialysis patients who regularly 
perform intra-dialytic exercise. Ethical approval was obtained from the NHS 
Research Ethics Committee and the study adhered to the declaration of Helsinki. 
Written informed consent was obtained from all participants. All patients were 
clinically well and non-infected at the time of study. Patients were treated with high 
flux haemodialysis or on-line haemodiafiltration with ultra-pure water using 
polysulphone dialysis membranes. The haemodialysis prescription was not altered 
during the course of the study. Exclusion criteria were those with active infection, 
HIV, viral hepatitis and active liver or gastrointestinal disease. 
Study design 
Participants were studied on two separate haemodialysis sessions – in one session 
patients were asked to abstain from intra-dialytic exercise during haemodialysis 
treatment (non-exercise day) and in the second session, patients were asked 
perform their routine intra-dialytic exercise program (exercise day). These sessions 
were carried out within one week of each other. Half of the studies were randomly 
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assigned to be carried with the non-exercise session following the exercise session. 
The remaining studies were carried out with the sessions completed in reverse order 
(see Error! Reference source not found.). 
 
 
Figure 9-1: Flow diagram of patients recruited 
Patients exercised using a specially-adapted cycle ergometer (Deluxe Pedal 
Exerciser, Digiterm Medical Equipment Ltd) during haemodialysis treatment and 
were advised to perform a 2 minute warm-up period using the lowest resistance 
setting on the cycle ergometer followed by cycling at their preferred resistance 
setting aiming for a minimum of 30 minutes at a consistent pace. Patients were 
allowed to rest or cycle as much as they preferred throughout the exercise session. 
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Exercise duration and perceived exertion of the exercise session was recorded using 
the Borg Scale of Perceived Exertion (Borg 1973).  
On each study visit, blood samples were collected at three time-points, 1) pre-
dialysis [pre-HD], 2) immediately post-dialysis [post-HD 1] and 3) 1-3 hours post-
dialysis [post-HD 2], for blood endotoxin, (1→3)-β-D glucan (BG), pro-inflammatory 
cytokines, high-sensitivity C-reactive protein (hs-CRP) and D-lactate – a sensitive 
marker of intestinal ischemia (Evennett et al. 2009) (Figure 9-2). Since endotoxins 
and cytokines can be adsorbed by dialysis membranes (Fujimori et al. 1998; Henrie 
et al. 2008) and there may be enhanced clearance due to convection with 
haemodiafiltration (Cole et al. 2004) and smaller endotoxins (10-20 kDa), BG, D-
lactate may also be removed during dialysis, additional blood samples were taken 1-
3 hours post dialysis to look for a potential rebound rise in any of these parameters 
caused by either intra-dialytic exercise or the haemodialysis procedure. Such 
rebound would be anticipated if endotoxin and inflammatory cytokine were generated 
by the dialysis procedure. For post-HD 1 samples, laboratory measurements were 
corrected for haemoconcentration by dividing the obtained measurement by the ratio 
of post-HD albumin to pre-HD albumin. 
 
Figure 9-2: Blood sampling was performed on an exercise day and non-exercise day. Pre-HD 1, 
pre-dialysis; Post-HD 1, immediately at the end of dialysis; Post-HD 2, 1-3 hours after 
completion of dialysis. At each time point, blood was collected for measurement of endotoxin, 
(1→3)-β-D glucan, IL-6, TNF-α, high-sensitivity CRP and albumin. 
Laboratory measurements 
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Endotoxin assay: Endotoxin measurements were carried using a kinetic turbidimetric 
LAL assay. The procedure is described in detail in Chapter 6. Endotoxin was 
measured with and without BG-blocking buffer as previously described. 
 
(1-3)-β-D glucan assay: BG measurements were carried out using the Fungitell 
assay as described in Chapter 8.  
 
Cytokine, albumin and hs-CRP measurements: serum was measured for IL-6 and 
TNF-α using enzyme-linked immunosorbent assays (Human Quantikine ELISA, R&D 
systems). For IL-6, intra- and inter-assay CV was 1.6-4.2% and 2.0-3.7% 
respectively. For TNF-α, intra- and inter-assay CV was 4.2-5.2% and 4.6-7.4% 
respectively. High-sensitivity CRP (hs-CRP) was measured using particle enhanced 
immunoturbidimetric assay (Roche Diagnostics, cobas c system). Serum albumin 
was measured using a colorimetric assay (Roche Diagnostics, cobas c system). 
 
D-lactate measurements: plasma samples were measured for D-lactate using an 
endpoint enzymatic spectrophotometric assay on an Olympus AU640 analyser 
(Megazyme International, Ireland). D-lactate originates from bacteria in the intestinal 
lumen and is a product of bacterial fermentation. Blood D-lactate levels are usually 
low in health, but in circumstances of bacterial overgrowth such as short bowel 
syndrome and acute mesenteric ischemia, large amounts of D-lactate are released 
into portal and systemic circulation. D-lactate is a marker of intestinal ischemia and a 
systematic review of biomarkers of intestinal ischemia found that D-lactate had the 
best overall diagnostic performance (Evennett et al. 2009).   
 
Statistical analyses 
 
Parametric and non-parametric data are presented as means and medians with 
respective 95% confidence intervals and interquartile ranges. Paired differences 
were evaluated with paired samples t-test and Wilcoxon-signed rank tests as 
appropriate. Statistical significance of variables were established at the level p<0.05. 
Data was analysed using statistical software (SPSS version 21.0, IBM, USA). 
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9.3 Results 
Patient characteristics 
 
Patient characteristics are shown in Table 9-1, mean age of the study cohort was 62. 
Most patients were treated with haemodiafiltration using an arterio-venous fistula. 
Most patients had good dialysis adequacy and retained useful residual kidney 
function. 
 
Parameter 
n=10 
Value 
 
Age (years) 
 
62 [48-76] 
 
Male gender (%) 
 
70 
 
Vascular access (%) 
 
 
Arteriovenous fistula 
 
80 
Dialysis catheter 20 
 
Charlson Comorbidity Index 
 
4 [3-6] 
 
Primary renal disease (%) 
 
Glomerulonephritis 
Hypertensive nephropathy 
Obstructive nephropathy 
Unknown 
 
 
 
30  
10  
10 
50 
 
Dialysis vintage (years) 
 
1.9 [IQR 1.3-3.9] 
 
Residual Urea Clearance (ml/min) 
 
1.5 [0.5-2.5] 
 
Kt/V 
 
1.5 [1.2-1.8] 
 
Haemodialysis modality (%) 
HDF 
High-flux HD 
 
 
80 
20 
Table 9-1: Demographic and clinical data 
HDF, haemodiafiltration; HD, hemodialysis 
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Dialysis and exercise variables 
 
Patients exercised for a mean of 100 minutes (95% confidence interval 57.7-142.2) 
and the mean Borg scale of perceived exertion score was 12 representing “fairly 
light” exertion for the exercise session. There was no significant difference between 
exercise and non-exercise days in terms of hemodynamic stability, pre-dialysis 
weight or ultrafiltration volume (Table 9-2). Post-dialysis systolic BP was lower 
compared to pre-dialysis systolic BP with intra-dialytic exercise although there was 
no significant differences in actual change in systolic BP (delta systolic BP). No 
adverse events were reported.  
 
(n=10) Exercise day Non-exercise day 
 
Exercise duration 
(minutes) 
 
 
100 [57.7-142.2] 
 
Borg scale of perceived 
exertion 
 
12 [11-13]   
Pre-HD weight (kg) 
 
69.7 [IQR 66.5-78.4] 69.8 [IQR 66.2-78.8] 
Post-HD weight (kg) 
 
68.5 [IQR 66-77.8] 68.7 [IQR 66.1-78.2] 
Ultrafiltration (L) 
 
1.18 [0.36-2.0] 1.26 [0.12-2.39] 
Systolic BP(mmHg) 
 
Pre-HD 
Post-HD 
 
p-value (pre-HD vs. 
post-HD) 
 
 
149 [135-163] 
128 [114-142] 
 
0.009* 
 
 
142 [130-155] 
132 [114-149] 
 
0.05 
 
Diastolic BP (mmHg) 
 
Pre-HD 
Post-HD 
 
p-value (pre-HD vs. 
post-HD) 
 
 
 
75 [65-86] 
66 [58-75] 
 
0.161 
 
 
 
81 [69-93] 
68 [56-79] 
 
0.1 
 
Delta systolic BP  
 
 
21 [6.8-35.2] 
 
10.6 [-5.1-26.3] 
Table 9-2: Exercise variables and haemodynamic parameters 
HD, haemodialysis; BP, blood pressure; Delta systolic BP = pre-HD systolic BP minus post-HD 
systolic BP 
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Effect of intra-dialytic exercise on blood endotoxin and (1→3)-β-D glucan levels 
 
Pre- and post-dialysis blood samples were measured for endotoxin initially using the 
LAL assay without BG-blocking buffers [LAL(-)]. Repeat measurement was carried 
out in samples that tested positive using a BG-blocking buffer [LAL(+)] to render the 
LAL reagent insensitive to stimulation by BG (Tsuchiya et al. 1990; Kambayashi et 
al. 1991), to determine if signals detecting using LAL(-) were due to false positive 
interference by BG. Samples were also separately measured for BG using the 
Fungitell® assay. 
 
Using the LAL assay without BG-blocking buffers (LAL[-]), only low level endotoxin 
signals were detected in patients (Table 9-3) with no significant effect of either intra-
dialytic exercise or the haemodialysis procedure itself on the level of endotoxin 
signals (Figure 9-3). Repeat measurement of samples with a BG-blocking buffer 
extinguished all endotoxin signals with the exception of one sample suggesting that 
the significant majority of previously detected endotoxin signals using LAL(-) may be 
due to false positive interference by BG (Table 9-3). BG was elevated (>80pg/mL) in 
43% of samples. Mean BG was not significantly altered by the haemodialysis 
procedure or intradialytic exercise (Table 9-4). 
 
 
Figure 9-3: Changes in endotoxin signals detected using LAL(-) across the haemodialysis 
session an exercise and non-exercise day 
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Patient 
number 
Exercise day 
 
 Non-exercise day 
Pre-HD Post-HD 1 
 
Post-HD 2  Pre-HD Post-HD 1 Post-HD2 
Endotoxin (EU/mL) 
 
 Endotoxin (EU/mL) 
LAL(-) LAL(+) LAL(-) LAL(+) LAL(-) LAL(+)  LAL(-) LAL(+) LAL(-) LAL(+) LAL(-) LAL(+) 
              
1 <0.025 - <0.025 - <0.025 -  0.031 <0.025 0.045 <0.025 0.029 <0.025 
2 <0.025 - 0.037 <0.025 0.030 <0.025  0.038 <0.025 0.051 <0.025 0.03 0.066 
3 <0.025 - <0.025 - <0.025 -  <0.025 - <0.025 - 0.029 <0.025 
4 <0.025 - <0.025 - 0.03 <0.025  <0.025 - <0.025 - <0.025 - 
5 <0.025 - <0.025 - <0.025 -  0.034 <0.025 <0.025 - 0.033 <0.025 
6 0.027 <0.025 0.031 <0.025 0.035 <0.025  0.040 <0.025 0.029 <0.025 0.035 <0.025 
7 0.038 <0.025 <0.025 - <0.025 -  <0.025 - 0.026 <0.025 0.033 <0.025 
8 <0.025 - <0.025 - <0.025 -  <0.025 - 0.025 <0.025 <0.025 - 
9 <0.025 - <0.025 - 0.026 <0.025  <0.025 - <0.025 - <0.025 - 
10 
 
<0.025 - <0.025 - <0.025 -  <0.025 - <0.025 - 0.029 <0.025 
Table 9-3: Endotoxin signals detected in study population on an exercise and non-exercise day using LAL(-) and LAL(+) 
Pre-HD, pre-dialysis; Post-HD 1, immediately post-dialysis; Post-HD 2, 1-2 hours post-dialysis; LAL(-), LAL assay without BG-blocking buffer; 
LAL(+), LAL assay with BG-blocking buffer 
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(n=10) Pre-HD Post-HD 1 Post-HD 2 P value 
 
    Pre-HD vs. Post- HD 
1 
Pre-HD vs. Post-HD 
2 
Post HD-1 vs. Post-
HD 2 
IL-6 (pg/mL)       
       
Exercise day 8.0 [IQR 6.5-10.1] 9.0 [IQR 6.8-15.5] 11.1 [IQR 8.4-15.7] 0.203 0.059 0.093 
Non-exercise day 6.3 [ IQR 3.9-8.9] 7.5 [IQR 6.6-10.3] 10.9 [IQR 9.9-14.8] 0.445 0.047* 0.007* 
       
hs-CRP (mg/L)       
       
Exercise day 2.9 [IQR 2.3-7.3] 2.9 [IQR 2.1-7.4] 3.4 [2.2-8.3] 0.404 0.068 0.013* 
Non-exercise day 2.5 [IQR 1.8-9.6] 2.3 [IQR 1.7-9.3] 3.6 [2.0-10.2] 0.952 0.036* 0.065 
       
TNF-α (pg/mL)       
       
Exercise day 11.7 [IQR 10.8-26.5] 9.6 [4.5-14.4] 8.8 [5.5-15.9] 0.007* 0.009* 0.093 
Non-exercise day 12.2 [IQR 9.4-21.1] 6.3 [4.4-12.0] 12.7 [7.6-18.3] 0.047* 0.959 0.005* 
       
(1→3)-β-D glucan (pg/mL)     
       
Exercise day 66.8 [39.6-94] 57.2 [46-66.5] 60.8 [53.2-68.4] 0.494 0.65 0.213 
Non-exercise day 50.1 [34.8-65.4] 
 
53.8 [47-60.5] 62.1[54.7-69.5] 0.627 0.083 0.1 
D-lactate μmol/L     
       
Exercise day 0 [IQR 0-6.5] 0 [IQR 0-10.3] 0 [0-12.5] 0.893 0.893 0.893 
Non-exercise day 0 [IQR 0-12.5] 0 [IQR 0-6.5] 0 [0-10] 0.357 1.0 0.285 
     
Table 9-4: Effect of haemodialysis and intra-dialytic exercise on markers of inflammation and (1→3)-β-D glucan levels 
 
IL-6, interleukin-6; hs-CRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α 
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Effect of intra-dialytic exercise on markers of inflammation and D-lactate 
 
The haemodialysis procedure resulted in a rise in circulating levels IL-6 and hs-CRP 
1-3 hours after treatment (both p<0.05), intra-dialytic exercise attenuated the rise in 
IL-6 and hs-CRP with no significant difference between pre- and post-HD levels. For 
TNF-α, there was no significant difference between pre- and post-HD levels on a 
non-exercise day. However, intra-dialytic exercise led to a significant fall in levels of 
TNF-α after HD. Most patients had undetectable D-lactate, the median D-lactate 
levels pre- and post-HD on both exercise and non-exercise days were below the 
detection limit (Table 9-4). 
 
9.4 Discussion 
The changes in levels of blood endotoxin in haemodialysis patients in relation to 
intra-dialytic exercise were investigated in this study. Due to the lack of endotoxemia 
detected in haemodialysis patients in the studies carried out in Chapter 8, blood 
endotoxin levels were measured in haemodialysis patients after haemodialysis 
treatment and after intra-dialytic exercise – potentially, endotoxemic inducing 
procedures. Using BG-blocking buffers to render the LAL assay insensitive to false 
positive activation by BG (Tsuchiya et al. 1990; Kambayashi et al. 1991) – with the 
exception of one sample, blood endotoxin was not detected in the study population. 
The majority of signals detected using LAL(-) were extinguished on repeat 
measurement with BG-blocking buffers (LAL[+]) suggesting that true endotoxemia 
may be rare in our population. BG was elevated in 43% of samples and given the 
reports of high blood BG reported in haemodialysis patients (Prattes et al. 2015), this 
further emphasises the importance of taking measures to prevent activation of factor 
G using the LAL assay.  
However, it may be possible that the LAL assay may not be sensitive enough to 
detect endotoxin due to its rapid clearance from the circulation by deacylation (Lu & 
Munford 2011) or due to the binding of endotoxin by proteins in plasma rendering it 
unavailable for detection by the LAL assay (Munford 2016). The significance of a 
single sample testing positive for endotoxin with LAL(+) is unclear, this may be a 
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genuine elevated blood endotoxin result or it could be due to external contamination. 
Endotoxin is an extremely ubiquitous molecule and there may have been inadvertent 
contamination during the blood sampling or analytical procedure despite meticulous 
precautions to minimise this risk. The cause of raised BG levels in our study cohort 
was unclear since all subjects dialyzed using polysulphone dialysis membrane which 
is not known to elevate blood BG levels (Prattes et al. 2015). It is unclear whether 
raised BG is an epiphenomenon of disrupted intestinal barrier due to uraemia or by 
being on haemodialysis treatment, although its levels were not significantly altered 
acutely by the haemodialysis procedure or intra-dialytic exercise. This finding will be 
further explored in Chapter 10. 
The study findings suggest that intra-dialytic exercise may attenuate the 
inflammatory response to the haemodialysis procedure. It has been proposed that 
the haemodialysis procedure induces an inflammatory response due to activation of 
peripheral blood mononuclear cells and complement activation in the extracorporeal 
circuit. IL-6, TNF-α and CRP are prognostically significant pro-inflammatory 
cytokines in the dialysis population (Carrero & Stenvinkel 2010). IL-6 and hs-CRP 
increased significantly 1-3 hours post-dialysis on a non-exercise day, however 
following intra-dialytic exercise, levels of IL-6 and hs-CRP did not increase after HD 
and remained similar to pre-HD values. TNF-α levels decreased significantly 
immediately post-dialysis (post-HD 1) but subsequently returned to baseline levels 1-
3 hours after completion of dialysis (post-HD 2) on a non-exercise day. An initial 
reduction in TNF-α with dialysis has also been observed in other studies (Ghysen et 
al. 1990) and post-HD levels frequently return to levels similar to their pre-HD levels 
(Ghysen et al. 1990). Given that TNF-α is adsorbed by dialysis membranes(Fujimori 
et al. 1998) and has a relatively short half-life (5-10 minutes) (Tarakçioğlu et al. 
2003), it has been suggested that the HD procedure may still be inducing a net influx 
or generation of TNF-α despite levels being similar before and after HD (Ghysen et 
al. 1990; Tarakçioğlu et al. 2003). Intra-dialytic exercise appeared to blunt the 
rebound rise in TNF-α after dialysis and levels remain significantly lower than pre-HD 
levels (Table 9-4), overall the observations from this study suggest there may be a 
potential anti-inflammatory benefit from intra-dialytic exercise.  
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The anti-inflammatory benefits of exercise have been reported in individuals with and 
without kidney disease (Parker 2016). The mechanistic reasons for the reported anti-
inflammatory effects of exercise are unclear although it appears that the duration and 
intensity of exercise performed is important. Prolonged and intense exercise 
increases IL-6 release from muscles significantly and stimulates the release of anti-
inflammatory cytokines such as IL-10 and IL-1ra. These anti-inflammatory cytokines 
inhibit the release of other classical pro-inflammatory cytokines including TNF-α and 
IL-1β leading to an overall anti-inflammatory effect (Dungey et al. 2013). Whereas 
short duration and low to moderate intensity activity (similar to the level completed by 
our study cohort) are still associated with an overall reduction in circulating levels of 
inflammatory biomarkers but do not stimulate IL-6 release. Dungey et al reviewed 
the long term effects of exercise on inflammation in dialysis patients and found 
conflicting evidence (Dungey et al. 2013). Proposed reasons for the conflicting data 
include lack of a control arms, small sample size, variable exercise protocols used 
and differences in laboratory assays used to measure different inflammatory 
biomarkers. The acute effect of intra-dialytic exercise on inflammation is even less 
clear with only a small number of published studies, one study found an upregulation 
of anti-inflammatory cytokines such as IL-10 (Peres et al. 2015), another study did 
not find any effect of exercise on circulating pro-inflammatory cytokines (Dungey et 
al. 2015), whilst one study found that intra-dialytic exercise reduced antioxidant 
enzyme activity, suggesting an exacerbation of oxidative stress (Esgalhado et al. 
2015). One of the strengths of our study was that samples were collected 1-3 hours 
after dialysis for better clarification of the effect of dialysis and exercise on 
inflammation since many molecules of interest such as endotoxin and cytokines are 
either removed or adsorbed by dialysis membranes.  
D-lactate was not a useful marker of intestinal ischemia in stable dialysis patients 
since most patients had undetectable D-lactate. It is possible that the level of 
intestinal ischemia experienced by HD patients (due to the low intensity nature of the 
exercise) was transient and not severe enough to trigger significant elevations in D-
lactate, since the diagnostic value of D-lactate is used mainly in patients with severe 
and extensive mesenteric ischemia.  
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There were a number of limitations with this study. Firstly, the sample size was small 
and cross-sectional in nature, these findings would need confirmation in a larger 
cohort study. Secondly, there may have been selection-bias since the study cohort 
was a selected group of prevalent patients who regularly participated in intra-dialytic 
exercise and were relatively well with less comorbidity, stable blood pressures and 
modest ultrafiltration volumes. The selected study participants may have been more 
resistant or less susceptible to the potential endotoxemic-inducing effect of intra-
dialytic exercise which could explain the lack of detectable endotoxemia observed. 
Thirdly, other relevant pro-inflammatory and anti-inflammatory cytokines such as IL-
1β, IL-10 and IL-1ra which may have better characterised the effect of intra-dialytic 
exercise on inflammation were not measured. Additionally, the majority of the study 
cohort was treated with haemodiafiltration with a small proportion on high-flux HD. 
Dialysis modality may affect cytokine levels since there is enhanced clearance with 
convection from HDF, future studies examining the acute effect of dialysis on 
inflammation should ideally control for the different cytokine clearance profiles of 
HDF vs. standard HD. Fourthly, exercise intensity was not measured in this study 
and only subjective measures were used. However, given the concerns with 
exercise-induced translocation of gut bacterial products and endotoxin, the main 
purpose of the study was to determine the effect of intra-dialytic exercise at the level 
of intensity and duration typical of that completed by dialysis patients who may have 
wide varying degrees of fitness. Finally, precise timing of the post-dialysis blood 
sample (post-HD 2) could not be controlled for all patients since it was impractical to 
keep patients in the dialysis unit after completion of dialysis treatment and blood 
sampling was performed after the patient had returned home. However, with the 
exception of one sample, all samples were taken within 1-2 hours of dialysis. 
In conclusion, the findings from this study suggest that acute intra-dialytic exercise 
does not have any adverse effects on patients. Intra-dialytic exercise does not 
appear to induce an influx of endotoxin as observed in other trials of healthy athletes 
during intense exercise. Additionally, intra-dialytic exercise may potentially have 
beneficial, anti-inflammatory effects. The long term impact of intra-dialytic exercise 
on inflammation in HD patients requires further investigation. Despite the use of 
ultra-pure water and biocompatible membranes, the haemodialysis procedure 
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induces a modest inflammatory effect which is not associated with a measurable 
increase in plasma endotoxin. This study further highlights the limitations of using the 
LAL assay to measure blood endotoxin in HD patients which is highly prevalent in 
the literature partly due to the problem with BG interference. Blood BG was elevated 
in a significant proportion of patients despite the use of non-cellulosic dialysis 
membranes, the source and significance of raised blood BG in HD patients warrants 
investigation. The findings from this study and in Chapter 8 suggest that the 
emphasis of endotoxemia as a phenomenon and potential trigger of chronic 
inflammation in stable non-infected HD may not be true and would require re-
examination. Elevated BG appears to play a significant role by inducing false positive 
signals in the LAL assay, potentially being misinterpreted as ‘endotoxemia’. 
However, the studies carried out in this and Chapter 8 are in relatively well, non-
inflamed haemodialysis patients. The sample size was also relatively small and 
without long term follow-up of the study participants. The reasons for elevated BG 
require further study. It is unclear whether BG is elevated due to renal impairment 
itself or whether this is due to the effects of being a long term haemodialysis. These 
issues are further explored in Chapter 10.  
  
173 
 
 Chapter 10 
 
10. Clinical significance of (1-3)-β-D glucan levels in CKD:  
association with endotoxemia and inflammation  
 
10.1 Introduction  
BG are major carbohydrate constituents of yeast, cereal and fungal cell walls which 
share a diverse common backbone structure consisting of β(1,3)-linked-D-
glucopyranosyl units and strongly differ in size and structure depending on the 
pattern of branching (Camilli et al. 2018). BGs are key pathogen-associated 
molecular pattern (PAMP) molecules that trigger a number of host immune 
responses and can stimulate the production of reactive oxygen species and 
inflammatory cytokines mediated by interaction with dectin-1 and toll-like receptors 
(Gantner et al. 2003; Brown et al. 2003). The studies carried out in Chapter 8 and 
Chapter 9 showed that BG was elevated in a significant proportion of haemodialysis 
patients and may produce false positive test results for blood endotoxin detection 
with standard methods of detection using the LAL assay. False positive endotoxin 
signals were detected in 50% of haemodialysis patients in the study described in 
Chapter 8, which were extinguished on repeat measurement with a BG-blocking 
buffer. However, these measurements were carried out in a relatively small number 
of patients without significant inflammation (mean CRP in the population was only 
7mg/L). In Chapter 9 patient blood samples were measured for endotoxin whilst in 
physiological states with the potential to generate endotoxin-influx such as during 
exercise or immediately after haemodialysis treatment, however there was no 
significant effect of haemodialysis or intra-dialytic exercise on endotoxin levels. Only 
low level endotoxin signals detected in the study population and similarly these 
signals were extinguished on repeat measurement with a BG-blocking buffer, further 
supporting the notion that BG present in blood samples results in false positive 
activation of the LAL assay. However, several issues require further exploration – 
could blood endotoxin be detected in patients with more significant and persistent 
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inflammation? Why is BG elevated in haemodialysis patients? What is the clinical 
significance of elevated blood BG in asymptomatic, non-infected individuals? 
The reasons for elevated BG in haemodialysis patients are unclear. Animal studies 
suggest that BG is predominantly degraded oxidatively in the mononuclear 
phagocytic system (MPS) (Young & Vincent 2005; Yoshida et al. 1997), so one 
would not expect a direct relationship to renal function. Dialysis membranes have 
been found to increase BG levels but the effect appears to be confined to now 
obsolete cellulose membranes and is not seen with modern biocompatible devices.  
Hence the cause for these elevated levels is not clear. Likewise, there is little 
understanding of the clinical consequences of high levels of beta-glucan. The 
prevalence and clinical significance of elevated BG levels in non-infected subjects 
with different stages of kidney disease has not been studied. Hence a study was 
carried out to investigate BG levels in patients with various severities of chronic 
kidney disease and the association of BG with inflammation, endotoxin levels, 
clinical symptoms and events.  
10.2 Methods 
Study population 
This was a single centre study conducted at the East and North Hertfordshire NHS 
Trust. Study participants were randomly recruited from patients with CKD, peritoneal 
dialysis and haemodialysis patients. Inclusion criteria were adults aged 18 years and 
over. Participants consisted of healthy controls, CKD 1-3, CKD 4-5, peritoneal 
dialysis (PD) and haemodialysis (HD) patients. Exclusion criteria include participants 
with active sepsis, positive HIV, hepatitis B or C status, those who were pregnant 
and those with active vasculitis or connective tissue disease. 
 
Study design 
There were two sub-studies. 
Sub-study 1 
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The study aimed to investigate BG levels in healthy controls, CKD patients and 
dialysis patients. Across this spectrum the associations of BG levels with markers of 
inflammation, endotoxin levels, clinical symptoms including fatigue and depression 
and clinical events were explored. 
  
A total of 135 subjects were recruited, 20 healthy controls, 20 patients with CKD 1-3 
(eGFR≥30mL/min), 20 patients with CKD 4-5 (eGFR<30mL/min), 15 PD patients and 
60 HD patients. The haemodialysis group consisted of two equal subgroups. High-
risk patients had chronic unexplained inflammation (CRP>5mg/L) measured on two 
separate occasions at least one month apart in the three months prior to study 
recruitment) together with a predilection for intradialytic hypotension (either an 
ultrafiltration rate >10mL/kg/hr (Flythe et al. 2011) or pre- or post-dialysis systolic 
blood pressure <100 mmHg within the week prior to study recruitment). Low-risk 
patients had none of these features. All patients were assessed clinically by to 
ensure there was no evidence of sepsis, no recent antibiotic treatment or receipt of 
blood products in the last month since these can elevate blood BG levels (Sulahian 
et al. 2014).  
 
Blood samples were drawn from subjects and measured for endotoxin, BG, IL-6, 
TNF-α and high sensitivity CRP. All CKD and dialysis patients were asked to 
complete several self-report questionnaires to investigate depression symptoms 
(PHQ-9) (Watnick et al. 2005), fatigue symptoms (MFI-20) (Smets et al. 1995) and 
kidney disease related symptoms (POS-S renal) (Collins et al. 2015). Subjects were 
followed up for 18 months from study recruitment for cardiovascular events, infection 
episodes requiring hospitalisation and mortality.  
 
Sub-study 2 
The study aimed to investigate the effect of haemodialysis initiation on blood levels 
of endotoxin and BG. Thirty patients with CKD stage 5 who were planned for dialysis 
were recruited for this sub-study. Blood samples were collected up to 6 months prior 
starting haemodialysis and repeated 1-6 months after initiating haemodialysis.  
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Blood sampling and processing 
 
Blood samples were collected peripherally using aseptic technique as previously 
described. For haemodialysis patients, this was done pre-dialysis through the arterio-
venous fistula or peripherally if patients did not have a functioning fistula. Blood 
samples were measured for BG, endotoxin (measured twice – LAL with and without 
BG blocking buffers) and cytokines (IL-6, CRP and TNF-α) using the same method 
as described in chapter 6. 
 
Statistical analysis 
 
Non-parametric data were presented as medians with interquartile range. Parametric 
data were presented as means with 95% confidence intervals. Analysis was 
performed using IBM SPSS statistics version 21. Comparison were made between 
groups using the Mann-Whitney U test or T-test as appropriate. Correlation between 
continuous variables was examined by Spearman rank correlation coefficient. 
Baseline measures of patients with elevated BG with outcomes was explored using 
unadjusted and adjusted Cox proportional hazard models. No patients were lost to 
follow-up during the study period. Co-variates specified in the adjusted models 
include age, gender, Charlson Co-morbidity index and CKD stage. 
 
10.3 Results 
Demographic and clinical characteristics  
The study cohort (Table 10-1) consisted of 20 healthy controls, 20 patients with CKD 
stage 1-3, 20 patients with CKD stage 4-5, 15 PD patients, 60 HD patients (30 high 
risk and 30 low-risk). Demographic, clinical and biochemical parameters are shown 
in Table 10-1 and Table 10-2. In general, patients with advanced CKD were older and 
more highly comorbid than those with lesser degrees of CKD and controls. PD 
patients had lower dialysis vintage and higher residual kidney function than HD 
patients. Standard Kt/V between PD and HD patients was not significantly different. 
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Low- and high-risk HD patient were similar with respect to age, co-morbidity, dialysis 
catheter use and treatment with haemodiafiltration (HDF) though low-risk patients 
had lower dialysis vintage, higher pre- and post- dialysis systolic BP, greater residual 
kidney function, lower body weight, lower sessional duration and higher standard 
Kt/V. Ultrafiltration rate tended to be higher in high risk patients but this did not reach 
statistical significance (Table 10-2). 
 
Table 10-1: Patient characteristics  
* eGFR applies to healthy and non-dialysed CKD patients, KRU applies to dialysis patients. 
PD, peritoneal dialysis patents; HD, haemodialysis patients; CCI, Charlson Co-morbidity 
index; eGFR, estimated glomerular filtration rate; KRU, residual urea clearance 
 
 Age 
(years) 
Weight 
(kg) 
eGFR/KRU* 
(mL/min) 
Anuric (%) CCI Diabetic 
(%) 
Dialysis 
vintage 
(years) 
Healthy 
(n=20) 
 
48 [44-52] 73.9 [67.4-
80.4] 
- - - - - 
CKD 1-3 
(n=20) 
 
50 [36-64] 79.9 [61.3-
98.4] 
54.4 [45.7-
63] 
- 1 [IQR 0-4] 25 - 
CKD 4-5 
(n=20) 
 
61 [54-68] 95.9 [86.1-
105.5] 
14.2 [11.6-
16.7] 
- 5 [IQR 4-8] 45 - 
PD 
(n=15) 
 
60 [51-69] 84.8 [77.3-
92.4] 
4.1 [IQR 
1.4-6.3] 
6.7 6 [IQR 3-7] 26.7 1 [IQR 0.3-
4] 
High-risk 
HD 
(n=30) 
 
61 [56-67] 82 [73.3-
90.7] 
0 [IQR 0-0] 80 5.5 [IQR 
3.8-8] 
33.3 3 [IQR 1.3-
6.1] 
Low-risk 
HD 
(n=30) 
67 [60-73] 73.7 [66.7-
80.7] 
1.62 [IQR 0-
2.7] 
33.3 7 [IQR 4.8-
9] 
40 1.6 [IQR 
0.9-4.3] 
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Table 10-2: Dialysis clinical parameters 
Data represent median with interquartile ranges or mean with 95% confidence interval. Ca, 
calcium; PO4, phosphate; PTH, parathyroid hormone; THL, tunnelled haemodialysis 
catheter; Td, session dialysis time; Qb, access blood flow; UFR, ultrafiltration rate; HDF, 
haemodiafiltration. Ϯ – P value for statistical comparison between high risk and low risk HD 
(haemodialysis) patients, there was no significant difference between PD and low-risk HD 
patients or high-risk HD . ɸ - standard Kt/V for HD patients represent urea clearance 
achieved by residual renal function (renal Kt/V) and dialysis Kt/V 
 
 PD 
(n=15) 
High-risk HD 
(n=30) 
Low-risk HD 
(n=30) 
P 
 
Ca 
 
2.34 [2.24-2.48] 2.32 [2.23-2.43] 2.37 [2.19-2.42] 0.812 
PO4 
 
1.61 [1.39-1.82] 1.8 [1.5-2.25] 1.55 [1.42-1.88] 0.128 
Albumin (g/L) 
 
39 [33-31] 41 [38-41.3] 38.5 [36-40.3] 0.058 
PTH (pmol/L) 
 
47.5 [27-66.3] 41.9 [22.5-83.8] 43.4 [27.3-63.7] 0.912 
Standard Kt/Vɸ 
 
2.2 [95% CI 1.9-2.6] 2.1 [95% CI 2.0-2.2] 2.5 [95% CI 2.3-2.7] <0.001 Ϯ 
Access with THL (%) 
 
- 23.3 16.7 0.519 
Td (min) 
 
- 240 [206-240] 203 [180-240] 0.015 
Qb (mL/min) 
 
- 300 [300-400] 325 [300-363] 0.972 
UFR (mL/kg/hr) 
 
- 5.9 [95% CI 4.6-7.2] 4.4 [95% CI 3.2-5.6] 0.064 
Treatment with HDF 
(%) 
 
- 73.7 90 0.095 
Pre-HD systolic BP 
 
- 129 [107-139] 152 [138-178] <0.001 
Pre-HD diastolic BP 
 
 65 [52-81] 74 [65-86] 0.173 
Post-HD systolic BP 
 
 106 [99-127] 135 [120-151] 0.004 
Post-HD diastolic 
BP 
 
 58 [49-74] 65 [54-71] 0.504 
 
 
Blood levels (1→3)-β-D glucan  
Blood levels of BG progressively increased with worsening CKD stage. BG levels 
were highest in high-risk HD patients and were significantly higher than PD, CKD 
and healthy controls although were not significantly different from low-risk HD 
patients (Figure 10-1 and Table 10-3).  Low-risk HD patients had similar BG levels 
to PD patients but significantly greater levels than CKD groups and controls. PD 
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patients had significantly greater levels than CKD groups and controls. BG levels in 
patients with CKD 4-5 were only marginally greater that those with CKD 1-3, but 
greater than controls. BG levels in patients with CKD 1-3 did not differ from those in 
controls. In 22% of HD patients (16.7% low-risk and 26.7% high-risk), 13.3% of PD 
patients, 0% of CKD 4-5 and 10% of CKD 1-3 patients had blood BG levels >80 
pg/mL which is considered positive in diagnostic work-up for invasive fungal disease. 
Across the whole CKD group there was a relationship of BG and Charlson 
Comorbidity index (rho=0.305, p=0.001) but not with age or gender. In HD patients 
BG levels were negatively correlated with KRU (rho=-0.414, p=0.001). Patients with 
minimal kidney function (KRU < 1 ml/min) had higher BG levels than those with more 
renal function (62 vs 38 pg/ml, p=0.001), and whereas patients receiving HDF had 
slightly higher levels than those on high-flux HD, these were not significantly different 
(57 vs. 45 pg/ml, p=0.151). There was no relationship between BG levels and Kt/V.  
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Table 10-3: Endotoxin, (1-3)-β-D glucan and inflammatory cytokines 
BG, (1-3)-β-D glucan; data shown represent median and interquartile ranges. Reference 
ranges for CRP, IL-6 and TNFα are <5mg/L, <3.1pg/mL and <15.6 pg/mL respectively. BG 
blocking buffer consists of highly concentrated carboxymethylated curdlan. Applying this 
buffer to the LAL assay the blocks the factor G pathway of the assay preventing any false 
activation by any circulating (1-3)-β-D glucan that may be present in the sample 
 
 
 
 
 
  
 High-risk HD 
(n=30) 
Low-risk HD 
(n=30) 
PD 
(n=15) 
CKD 4-5 
(n=20) 
CKD 1-3 
(n=20) 
Healthy 
control 
(n=20) 
       
BG (pg/mL) 
 
57 [46.5-81] 55.5 [34.8-
73.4] 
37 [31-67] 22.5 [16.5-27] 15.5 [10-26] 13.5 [11-17.5] 
CRP (mg/L) 
 
12.9 [7.4-19.3] 2 [0.75-3.8] 4.1 [2.4-11.7] 3.9 [2.3-6.1] 2.9 [1-8.1] 1.5 [0.7-3.5] 
IL-6 (pg/mL) 
 
14.3 [9.6-22.8] 8.6 [6.4-11.6] 6.3 [3.3-11.2] 2.4 [1.4-7.3] 3.1 [0.3-7] 0 [0-0.8] 
TNF-α 
(pg/mL) 
 
23.9 [21.5-
28.5] 
22.4 [19.1-
27.1] 
15.9 [13.2-
19.7] 
15.9 [14.1-
20.7] 
7.6 [5-12] 8 [6.8-10.9] 
Endotoxin 
level (EU/mL) 
[without BG 
blocking 
buffer] 
 
0.027 [0-
0.041] 
 
0 [0-0.036] 0 [0-0.049] 0 0 0 
Detectable 
endotoxin 
signal (%)  
[without BG 
blocking 
buffer] 
 
53.3 (16/30) 36.7 (11/30) 46.7 (7/15) 15 (3/20) 10 (2/20) 0 (0/20) 
Detectable 
endotoxin (%) 
[with BG 
blocking 
buffer] 
 
6.7 
(2/30) 
3.3 
(1/30) 
0 0 0 0 
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Figure 10-1: (1-3)-β-D-glucan in study cohort. Median blood levels of (1-3)-B-D-
glucan in study cohort. Error bars represent interquartile range. HD, haemodialysis; 
PD, peritoneal dialysis; CKD 4-5, chronic kidney disease stage 4-5; CKD 1-3, chronic 
kidney disease stages 1- 3; NS, not significant. 
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Associations of blood (1→3)-β-D glucan levels with markers of inflammation 
Levels of inflammatory cytokines interleukin-6 (IL-6), tumour necrosis factor-α 
(TNFα) and high-sensitivity C-reactive protein (hs-CRP) levels in the different groups 
are shown in Table 10-3. High–risk HD patients had higher levels of CRP and IL-6 
than all other groups. TNF-α was similar in low-and high-risk HD patients but higher 
than in all other groups. Levels of BG correlated significantly with markers of 
inflammation. In particular in the whole CKD group there were significant correlations 
with CRP (rho=0.271; p=0.003), IL-6 (rho=0.520; p < 0.001) and TNF-α (rho = 0.486; 
p<0.001). On sub-group analysis of the HD group, BG was correlated with CRP only 
(r=0.277; p=0.032).  
 
Association of blood (1→3)-β-D glucan levels with endotoxemia 
 
Endotoxin levels are shown using the standard LAL assay and using the LAL assay 
combined with a BG blocking buffer which inhibits the factor G pathway rendering 
the LAL assay insensitive to BG stimulation and endotoxin-specific. Endotoxin 
measurements obtained using the standard LAL assay revealed low level blood 
endotoxin in HD, PD and CKD patients (Table 10-3 and Figure 10-2). Both HD and 
PD patients had significantly higher amounts of endotoxin signal than CKD and 
healthy controls (p<0.05 for both). However, following repeat measurement with a 
BG-blocking buffer, nearly all of these signals became negative with only three HD 
patients in the whole cohort testing positive for blood endotoxin (Figure 10-2). Two 
patients in the high-risk and one from the low-risk HD group had detectable 
endotoxin (0.06, 0.071 and 0.037 EU/mL respectively).  
 
Endotoxin signal derived from the LAL assay without blocking buffer correlated 
strongly with levels of BG (r = 0.545, p<0.001). Endotoxin signal was highest in 
subjects with high BG (>80 pg/mL) and lowest in patients with low levels (<60 pg/mL) 
[Figure 10-3]. These collective findings strongly suggest that endotoxin signal detected 
using the LAL assay in the majority of CKD patients may be artefactual due to 
elevated BG.   
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Figure 10-2: Proportion of patients with detectable endotoxin using the LAL assay with and 
without a BG-blocking buffer 
 
 
Figure 10-3: Endotoxin signal detected using LAL without blocking buffer displayed against 
serum (1-3)-β-D glucan. *Denotes statistical significance p<0.05 
 
 
Clinical associations of (1-3)-β-D glucan levels 
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Table 10-4 shows the results of fatigue (MFI-20), depression scores (PHQ-9) and 
kidney disease-related symptoms (POS-S renal) across the CKD subject groups. For 
MFI-20, there were differences in relation to physical fatigue, reduced activity and 
reduced motivation subscales (only the former shown in Table 10-4) which were 
highest in the high risk HD group (significant compared to patients with CKD 1-3, but 
comparable with other groups). All HD patients had higher depression scores than 
subjects with CKD 1-3 but levels were similar to all other groups. High-risk HD 
patients reported a higher burden of symptoms (POS-S) than other groups, though 
this was only significantly higher than CKD 1-3 patients.  
 
Table 10-4: Fatigue, depression and kidney disease related symptom scores across study 
population 
MFI-20, multidimensional fatigue inventory-20; PHQ-9, patient health questionnaire 9; POS-
S, palliative care outcome scale  
*P<0.05 – High risk HD patient vs. CKD1-3 
ɸP<0.05 – High and low risk HD patients vs. CKD1-3 
†P<0.05 – High risk HD patients vs. CKD 1-3 
 
 CKD 1-3  
(A) 
CKD 4-5  
(B) 
PD  
(C) 
Low risk HD  
(D) 
High risk HD 
(E) 
MFI-20 
(Physical 
fatigue) 
 
13 [9-17.3] 14 [7-20] 13 [9-15] 15 [12.8-16.5] 15 [13-18.8]* 
PHQ-9 
(Depression) 
 
2.5 [0.3-5] 3 [2-7] 5.5 [0.8-9.8] 5 [2-9] 
ɸ
 7 [3.5-11.5]
ɸ 
 
POS-S renal 
(Kidney 
disease related 
symptoms) 
7 [1.25-11.5] 8 [2-15] 6.5 [3.8-14.5] 9.5 [7.8-13.3] 14 [4.3-18.5]
Ϯ
 
 
 
Across the whole CKD group BG levels correlated with physical fatigue scores 
(rho=0.269; p=0.005), reduced activity (rho=0.270; p=0.005) and reduced motivation 
(rho=0.318; p=0.001) There were also correlations between BG and PHQ-9 
(rho=0.290; p=0.005) and POS-S scores (0.203; p=0.035). For POS-S, individual 
symptoms including breathlessness, drowsiness and sleep disturbance correlated 
significantly with BG levels.  
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All CKD patients were followed up for 18 months for cardiovascular events, time to 
hospitalisation with sepsis, and mortality. In univariate Kaplan-Meir analysis, 
unadjusted hazard ratio (HR) for time to hospitalisation with sepsis was significantly 
higher in patients with BG>80pg/mL (p=0.007 log rank test) [Figure 10-4].  In a Cox 
regression model, after adjusting for  age, gender, CCI and CKD stage, this 
association was no longer significant (HR=2.22 [95% CI 0.88 -5.59]; p=0.089). There 
was no significant relationship of high BG level with mortality or cardiovascular 
events. 
 
 
Figure 10-4: Unadjusted Cox proportional hazard for time to hospitalisation with infection over 18 month period. 
Population divided based on positive or negative test for BG (cut-off value 80 pg/mL) 
 
Determining the effect of haemodialysis initiation on serum (1-3)-β-D glucan 
 
The effect of HD initiation on endotoxin and BG levels was explored in a separate 
cohort of 30 pre-dialysis patients with CKD 5 (Table 10-5). Blood samples were 
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collected prior to and after starting HD. Serum BG was higher after initiation of HD 
(26 vs. 41 pg/mL, p=0.002). IL-6 and CRP were not significantly different pre- and 
after HD initiation but TNF-α levels increased following initiation. All patients had 
undetectable endotoxin using the LAL modified with a BG-blocking buffer. One 
patient tested positive for endotoxin after initiation of HD with low level endotoxemia 
(0.027 EU/mL).  
 
Table 10-5: Patient characteristics with endotoxin, 1-3)-β-D glucan and inflammatory cytokines 
pre- and after initiation of haemodialysis.  
BG blocking buffer consists of highly concentrated carboxymethylated curdlan. Applying this buffer to 
the LAL assay the blocks the factor G pathway of the assay preventing any false activation by any 
circulating (1-3)-β-D glucan that may be present in the sample; CCI, Charlson Co-morbidity index 
 
Parameter (n=30) Value 
 
Age (year) 
 
57 [51-62] 
Male gender (%) 70 
CCI 5 [IQR 3-7] 
Weight (kg) 86.7 [80.4-93.1] 
 
 
 
Analyte 
 
Before HD Post HD initiation  P 
BG (pg/mL) 
 
26 [20-38] 41 [24-49] 0.002* 
IL-6 (pg/mL) 
 
5.9 [3.7-13.4] 7.3 [4-11.8] 0.434 
TNF-α (pg/mL) 
 
19.4 [17.5-25] 21.9 [18.5-25.6] 0.005* 
CRP (mg/L) 
 
5 [2-12.6] 5.6 [1.5-11.3] 0.792 
Endotoxin (EU/mL) 
(without BG blocking buffer) 
 
0 [0-0.032] 
 
0 [0-0.026] 0.552 
Detectable endotoxemia  
(without BG blocking buffer) 
[%] 
 
30 
(9/30) 
26.7 
(8/30) 
0.774 
Detectable endotoxemia 
(with BG blocking buffer) [%] 
 
0 
(0/30) 
3.3 
(1/30) 
0.313 
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10.4 Discussion 
This study showed that blood BG levels increased progressively with worsening CKD 
stage. BG levels were highest in HD patients and nearly a quarter of patients had 
levels above the cut-off value of 80 pg/mL for diagnosis of fungaemia. Elevated BG 
was associated with increased levels of inflammatory biomarkers, higher fatigue, 
depression and symptom scores.  There was also a possible association with sepsis-
related hospitalisation. In addition this study also confirmed the association between 
high BG levels and false positive endotoxin tests in this setting. The prevalence of 
true endotoxemia in this cohort was 5% which is much lower than that reported in 
many other studies (see Chapter 2) but more in keeping with the clinical state of 
study participants. The source of elevated BG in our population is uncertain as 
neither kidney failure nor the HD procedure itself are thought to lead to accumulation 
of BG. BG are large molecules and depending on its branching structure molecular 
weights vary from tens to thousands kD (Rop et al. 2009). Hence they would not be 
easily removed by dialysis. Although dialysers constructed with cellulose materials 
may raise blood BG levels (Kanda et al. 2001; Pearson et al. 1984; Yoshioka et al. 
1989), HD patients in this study were treated with modified polysulfone membranes 
which do not significantly influence blood levels of BG (Prattes et al. 2015; Prattes et 
al. 2017). BG levels were inversely related to residual kidney function in dialysis 
patients although there was no relationship to either Kt/V or use of 
haemodiafiltration. Higher BG levels were also observed after initiation of HD, 
however we think it is unlikely that loss of residual kidney function or the dialysis 
membrane itself contributed to high BG levels.  
 
A potential source of BG could be the gut, since translocation of BG from the gut has 
been described and high blood level of BG has been proposed as a marker of 
intestinal permeability (Yang et al. 2017; Leelahavanichkul, Worasilchai, et al. 2016). 
In addition there is a large body of evidence which suggests advanced kidney 
disease is associated with impaired intestinal barrier function, altered gut microbiome 
and translocation of gut bacterial products into the circulation (March et al. 2017).  
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Other factors could be related to the clearance mechanisms of BG. The clearance 
and metabolism pathways of BG in humans are not well understood, but in animal 
models BG is primarily removed by the Kupffer cells of the liver. Kupffer cells 
comprise the major phagocytic activity of the mononuclear phagocyte system (MPS) 
(Dixon et al. 2013). Following intraperitoneal injection, the majority of BGs are 
distributed in organs prominent in the MPS such the liver and spleen (Yoshida et al. 
1997; Suda et al. 1996) and metabolised by oxidative degradation (Young & Vincent 
2005; Suda et al. 1996; Nono et al. 1991). There is little data on Kupffer cell function 
in CKD, though dysfunction of the MPS has been described (Hörl 2004).  Specific 
defects of immunity including defective phagocytic function, impaired maturation of 
monocytes and monocyte-derived dendritic cells have also been reported (Verkade 
et al. 2006; Lim et al. 2007; Anding et al. 2003; Kato et al. 2008).  Elevated blood BG 
levels detected in our population could therefore relate to a combination of increased 
intestinal permeability and MPS dysfunction in advanced CKD. In a similar way, the 
appearance of endotoxin in the systemic circulation in advanced liver disease is 
thought to result from gut translocation together with MPS dysfunction (Wang et al. 
2015). 
 
The immunobiology of BG in humans is complex and not yet fully understood. 
Interpretation of results from previous studies has been difficult due to the different 
types of BG used for studies varying from crude extracts from fungal cells to purified 
BG (Camilli et al. 2018). BG can mediate pro-inflammatory effects via its action on 
complement receptor 3, dectin-1 and toll-like receptors stimulating phagocytosis and 
generation of reactive oxygen species. On the other hand, consumption of fungi high 
in BG have been used for thousands of years in ancient civilisations for health 
benefits (Rop et al. 2009). BG also appears to have anti-tumour effects (Nono et al. 
1991),  anti-inflammatory effects and improves survival in animal sepsis models 
(Camilli et al. 2018). Hence the characteristics of immune responses elicited by BG 
are variable and depend on cell types, receptors, size and structure of BG.  
 
This is the first study to explore BG levels and their clinical significance in non-
infected subjects with different stages of kidney disease. BG and levels were highest 
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in HD patients and especially in those with increased levels of inflammation, higher 
UFR and peri-dialytic hypotension and hence a higher likelihood of intradialytic 
intestinal hypo-perfusion. These findings are consistent with a role for increased 
intestinal permeability in increasing systemic BG levels. These findings also suggest 
possible contributions of high BG levels to chronic inflammation, clinical symptoms 
and susceptibility to sepsis in advanced kidney disease but further studies are 
required to explore these issues. This study has also confirmed previous 
observations carried out in chapter 8 and those of  others (Taniguchi et al. 1990) that 
high BG levels cause false positive tests for blood endotoxin, and that the 
prevalence of endotoxemia in the dialysis population is much lower than widely 
reported. 
 
There are a number of limitations to this study. Patient sub-groups were not well 
matched. Residual renal function and dialysis vintage differed between HD and PD 
groups. Kt/V was higher in low-risk groups compared to high-risk HD patients. 
However, other parameters such as bone chemistry and use of dialysis catheters 
were similar. The Fungitell assay is a biological assay and also based on the Limulus 
assay which has its inherent limitations (Cohen 2000), although it has been well 
validated in many studies in other patient groups as a pan-fungal marker (Theel & 
Doern 2013), reports of its accuracy in patients with renal failure are more limited. 
Furthermore it must be stressed that the relationships between BG levels, 
inflammation and clinical sequelae are associations only and further work is 
necessary to establish whether there are any causal relationships. 
 
In conclusion, blood BG levels are elevated in CKD patients, especially dialysis 
patients, perhaps contributed to by translocation from the gut and MPS dysfunction. 
High levels appear to be associated with inflammation and adverse clinical sequelae. 
Increased BG levels can also affect current limulus based endotoxin detection 
assays leading to apparently high blood endotoxin levels.  This study suggests that 
BGs may play an important clinical role in patients with advanced kidney disease 
and that further study of BG in this setting is warranted.  
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 Chapter 11 
11. Intestinal permeability in haemodialysis patients 
 
11.1 Introduction 
Chronic systemic inflammation is highly prevalent in patients with advanced kidney 
disease. It is a strong cardiovascular risk factor and is associated with other 
complications including malnutrition, cachexia, anaemia and early mortality (Carrero 
& Stenvinkel 2010). Previous studies have implicated endotoxemia as a potential 
driver for sustained chronic inflammation although the studies carried out in chapter 
8 to chapter 10 do not support this hypothesis, but ‘endotoxin’ detected in blood 
samples of dialysis patients appear in part, to be due to false positive activation of 
detection assays by BG. As mentioned in Chapter 10, serum BG level increases 
progressively with worsening CKD stage. The source of elevated BG in the absence 
of invasive fungal infection is unclear. One potential source of elevated BG could be 
the gastrointestinal tract and it the gut is increasingly being recognised to be a major 
source of chronic inflammation in the dialysis population (March et al. 2017; Vaziri et 
al. 2016).  
Development of renal impairment leads to alteration in the intestinal microbiome due 
to changes in the biochemical milieu of the alimentary tract which are known to 
influence and damage gut barrier function (Kelly et al. 2015; Vaziri 2012). The 
intestinal barrier acts as a semipermeable membrane for the selective absorption of 
essential dietary nutrients, electrolytes and water from the intestinal lumen whilst 
preventing translocation of harmful microbial products and pathogens into circulation 
(Groschwitz & Hogan 2009). The intestinal barrier consists epithelial cells which 
regulate transcellular transport of solutes and intercellular junctional complexes or 
‘tight junctions’ which seal the spaces between epithelial cells regulating the entry of 
luminal contents through these paracellular routes (Turner 2009). These tight 
junctions consists of adhesive transcellular proteins (occludin and claudin families) 
and actin-binding cytosolic proteins (zonula occludens family) (Vaziri et al. 2016).  
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A large number of in-vitro and observational studies in animal and humans with 
chronic kidney disease (CKD) strongly suggest that there is breakdown of intestinal 
barrier function [reviewed in (Vaziri et al. 2016; Lau & Vaziri 2017; March et al. 
2017)]. Studies in non-dialysed CKD patients and uraemic rats demonstrate 
increased absorption of large size polyethylene glycols indicating increased intestinal 
permeability or ‘leakiness’. In-vivo work in animals has demonstrated marked loss of 
occludin, claudin and zona occludens from the intestinal tracts of CKD subjects 
(Vaziri, Yuan, et al. 2012). Breakdown in intestinal barrier function has been 
hypothesised to contribute to systemic inflammation due to the translocation of large 
quantities of bacterial components across the ‘leaky’ intestinal wall and entry to the 
blood circulation (Wang, Jiang, et al. 2012; Ritz 2011; Khoury et al. 2017).  
Postulated mechanisms of intestinal barrier damage include direct disruption of tight 
junctions caused by uremic toxins (Vaziri, Goshtasbi, et al. 2012; Vaziri et al. 2013) 
and in haemodialysis patients, ultrafiltration during treatment may also cause 
hypotension leading to bowel ischemia (Rossi et al. 2012; Yu et al. 1997; Jakob et al. 
2001), exacerbating uraemia-induced intestinal barrier dysfunction (Vaziri et al. 
2016). However, intestinal permeability has not been measured in vivo in 
haemodialysis patients and direct intestinal permeability changes, induced by the 
acute effect of haemodialysis, have not been studied. If haemodialysis-induced gut 
permeability were to be demonstrated, interventions could be targeted at the 
haemodialysis procedure to minimise this effect. 
The lack of studies of intestinal permeability in dialysis patients is likely due to the 
difficulties in applying the conventional method of measuring intestinal permeability 
in this population. Intestinal permeability in vivo is measured by determining the 
urinary excretion of orally administered test substances. These test substances 
typically consist of a disaccharide and a monosaccharide, the ratio of the urinary 
concentrations of both providing a specific index of intestinal permeability (Bjarnason 
et al. 1995). Since a significant proportion of dialysis patients are anuric, 
measurement of intestinal permeability using this method is not possible. A sensitive 
assessment of sugars based on liquid chromatography in combination with mass 
spectrometry (LC-MS) has been developed which allows measurement of sugars in 
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plasma (van Wijck & Lenaerts 2011b; van Wijck & Lenaerts 2011a; van Wijck et al. 
2013).  
The purpose of this study was to two-fold, 1) to determine if intestinal permeability is 
increased in haemodialysis patients and 2) to determine the acute effect of 
haemodialysis on intestinal permeability.  
11.2 Methods 
Participant characteristics 
Ten patients on maintenance haemodialysis patients and five healthy volunteers 
were recruited for this study. Haemodialysis patients were medically stable with no 
active illness at the time of the study.  Exclusion criteria were positive HIV or 
hepatitis B/C status, active gastrointestinal symptoms or disease, liver disease and 
history of previous bowel surgery. 
Gut permeability testing 
The classical assays for gut permeability are usually based on a difference in 
intestinal absorption of two supplied sugars, usually a disaccharide and 
monosaccharide. A ratio of the concentration of disaccharide over the 
monosaccharide recovered in the urine or plasma following oral administration is 
used as an index of intestinal permeability. In states of increased intestinal 
permeability, there is a relative increase in the absorption of the larger disaccharide 
molecule due to increased paracellular transport leading to a higher disaccharide to 
monosaccharide ratio. A multi-sugar solution consisting of lactulose, rhamnose, 
sucralose and erythritol was used in this study for the assessment of intestinal 
permeability. Lactulose (disaccharide) and rhamnose (monosaccharide) was used as 
a marker for small intestinal permeability since they are degraded by the microbiota 
in the colon (Fink 2002; Hietbrink et al. 2007). Sucralose (disaccharide) and erythritol 
(monosaccharide) was used as a marker for whole gut permeability since they resist 
colonic bacterial fermentation (Farhadi et al. 2003). Sugar concentrations in plasma 
were measured at repetitive time points using liquid chromatography-mass 
spectrometry as described below. The calculated lactulose: rhamnose ratios (L/R) 
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were used to assess small intestinal permeability and sucralose: erythritol ratios 
(S/E) for whole gut permeability. Plasma concentrations of sugars were measured 
over a 10 hour period. The optimum time period to assess sugar ratios derived from 
plasma have not yet been established, although for sugar ratios derived from urinary 
fractions, 0-5 hours and 5-24 hours appear to best reflect small and large intestine 
permeability respectively (Camilleri et al. 2012). Therefore for comparison of small 
intestinal permeability between haemodialysis patients and healthy controls, L/R 
ratios were assessed for 5 hours after sugar ingestion, for whole bowel permeability 
S/E ratios were assessed for 10 hours. However, since sugar profiles in 
haemodialysis patients have not been studied previously and may be different from 
healthy volunteers, comparison of L/R and S/E ratios between dialysis and non-
dialysis days were studied during the early period (0-5 hours post sugar ingestion), 
late period (5-10 hours post ingestion) and over the whole 10 hour study period. 
Study design and sampling 
On the day before and during the test days, all participants were asked to avoid 
intense physical exercise and consumption of any sweets, confectionary, desserts, 
sugar-free chewing gum and non-steroidal anti-inflammatory drugs. Products 
containing erythritol or sucralose were avoided. Participants were tested after an 
overnight fast, a baseline blood sample was collected from either a cannula inserted 
in the forearm or from an existing tunnelled dialysis catheter (for haemodialysis 
patients) using standard aseptic technique. A multi-sugar solution consisting of 1g 
lactulose (TEVA UK Limited, 3.35g/5mL), 1g rhamnose (Danisco Sweeteners), 1g 
sucralose (Brenntag, Netherlands), and 1g erythritol (Danisco Sweeteners) dissolved 
in 100ml water was orally administered. Following ingestion, blood samples were 
collected hourly for 10 hours. At each sampling point, blood was collected into EDTA 
tubes and centrifuged at 2300g for 15min to obtain plasma. Plasma samples were 
aliquoted, frozen and stored at -80°C. Subjects were allowed to eat 2 hours after 
ingestion of sugars although all sweets, products containing sweeteners were 
avoided throughout the study period. Participants were not restricted in position or 
mobility although subjects were not allowed to carry out intense exercise during the 
study period. 
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For haemodialysis patients, intestinal permeability was measured on a non-dialysis 
day and on a haemodialysis day. Both study days were carried out within one week 
of each other. Testing was randomised such that half of the cohort had initial 
permeability measurements carried out on a non-dialysis day followed by repeat 
testing carried out on a dialysis day. The remainder of the cohort were tested in 
reverse order. For intestinal permeability measurements performed on a 
haemodialysis day, the study commenced immediately at the end of the dialysis 
session. The concentration of sugars post dialysis were corrected for dialysis-
induced changes in blood volume by multiplying the concentration of the sugar after 
dialysis with the ratio of serum albumin before and after dialysis at each time point 
(Korevaar et al. 2004).  
Analysis of sugars 
Measurement of sugar probes in plasma was carried out using isocratic ion 
exchange high performance liquid chromatography (Model PU-1980 pump, Jasco 
Benelux, Netherlands) and mass spectrometry (Model LTQ-XL, Thermo Electron, 
Netherlands) (van Wijck & Lenaerts 2011b). 300µL of plasma was transferred into 
Eppendorf cups containing a 3000 Da cut-off filter (Amicon Ultra 0.5mL 3K, Millipore) 
to remove plasma proteins. The filter cups were centrifuged for 30 minutes at 
11,000g at 4ºC to obtain clear plasma filtrate. The plasma filtrate was transferred into 
300µL glass insert, spring loaded in a 4mL WISP style vial (Waters, Milford, USA) 
and placed into a Peltier chilled Gilson 233XL sample processor (Gilson, USA). 
Chromatographic separation was based on isocratic elution of individual sugars 
probes on an IOA-1000 9μm cation-exchange column (300mm×7.8mm ID; Illinois), 
mounted in a Mistral column oven (Separations, Netherlands) at 30ºC. An aqueous 
solution of 20mmol/L formic acid and 10mmol/L trichloroacetic acid was delivered 
using a Model PU-1580 HPLC pump (Jasco Easton, Maryland) at a flow rate of 
0.225mL/min. Samples and standards were injected using a Model 233XL sample 
processor with Peltier chilled sample storage compartments (10◦C), equipped with a 
20µL sample loop. After separation, the column effluent was mixed with 30 mmol/L 
ammonia in 20% methanol/water (v/v) delivered by an additional Model PU 980 
pump to allow the formation of ammonium adducts. MS detection was performed 
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using a model LTQ XL (ThermoFisher Scientific, Massachusetts) equipped with an 
ion-Max electrospray probe. The mass spectrometer was operated in positive mode. 
Spray voltage was 4.8kV. Sheath and auxiliary gas were 99 and 30 units 
respectively with capillary temperature of 220ºC. The system was set to a mass 
range of 125–460Da in full scan enhanced mode. 
 
Statistical analysis 
 
Statistical analysis was performed using Graphpad Prism and SPSS Statistics 
software. Sugar concentrations were plotted against time for each participant and 
visually inspected for outliers. Outliers were excluded from the analysis. Area under 
curve (AUC) was calculated for each sugar, L/R and S/E ratios for all subjects. 
Derived AUC data for sugars was not normally distributed therefore comparison of 
AUC between haemodialysis patients and controls were evaluated using Mann-
Whitney U test and comparison of sugar profiles between haemodialysis and non-
haemodialysis days were evaluated using Wilcoxon signed rank test. 
 
11.3 Results 
Patient and healthy control characteristics are displayed in Table 11-1. 
Haemodialysis patients and controls were similar in terms of age, weight and body 
mass index. All haemodialysis patients had stable blood pressures before, during 
and after dialysis, ultrafiltration requirement and rate was moderate. Mean 
ultrafiltration volume and rate was 1.91L and 6.3mL/kg/hr respectively. 40% of 
patients were anuric. The median dialysis vintage was 0.85 years. Haemodialysis 
patients were on several medications as displayed in Table 11-2, no patients were 
on antibiotics or non-steroidal anti-inflammatory drugs medications at the time of the 
study. Some patients were on medications that could affect gut motility including 
opiates (n=3), steroids (n=1). Four patients were on proton pump inhibitors at the 
time of the study which have been reported to increase upper gastrointestinal tract 
permeability (MULLIN et al. 2008).  
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Table 11-1: Subject clinical and demographic data 
Variable HD patients (n=10) Controls (n=5) 
Age (years) 
 
49 ± 3.7 46.2 ± 4.4 
Weight (kg) 
 
84 ± 7 66 ± 4.2 
Height (m) 
 
1.72 ± 0.03 1.6 ± 0.02 
BMI 
 
28.1 ± 1.9 25.5 ± 0.98 
Charlson Comorbidity 
index 
 
3 [IQR 2.5]  
Ultrafiltration volume (L) 
 
1.91 ± 0.3  
Ultrafiltration rate 
(mL/kg/hr) 
 
6.3 ± 1.3  
Dialysis session time 
(min) 
 
230 [IQR 30]  
Pre-dialysis BP (mmHg) 
 
149/76  
Post-dialysis BP (mmHg)  
 
130/78  
Kt/V 
 
1.32 ± 0.1  
Residual urea clearance  
(mL/min) 
 
1.1 [IQR 2.8]  
Proportion with no 
residual kidney function 
(%) 
 
40%  
Proportion with tunnelled 
dialysis catheter (%) 
 
40%  
Dialysis vintage (years) 
 
0.85 [IQR 2.6]  
BP, blood pressure; BMI, body mass index; HD, haemodialysis 
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Table 11-2: Medication use by haemodialysis patients 
Medication 
 
Number of patients (n = 10) 
Vitamin D analogues 
Alfacalcidol 
 
7 
 
Calcimimetic 
Cinacalcet 
 
 
2 
 
Antihypertensives 
Calcium channel blockers 
Beta-blockers  
Diuretics  
Alpha blockers  
Angiotensin receptor blockers  
Vasodilators  
 
 
6 
3 
4 
3 
1 
1 
 
Opiates (codeine phosphate) 
 
3 
 
Proton pump inhibitors 
 
4 
 
Hypoglycaemic agents 
Insulin 
 
 
2 
 
Phosphate binders 
 
9 
 
Antidepressants 
Selective serotonin reuptake inhibitor 
 
 
3 
 
Immunosuppressive medications 
Calcineurin inhibitors 
Steroids 
 
 
1 
1 
 
Statins 
 
3 
 
Antiplatelets 
Aspirin (omitted 24 hrs prior to study) 
Ticagrelor 
 
 
3 
1 
 
Others 
Gabapentin 
Allopurinol 
Montelukast 
Quinine sulphate 
 
 
5 
3 
1 
5 
 
 
The effect of haemodialysis on intestinal permeability 
 
AUC of studied sugar probes were compared in haemodialysis patients on a non-
dialysis day and immediately after dialysis to determine the effect of the 
haemodialysis procedure on intestinal permeability. During the early phase (0-5 hrs) 
AUC for rhamnose was significantly higher after haemodialysis treatment however, 
the lactulose levels and L/R ratio were not significantly different (Figure 11-1, Table 
11-3). There were no significant differences in lactulose, rhamnose or L/R ratios 
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between dialysis and non-dialysis days assessed in the late period (6-10 hrs) or over 
the whole study period (0-10 hrs).  Similarly, there were no significant differences in 
AUC of sucralose, erythritol and S/E ratio between non-dialysis days and after 
haemodialysis treatment (Figure 11-2, Table 11-2). 
 
Table 11-3: Area under curve and plasma concentrations of sugar probes on non-dialysis days 
and after haemodialysis treatment 
 Non-HD day 
(n=10) Ϯ 
HD day 
(n=10) Ϯ 
 
P 
Early period (0-5 hrs)    
Lactulose  5.48 [4.72-8.01] 5.48 [5.01-8.84] 0.72 
Rhamnose  273.1 [234.3-393.5] 308.5 [273.3-464.7] 0.01* 
L:R ratio  0.073 [0.063-0.112] 0.078 [0.064-0.086] 0.72 
Sucralose  26.6 [14.5-29.8] 19.9 [17.1-29.9] 0.95 
Erythritol  1411 [1098-1788] 1635 [1420-1905] 0.26 
S:E ratio  0.055 [0.047-0.09] 0.067 [0.044-0.076] 0.37 
    
Late period (6-10 hrs)    
Lactulose  6 [5.29-10.86] 8.43 [5.91-10.47] 0.51 
Rhamnose  177.4 [127.7-230.7] 217 [156.6-278.3] 0.17 
L:R ratio  0.146 [0.098-0.19] 0.157 [0.132-0.2] 0.96 
Sucralose  16 [7.4-26.2] 15.3 [10.3-22.5] 0.86 
Erythritol  1021 [779-1277] 1333 [1092-1474] 0.05 
S:E ratio  0.067 [0.029-0.081] 0.051 [0.038-0.062] 0.59 
    
Whole study period  
(0-10 hrs) 
   
Lactulose  12.62 [11.08-21.17] 19.39 [12.58-21.17] 0.45 
Rhamnose  541.2 [428.9-702.7] 634.5 [497.7-805.7] 0.09 
L:R ratio  0.242 [0.188-0.338] 0.274 [0.223-0.314] 0.96 
Sucralose  48.5 [24.6-63.0] 42.8 [30.4-56.7] 0.59 
Erythritol  2800 [2076-3514] 3131 [2943-3743] 0.14 
S:E ratio  0.15 [0.087-0.194] 0.136 [0.094-0.153] 0.31 
 
AUC, area under curve; HD, haemodialysis; L:R ratio, lactulose: rhamnose ratio; S:E, sucralose: erythritol ratio;  
*denotes statistical significance P<0.05; Ϯ one haemodialysis patient with high baseline plasma concentrations of 
sucralose was excluded and not included in analysis with regards to sucralose, erythritol, and S:E ratios. Data 
shown are median and interquartile range. 
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Figure 11-1: Plasma concentrations of lactulose, rhamnose and lactulose: rhamnose ratios on 
a non-dialysis day and after haemodialysis treatment 
 
 
L:R, lactulose: rhamnose ratio; Non-HD day, non-dialysis day; HD day: intestinal permeability testing 
after haemodialysis treatment. Data points and error bars represent median and interquartile range 
respectively 
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Figure 11-2: Plasma concentrations of sucralose, erythritol and sucralose: erythritol ratios on a 
non-dialysis day and after haemodialysis treatment 
 
 
 
S:E ratio, sucralose: erythritol ratio; Non-HD day, non-dialysis day; HD day: intestinal permeability 
testing after haemodialysis treatment. Data points and error bars represent median and interquartile 
range respectively 
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Comparison of intestinal permeability between haemodialysis patients and healthy 
controls 
 
Small bowel permeability 
 
Small bowel permeability was assessed by comparing the differential absorption of 
lactulose and rhamnose. Plasma levels of lactulose increased rapidly after ingestion 
for both haemodialysis patients and controls (Figure 11-3), for healthy controls 
lactulose levels peaked after 1 hour, for haemodialysis patients lactulose levels 
continued to rise throughout the study period and were approximately 3 times 
greater than peak levels reached by healthy controls (2.05 uM vs. 0.67uM, p=0.002). 
AUC of lactulose was significantly higher than healthy controls (5.27 vs 2.66, 
p=0.001). Plasma levels of rhamnose peaked at 1 hour after ingestion for healthy 
controls, for haemodialysis patients rhamnose concentration reached peak levels 
later at approximately 4 hours after ingestion, the peak concentration reached was 
similar for both groups. There was no significant difference in AUC of rhamnose 
levels between both groups (283 vs. 307.4, p=0.679). AUC for L/R ratios were 
significantly higher in haemodialysis patients compared to healthy controls (0.071 vs. 
0.034, p=0.001) [Figure 11-3, Table 11-4].   
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Figure 11-3: Plasma concentrations of lactulose, rhamnose and lactulose: rhamnose (L:R) 
ratio in haemodialysis patients and healthy controls 
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Table 11-4: Area under curve and median plasma concentrations of sugar probes in 
haemodialysis patients and healthy controls 
 
 Healthy controls 
(n=5) 
HD patients 
(n=10)Ϯ 
 
P 
    
Lactulose  2.66 [2.16-3.31] 5.27 [4.43-7.74] 0.001* 
Rhamnose 307.4 [267.4-353.8] 283 [242.2-380.4] 0.679 
L:R ratio 0.034 [0.03-0.048] 0.071 [0.058-0.11] 0.001* 
Sucralose  16.5 [15.2-34.2] 48.5 [24.6-63] 0.019* 
Erythritol 1150 [1111-1732] 2800 [2076-3514] 0.001* 
S:E ratio 0.13 [0.12-0.21] 0.15 [0.09-0.19] 0.797 
 
AUC, area under curve; HD, haemodialysis; L:R ratio, lactulose: rhamnose ratio; S:E, sucralose: erythritol ratio;  
*denotes statistical significance P<0.05; Ϯ one haemodialysis patient with high baseline plasma concentrations of 
sucralose was excluded and not included in analysis with regards to sucralose, erythritol, and S:E ratios. 
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Whole bowel permeability 
 
One haemodialysis patient had very high baseline levels of sucralose and was 
excluded from whole bowel permeability analysis using sucralose and erythritol. 
Sucralose levels increased post ingestion peaking at 2 hours for healthy controls, for 
haemodialysis patients sucralose levels peaked at 5 hours and the magnitude of 
peak levels reach were approximately two-fold greater compared to controls (7.09 
uM vs. 3.59 uM, p=0.205). Erythritol levels peaked at 1 hour and reached similar 
level of magnitude for both haemodialysis patients and healthy controls, however for 
haemodialysis patients, erythritol levels remained persistently elevated with no 
discernible reduction in levels for the whole study period, probably reflecting the lack 
of renal clearance. AUC for S/E ratios were not significantly different between 
haemodialysis patients and healthy controls (Figure 11-4, Table 11-4).  
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Figure 11-4: Plasma levels of sucralose, erythritol and sucralose: erythritol ratios in 
haemodialysis patients and healthy controls 
 
S:E, sucralose: erythritol ratio. Data points and error bars represent median and interquartile range 
respectively 
 
The pharmacokinetics of these sugar probes are strongly affected by the lack of 
renal function as these sugars are predominantly removed by the kidneys. Use of 
ratios to compare intestinal permeability in haemodialysis patients with healthy 
controls may not be reliable (see Discussion).  
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Relationship between level of residual kidney function and concentration of sugar 
probes 
 
Due to the strong effect of renal function on the clearance of sugar probes. The 
relationship between of residual renal function in haemodialysis patients with profiles 
of sugar probes was investigated. There was no significant correlation between 
residual urea clearance (KRU) and AUC for lactulose, rhamnose, sucralose or 
lactulose. Differences in AUC for all four sugar probes were compared between 
anuric HD patients and those with residual kidney function (Table 11-5), there were 
no significant differences in AUC for all sugar probes between HD patients with and 
without residual renal function. 
 
Table 11-5: AUC for sugar probes in haemodialysis patients with and without residual 
renal function 
 
 No residual renal 
function (anuric) 
 
[n=4] 
Residual renal function 
present (KRU 1.1 to 3.2 
mL/min) 
 
[n=6] 
 
P 
AUC Lactulose 16.6 [11.7-30.8] 
 
12.6 [10.7-17.4] 0.394 
AUC Rhamnose 566 [470.5-730.2] 
 
541.2 [375.7-767.8] 0.67 
AUC Sucralose 39.4 [26.7-54.1] 
 
62.5 [21.3-98] 0.624 
AUC Erythritol 2451.5 [2061.8-3202] 
 
3482 [2373-3683] 0.327 
AUC, area under curve. Data shown are median and interquartile ranges. 
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11.4 Discussion 
This is the first study to evaluate intestinal permeability in haemodialysis patients and 
the acute effect of haemodialysis on intestinal permeability in vivo. Breakdown of 
intestinal barrier function and increased permeability is associated with a number of 
diseases such as inflammatory bowel disease and is increasingly believed to be 
implicated in systemic inflammation in uraemic states (Visser et al. 2009; March et 
al. 2017; Lau & Vaziri 2017). Researchers have attempted to assess gut barrier 
function using several methods, although each method has its own limitations. 
Assessment of in vitro gut barrier function with the use of conventional histological 
methods does not permit measurement of changes in intestinal permeability and 
data collected from biopsies taken from a small area of the bowel may not be 
representative for the whole gut.  
 
The classical method to measure intestinal permeability in vivo is with the use of 
orally administered oligosaccharides first described in 1974 by Menzies (Menzies 
1974), initially single test substances of large molecular weights (such as lactulose 
and polyethylene glycol) were used, however the absorption of these substances 
could be influenced by pre- and post-mucosal factors other than intestinal 
permeability such as bacterial degradation, absorptive surface area, gastric dilution 
and gastrointestinal transit time, differences in systemic distribution of sugars and 
renal clearance. Thus, the test was modified by introducing a second smaller probe 
since this is thought to traverse the intestinal barrier freely independent of barrier 
loss but similarly affected by pre- and post-mucosal factors. A ratio of the urinary 
concentration of both probes provides a more accurate assessment of para-cellular 
passage across the gut wall than a single probe (Bischoff et al. 2014). By measuring 
the appearance of oligosaccharide probes in plasma rather than urine, we attempted 
to determine intestinal permeability in haemodialysis patients. 
 
The haemodialysis procedure itself did not lead to acute changes in intestinal 
permeability. There were no significant differences in the L/R and S/E ratios between 
non-dialysis days and post-dialysis implying that the haemodialysis procedure itself 
does not appear to induce increased gut permeability. This is in contrary to previous 
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suggestions that haemodialysis may exacerbate increased gut permeability due to 
observations of reduced intestinal perfusion from ultrafiltration during haemodialysis 
(Rossi et al. 2012; Yu et al. 1997; Jakob et al. 2001). Thus, intestinal barrier 
dysfunction in kidney disease may be due to other causes such as gut oedema 
(Sandek & Rauchhaus 2008; Sandek & Bauditz 2007; Vaziri et al. 2016) and/or 
retained uraemic toxins. Previous studies have found that incubating human 
colonocytes in media containing pre-dialysis serum resulted in a marked drop in 
transepithelial electrical resistance indicating increased permeability. This was 
accompanied by loss of transcellular and intracellular protein constituents of the tight 
junction. The extent of epithelial barrier damage and dysfunction was reduced in 
cells exposed to serum obtained post-dialysis suggesting that intestinal barrier 
function is impaired by dialysable retained uraemic toxin(s) (Vaziri, Goshtasbi, et al. 
2012). Future studies should be directed at the identification and maximising 
clearance of these permeability inducing toxins.  
 
Several limitations may account for our findings. Firstly, patients selected for this 
study were relatively young with little co-morbidity and modest ultrafiltration 
requirements. Increased intestinal permeability induced by haemodialysis may be 
detected in patients with greater co-morbidity, high ultrafiltration requirements or 
haemodynamic instability. Secondly, the study sampling period lasted only 10 hours, 
previous studies have shown that elimination of some of the sugar probes such as 
sucralose and erythritol can last up to 48 to 72 hours even in subjects with normal 
kidney function (Roberts et al. 2000; Bornet et al. 1996; Munro et al. 1998). Intestinal 
transit time is delayed in uraemia thus 10 hours may have been insufficient to study 
colonic permeability. Additionally since, sugar probes (sucralose, lactulose) peaked 
late and did not return to baseline by the end of the study period, AUC for 10 hours 
could have underestimated intestinal absorption.   
 
Compared to healthy controls, plasma lactulose levels were significantly higher in 
haemodialysis patients although rhamnose levels were not significantly different. 
Plasma levels of lactulose progressively increased late into the study period and only 
started to reduce after 8 hours. The peak levels of lactulose in haemodialysis 
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patients were significantly higher than controls (approximately 3-fold higher). 
Whereas for rhamnose, peak levels and AUC for haemodialysis patients were similar 
to healthy controls, although the high levels of rhamnose were sustained for a longer 
period in haemodialysis patients (figure 1).  This effect is likely to be due to reduced 
clearance from lack of renal function. Since both lactulose and rhamnose are 
primarily excreted by the kidney (Maxton et al. 1986; Bjarnason et al. 1994), it would 
be expected that the magnitude of rise of both sugar molecules in haemodialysis 
patients relative to healthy controls would be similar. However for lactulose, the 
degree of absorption by haemodialysis patients is significantly higher than healthy 
controls whilst there was no significant difference in plasma levels of rhamnose 
leading to a significantly higher L/R ratio. Although these findings suggest increased 
small bowel permeability in haemodialysis patients it is difficult to ascertain whether 
this reflects increased absorption of lactulose due to increased intestinal permeability 
or accumulation of lactulose due to lack of kidney function. Differences in absorption 
profiles of these two sugars may also contribute. Studies in humans show that 
rhamnose is rapidly absorbed after ingestion and further absorption does not occur 
beyond 1.5 hours post-ingestion despite a significant amount of rhamnose remaining 
in the gut (McCance & Madders 1930). On the other hand, absorption of lactulose 
occurs more uniformly in the small intestine and can continue for up to 4 hours after 
ingestion (Sequeira et al. 2014) which may lead to accumulation and progressively 
rising plasma lactulose levels in patients who lack kidney function.  
 
Sucralose and erythritol resist bacterial degradation in the colon and were used to 
evaluate whole intestinal permeability. Both sucralose and erythritol are primarily 
excreted by the kidney, with the clearance rate of erythritol estimated to be 
approximately half the rate of creatinine (Meddings & Gibbons 1998; Munro et al. 
1998), both are also known to undergo a small but currently unquantified amount of 
extra-renal metabolism (Bornet et al. 1996; Roberts et al. 2000). In accordance with 
previous studies, sucralose and erythritol in healthy controls reached peak levels at 
around 1-2 hours after ingestion (Roberts et al. 2000; Munro et al. 1998; Bornet et al. 
1996). Erythritol levels in haemodialysis patients peaked at a similar time scale and 
magnitude as healthy controls whereas in haemodialysis patients, peak sucralose 
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levels occurred later in the study period (at around 5 hours post ingestion) and were 
2-fold greater than healthy controls. Similar to lactulose, the later peaking of 
sucralose levels is likely due to accumulation secondary to renal impairment. The 
S/E ratio in the two groups was not significantly different but the interpretation of this 
is complicated by the influence of kidney function (Wang et al. 2015), The higher 
sucralose levels in haemodialysis levels may well reflect increased intestinal 
permeability but may also indicate the effect of other factors, particularly lack of 
kidney function 
 
In addition to the effect of kidney function, other factors may contribute to the 
differences in plasma oligosaccharide levels between haemodialysis patients and 
controls. Uraemia may induce delays in gastric emptying and reduce gut motility 
(Strid et al. 2004). In addition, the haemodialysis patients were on a large number of 
medications (Table 11-2) including drugs that are known to affect gastrointestinal 
motility such as proton pump inhibitors and opiates. The effect of medications such 
as statins and phosphate binders that are frequently used by haemodialysis patients 
on intestinal permeability has not been studied in detail and it is unclear if medication 
use may have influenced the plasma levels of sugar probes in this study. Hence, 
although the differences in renal clearance appear to be the major factor 
complicating the interpretation of the study findings in relation to differences between 
haemodialysis patients and controls, there may well be other factors which need to 
be taken into account. 
 
In summary, an accurate and convenient method of measuring intestinal 
permeability in haemodialysis patients remains elusive. The study findings suggest 
that small bowel permeability may be increased in haemodialysis patients although 
due to the dependence of sugar probes on kidney function for clearance, 
interpretation and comparison of permeability index between individuals with differing 
degrees of kidney function is difficult. Use of probes that are not removed by the 
kidney may overcome this problem but none of the currently available intestinal 
permeability probes are suitable from this perspective. The intestinal permeability 
measurement technique described in this study may be used to measure gut 
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permeability changes in response to an intervention or stimuli, although the need for 
a prolonged sampling period would make it difficult to apply in the clinical setting. 
However, it is important to recognise that although intestinal permeability assays 
have been used frequently in gastroenterology research, the mechanisms that 
determine oligosaccharide intestinal permeability may be different from that used by 
bacterial products and intestinal permeability determined by these methods may not 
correlate with clinically significant bacterial intestinal translocation (Bischoff et al. 
2014; Quigley 2016). In conclusion, this is the first study to measure intestinal 
permeability in dialysis patients in vivo, contrary to previous suggestions this study 
did not detect any significant acute changes in intestinal permeability in relation to 
the haemodialysis procedure.  
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 Chapter 12 
12. General Discussion 
12.1 General overview 
Patients with significant reduction in kidney function experience a spectrum of 
metabolic abnormalities including anaemia, disorders of bone mineral metabolism, 
acidosis and increased vascular calcification and cardiovascular risk. Chronic and 
persistent low-grade inflammation is a common feature amongst patients with end-
stage kidney disease and those with this syndrome have worse prognosis compared 
to non-inflamed patients and may exhibit other features such as malnutrition and 
cachexia. Despite the prevalence and increasing recognition of the significance of 
this problem (Figure 5-1), chronic inflammation in dialysis patients remains a poorly 
understood phenomenon and targeted anti-inflammatory interventions are needed.  
The underlying cause of chronic inflammation may be multifactorial but endotoxin 
has been proposed to be a central mediating factor (C McIntyre 2011). Potential 
sources of endotoxin entering the systemic circulation include biofilm formed in 
dialysis apparatus or within dialysis catheters, periodontal disease or translocation of 
endotoxin via the gastrointestinal tract. Thus, endotoxin represents a potential 
therapeutic target given the advent of extracorporeal filters capable of adsorbing 
endotoxin and trials have reported short term successes using endotoxin-adsorption 
as adjunctive-therapy for the treatment of sepsis (Cruz et al. 2009).  
However, as discussed in Chapter 2, the published studies reporting endotoxemia in 
dialysis population are difficult to interpret due to the wide varying degrees of 
endotoxemia reported, with some studies reporting low level or prevalence of 
endotoxemia to some studies reporting very high levels of endotoxemia which 
greatly exceed the pyrogenic threshold in humans and do not appear to correlate 
with the clinical picture (Table 2-1). Additionally, there are significant methodological 
issues with endotoxin testing in blood samples and interpretation of studies is 
complicated by the different types of endotoxin assays used. The overarching aim of 
this thesis was to explore the association of endotoxemia with chronic inflammation 
in haemodialysis patients. Confirmation of this association would be of clinical 
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significance since this would justify embarking on clinical trials of endotoxin lowering 
interventions to treat chronic inflammation in this population.  
In order to achieve this aim, the initial step was to determine an optimum assay that 
could detect blood endotoxin accurately in dialysis patients. Endotoxin testing in 
biological samples such as blood is complicated and due to the different types of 
assays available, it was necessary to carry out some validation work to ensure that 
assay performance was not affected by uraemic solutes present in the blood of 
dialysis patients. Chapter 6 describes the pre-analytical work carried out to optimise 
sample conditions (from blood collection to preparation) for endotoxin detection 
before direct head-to-head comparative studies between several endotoxin detection 
assays were carried out. Following this initial phase of validation and laboratory 
work, the kinetic turbidimetric LAL assay was found to be the most accurate and 
precise assay for blood endotoxin detection in uraemic blood samples.  
However, one of the drawbacks of the LAL assay is that it is not specific for 
endotoxin and can be activated by (1-3)-β-D glucan (BG), cell wall components of 
fungi and yeast. Serum levels of BG are also used as a diagnostic adjunct in 
invasive fungal infections. In a study of non-inflamed haemodialysis patients 
(Chapter 8), 50% of patients had detectable ‘endotoxin’, although on re-testing 
samples testing positive for endotoxin with a BG-blocking buffer, these signals were 
extinguished. Importantly, BG was found to be elevated in a significant proportion of 
HD patients which could falsely activate endotoxin detection assays therefore for 
subsequent studies BG-blocking buffers were used to measure blood endotoxin in 
dialysis patients. 
The large body of work carried out to test the accuracy of blood endotoxin detection 
assays described in chapter 6 and 8 have significantly contributed to our 
understanding of the limitations of blood endotoxin detection methods and highlights 
the potential pitfalls of interpreting blood endotoxin levels obtained using the LAL 
assay – the most commonly used blood endotoxin detection assay in the literature. 
Our ability to understand the prevalence and effects of endotoxemia in patients will 
be limited until a more accurate blood endotoxin detection assay is developed. 
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12.2 The association of endotoxemia with inflammation in dialysis patients 
The prevalence of endotoxemia in haemodialysis patients in initial studies (Chapter 
8) was lower than previously seen in other studies (C McIntyre 2011; Szeto et al. 
2008; Szeto et al. 2010; Terawaki et al. 2010), therefore blood endotoxin was 
measured in two different states experienced by haemodialysis patients that were 
hypothesised to increase endotoxin-influx – during exercise and during the 
haemodialysis procedure. Intense exercise has been frequently reported to 
contribute to increased blood endotoxin in athletes due damage to the gut wall 
leading to endotoxin translocation (Pals et al. 1997) and it has been proposed that 
haemodialysis induces mesenteric ischemia leading to intestinal barrier dysfunction 
(Rossi et al. 2012; March et al. 2017). In studies described in Chapter 9, neither 
intra-dialytic exercise nor the haemodialysis procedure itself acutely influenced blood 
endotoxin or levels of inflammation. In addition, after accounting for BG activation, 
only one sample tested positive for low level endotoxin but BG was elevated in 43% 
of samples. Thus, after accounting for important pre-analytical factors such as 
external contamination of samples and false positive activation of the LAL assay for 
BG, endotoxemia appears to be a rare phenomenon in haemodialysis patients. 
Several questions remain unanswered :- 1) Why is BG elevated in haemodialysis 
patients? 2) What is the relationship between BG and kidney function? 3) Is elevated 
BG (in the absence of fungal infection) clinically significant? 
12.3 Clinical significance of (1-3)-β-D glucan in kidney disease 
The significance of elevated BG in the context of invasive fungal infection has been 
well studied (Sulahian et al. 2014), although its significance in non-infected 
individuals is less clear. BG levels were measured in healthy controls and patients 
with progressively more severe stages of kidney disease. In a study of 135 clinically 
stable subjects, levels of BG progressively increased with worsening renal failure 
(Chapter 10) and highest in patients on dialysis. Elevated BG was also significantly 
correlated with biomarkers of inflammation, physical fatigue, depression and renal-
disease related symptoms scores. On follow-up of subjects with elevated BG 
(>80pg/mL) after adjusting for important confounding factors such as CKD stage, 
there was a near significant increased risk of developing sepsis in the 18 month 
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follow up period (p=0.09). Importantly, BG was closely correlated with ‘endotoxin’ 
signal obtained from the LAL assay which highlights the importance of using 
endotoxin detection assays that are resistant to BG interference when testing for 
blood endotoxin in dialysis patients. It is possible that previous reports of high levels 
of endotoxin in dialysis patients may in part be due to BG interference since nearly 
all published studies do not use endotoxin detection assays which account for BG 
interference.  
The cause of elevated BG in the CKD population is unclear although it appears to be 
associated with clinical harm. BG is minimally excreted by the kidneys and the 
dialysis procedure is not known to impact on BG levels (Prattes et al. 2015). A 
potential source of elevated BG could be the gastrointestinal tract. The harmful 
effects of uraemia on the intestinal barrier has been investigated in both histological 
studies and animal models (Vaziri 2012; Lau & Vaziri 2017). Increased translocation 
of BG has been documented in studies of animals with impaired/altered gut flora 
(Yang et al. 2017; Leelahavanichkul, Panpetch, et al. 2016) and elevated BG has 
been reported in Crohn’s disease patients with increased intestinal permeability (Guo 
et al. 2015). However, increased intestinal permeability has never been proven in 
dialysis patients since conventional assays currently determine intestinal 
permeability by measuring the quantity of orally ingested sugar probes that are 
absorbed into the blood circulation from the gastrointestinal tract and excreted into 
the urine. This technique would therefore not be possible in many anuric dialysis 
patients. Utilising a novel technique that measures sugar probes in plasma rather 
than urine, intestinal permeability was measured in haemodialysis patients and 
compared with healthy controls (Chapter 11), although there was a suggestion of 
increased small bowel permeability in the haemodialysis group, valid comparison 
with healthy controls was difficult due to the strong effect of renal function on the 
pharmacokinetics of ingested sugar probes.  
12.4 General limitations 
The studies reported in this thesis have certain general limitations. Firstly, to 
determine an optimum blood endotoxin detection assay, extensive pre-analytical and 
comparative work was carried out using variations of the LAL assay. The studies 
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described in this thesis were carried out using a specific type of the LAL assay only. 
A number of other novel types of blood endotoxin detection methods exist such as 
the Endotoxin Activity Assay (Romaschin et al. 2012) and cell-based biosensor 
assays (Hacine-Gherbi et al. 2017) were not studied. Use of these assays may have 
provided a more accurate means of testing for blood endotoxin and yielded different 
results. Secondly, although BG appears to play a role in contributing to false positive 
signals and elevated levels may be of clinical significance, BG was measured using 
the Fungitell assay, which itself is based on the coagulation cascade derived from 
LAL extracts. Although this assay is extensively validated as a diagnostic adjunct for 
fungal infection based on cut-off levels, no validation work has been done on the 
accuracy of this assay in uraemic blood samples. Hence the possibility that uraemic 
blood contains an unidentified component that is able to activate the LAL assay, 
causing false positive signals, cannot be excluded.  
12.5 Future directions 
There are a number of topics that are discussed in this thesis where further research 
is needed.  
12.5.1 Mediators of chronic inflammation in dialysis patients 
The evidence derived from the studies in this thesis do not unequivocally support 
endotoxin as a mediator of chronic inflammation in dialysis patients. The lack of 
endotoxemia seen in the studies described in this thesis may be due to endotoxemia 
being intermittently released or due to is rapid inactivation, several authors have 
suggested using indirect methods of endotoxemia such as the endotoxin neutralising 
activity of plasma, anti-endotoxin antibody levels and measuring host response 
molecules that are released by endotoxin-stimulated cells such as CD14 (D. S. C. 
Raj et al. 2009). Using of indirect assays in dialysis patients would further increase 
understanding of the significance of endotoxemia in inflammation. 
Other microbial products may be a source of inflammation such as BG. Circulating 
bacterial DNA and products originating from the gastrointestinal tract has been 
proposed to be a source of inflammation in dialysis patients (Bossola et al. 2009; 
Wang, Zhang, et al. 2012). Identification of microbial molecules which mediate 
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inflammation would be useful to further elucidate understanding of the pathogenesis 
of chronic inflammation. 
12.5.2 The significance of elevated BG in CKD patients 
The studies in this thesis have identified BG as a potentially harmful molecule which 
progressively increases with increasing kidney failure. Several questions remain 
unanswered: - 
12.5.2.1 Is elevated BG harmful? 
The study carried out in Chapter 10 observed a cross-sectional association between 
elevated BG and markers of inflammation. On follow-up over 18 months there was 
no significant association with mortality, cardiovascular outcomes although there was 
a suggestion of increased risk of developing sepsis. However, the number of patients 
with a significantly elevated BG (>80pg/mL) was relatively small (around 22% of HD 
patients), which may have explained the non-significant finding. Therefore, it remains 
unclear whether BG itself is a harmful molecule. The clinical significance of elevated 
BG was require exploration in a more long term study and larger cohort of patients 
with elevated BG. 
12.5.2.2 What is the source of elevated BG? 
The source of elevated BG in CKD patients is unclear and requires further 
exploration. Elevated BG in kidney disease may represent either increased influx 
(e.g. from the gastrointestinal tract) or defective clearance. BG is primarily removed 
by the reticul-oendothelial system (RES), including Kupffer cells. Specific defects of 
the immunity including defective phagocytic function, impaired maturation of 
monocytes and monocyte-derived dendritic cells have been reported in patients with 
ESKD (Verkade et al. 2006; Lim et al. 2007; Anding et al. 2003; Kato et al. 2008). 
Abnormalities in immune function are thought to contribute to low-grade chronic 
inflammation (Kato et al. 2008). Elevated BG detected in our population could be a 
feature of immune dysfunction in advanced CKD and may explain the association 
with inflammation. Further work should be aimed at exploring the association 
between BG and immune function in dialysis patients. 
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12.5.2.3 BG as a marker of intestinal permeability in CKD patients 
 
As discussed earlier, the gastrointestinal tract could be a potential source of BG 
originating from intestinal fungi or from dietary sources. Current assays of gut barrier 
function in dialysis patients are not suitable due to the dependence on renal function 
for clearance of assay probes. Further work should be directed at identifying means 
of reliably and easily measuring gut barrier function in dialysis patients to allow its 
association with BG to be investigated. Given the strong suspicion of the uraemic gut 
being a significant source inflammation in dialysis patients, it is necessary to 
determine a reliable test of gut barrier function which can be easily applied in the 
clinical setting so that the efficacy of interventions (e.g. probiotics) can be assessed. 
The significance of BG as a marker of intestinal permeability could be tested by 
measuring BG levels in dialysis patients and controls in response to oral BG loading. 
 
12.6 Summary 
In summary, the studies in this thesis have demonstrated that chronic inflammation 
is a highly prevalent and problematic condition in patients with end-stage kidney 
disease. Developing our understanding of this condition is important so that 
interventions can be developed to improve quality of life and survival in dialysis 
patients. Endotoxin may not be the mediating factor of inflammation as previously 
proposed. Previous reports of high endotoxin in dialysis patients may have been due 
to assay interference, in particular by BG – which is, itself, associated with increased 
inflammation, physical fatigue, depression and kidney disease-related symptoms. 
Further studies are required to explore the long term significance of elevated BG and 
the reasons for its increase in patients with kidney disease. 
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